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ABSTRACT 
 
In macrophages, the inflammatory stimulus drives a fine rearrangement of cell-
specific chromatin regulatory regions to orchestrate the adaptive immune response and 
activate inflammatory genes transcription. The fine-tuning of gene expression in time and 
space is controlled by the synergistic cooperation among different chromatin determinants, 
thus suggesting a strong link between the composition of these chromatin regions and their 
function. While promoter regions are well characterized, the enhancers of macrophage are 
largely unexplored; indeed the only known markers are the enrichment of mono-
methylation on lysine 4 of histone H3 (H3K4me1) and the binding of the master regulator 
Pu.1.  
The aim of this thesis is therefore the global characterization of the enhancers’ 
determinants and their dynamic profiling during the inflammatory response. We addressed 
this issue by adopting the ChroP approach recently established in our laboratory; this 
strategy combines chromatin immunoprecipitation (ChIP) and mass spectrometry-based 
proteomics for the comprehensive dissection of histone post-translational modifications 
(modificome) and chromatin-binding proteins (interactome), associated with a specific 
chromatin region. 
ChroP approach was employed in RAW 264.7 macrophage-like cell line and 
optimized to be amenable to the immunoprecipitation not only of H3K4me1 but also of the 
transcription factor Pu.1 used as bait in ChIP. In order to profile the dynamics of the 
enhancers’ determinants during the early phases of the inflammatory response, we 
performed ChroP experiments in time-course (tc-ChoP), in cells untreated or treated for 1h 
or 4hrs with lypopolysaccharide (LPS). We characterized three different scenarios: 
proteins stably associated to enhancers during the inflammatory response and proteins 
evicted or recruited to these regulatory regions upon the stimulus. 
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Our findings suggest a general model where at macrophage enhancers a high-
ordered structure pre-exists to the stimulus and consists of both positive and negative 
transcriptional regulators in association with hPTM patterns typically marking a more open 
chromatin state. During the inflammatory response, the general high-ordered structure of 
enhancers is overall maintained but we determined a dynamic behaviors of a set of proteins 
which are either recruited (as the PBAF complex) or evicted (like Dnmt1) from enhancers 
and synergize with the enrichment (hyper-acetylation of histone tails) or depletion 
(H3K9me3) of specific histone marks, to set an environment permissive to transcriptional 
activation. 
Interestingly, some proteins are newly recruited at enhancers after the inflammatory 
stimulus to fine-tune the appropriate gene expression profile; among these we identified 
some proteins already known to be involved in the inflammatory response, such as Junb 
and Stat1, while others were completely unexpected, thus very interesting to be further 
investigated. 
Finally, among the enhancers’ determinants that show a stable enrichment we 
focused our attention on Mpeg1 protein, which has been described as macrophage-specific 
but whose functional role is almost unexplored.  
ChroP strategy allowed the dissection of enhancers’ determinants in basal as well 
as upon massive transcriptional activation; through this approach, we were able to 
corroborate already known findings and dynamics but -more interestingly- we could 
identify novel potential markers for enhancer, which will be further investigated through 
ChIP-seq. The combination of these two ChIP-based strategies indeed allows a 
comprehensive characterization of the same chromatin region from two different, but 
complementary, perspectives.  
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INTRODUCTION 
In this introductory section, I will begin with the description of the general concept 
of epigenetic regulation mediated by chromatin, with a focus on histone post-translational 
modifications (hPTMs) and their interplay with other chromatin determinants. 
I will then introduce the two main approaches to study hPTMs, with more focus on 
mass spectrometry (MS) methods and MS-based proteomics, which are the strategies that I 
employed extensively in my study. 
I will then describe the most common MS-approaches to characterize the protein 
determinants of chromatin, such as hPTMs and chromatin interactors and modifiers, by 
means of the combination of biochemistry and MS-based proteomics strategies. 
Finally, I will conclude with a short description of macrophages’ enhancers of 
inflammatory genes as prototypic example of genomic regulatory regions where an in-
depth dissection of its chromatin determinants is crucial to understand the molecular 
mechanism of their function. 
 
2.1 Epigenetics, chromatin composition and hPTMs 
The concept of epigenetics was introduced by Waddington in 1942 (Waddington 
1942) to define the molecular pathways that modulate the expression of the same genotype 
to produce different phenotypes. Literally, epigenetics means “above” or “on top” of 
genetics and in the last years the meaning of this word has gradually changed toward a 
definition that refers to all the inheritable but reversible phenomena that modulate gene 
expression without altering the DNA sequence (Wu et al. 2001). A univocal definition of 
epigenetic is still under debate but it is generally accepted to consider as epigenetic marks 
many chromatin determinants like DNA methylation, modifications on histone proteins, 
microRNA (miRNA) and chromatin remodeling complexes, even though heritability has 
not been demonstrated for all of them (Tammen et al. 2013). 2013). All these epigenetic 
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determinants impinge on and modulate chromatin which is composed at the structural level 
of nucleosomes: repeated units of 147 bp of DNA wrapped around the octamer core 
constituted by one H3-H4 tetramer and two H2A-H2B dimers (Kornberg 1974). Chromatin 
is a dynamic and highly structured nucleoprotein complex that in eukaryotes mediates both 
the DNA compaction into the nucleus and the regulation of different nuclear functions 
such as transcription, replication and DNA repair. In this thesis we will focus on the 
proteinaceus components of chromatin, namely transcription factors, chromatin-binding 
proteins, histones and their post-translational modifications. Part of the epigenetic 
modulation mediated by reversible hPTMs, which mainly occur at the protruding N-
terminal regions of histones (the so-called “histone tails”) and are recognized as key 
regulators of chromatin structure and function. Distinct enzymatic familiesadd a large 
panel of different covalent PTMs on histones: acetylation on lysines (K-Ac), methylation 
on arginines or lysines (R or K-me), phosphorylation on serine, threonine and tyrosine (S, 
T or Y-ph), ubiquitination and sumoylation on lysines (K-ub and K-su) (Kouzarides 2007) 
and lysine crotonylation (K-cr) (Tan, Luo et al. 2011) (Fig. 1).  
 
Fig. 1: Histone post-translational modifications. Nucleosome and core histone N-terminal tails 
with annotation of sites of post-translational modifications. The most common types of 
hPTMs are listed in the box with the legend and indicated by colored symbols. Monomers 
of histones are represented: H3 (yellow), H4 (blue), H2A (red) and H2B (green); the other 
half of the nucleosome is in grey. (Adapted from Briggs’s personal page 
https://ag.purdue.edu/biochem/Pages/Profile.aspx?strAlias=sdbriggs&intDirDeptID=9) 
The repertoire, location and combination of these hPTMs are extremely variegated and the 
cell uses combinations of such modifications to code for different gene expression patterns 
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and thus different functional effects. The concept of the specific functional outcome 
associated with a distinct modification pattern has led to the elaboration of the “histone 
code hypothesis” that suggests that hPTMs, singly or in combination, can define a sort of 
molecular language that modulates the functional state of the underlying DNA. Indeed, 
hPTMs are placed and removed by enzymes known as “writers” and “erasers”, 
respectively (Fig. 2).  
 
 
Fig. 2: Histone writers, readers and eraser of hPTMs important in transcription regulation. Example 
of enzymes able to add (writers), remove (erasers) and bind (readers) to hPTMs to 
determine the functional role of these modifications. (Adapted from Calo and Wysocka, 
2013)  
Post-translational modifications may exert their function through two distinct mechanisms: 
either the chromatin compaction is altered via changes in inter-nucleosomal or histone-
DNA interactions, thus controlling the accessibility of DNA-binding proteins such as 
transcription factors or co-regulators (cis mechanism). Alternatively, hPTMs can generate 
binding platforms for the recruitment of macromolecular complexes, named “readers”, 
containing specialized domains (trans mechanism) able to “read” these marks and translate 
them into a specific process on the DNA (Nightingale, Gendreizig et al. 2007; Turner 
2007). Alteration of chromatin architecture directly affects gene expression and other 
cellular processes; as a consequence, aberrant hPTMs patterns have been observed in 
several diseases, among them cancer. For this reason, decrypting this “code” would boost 
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the comprehension of physiological and pathophysiological conditions based on chromatin. 
In addition to hPTMs, chromatin is also characterised by local enrichment of histone 
variants, DNA methylation, chromatin binding proteins and differential nucleosome 
density and positioning; all these features synergize together to create a specific 
“chromatin landscape” and modulate gene expression at specific loci (Margueron and 
Reinberg 2010) (Fig. 3). 
 
 
Fig. 3: Determinants of chromatin landscapes. (Adapted from Dulac C. 2010)  
 
2.1.1  Technical approaches to study hPTMs 
 During the past years, two main approaches have been successfully employed to 
characterise chromatin composition and architecture: assays based on antibodies 
specifically raised against hPTMs or proteins of interest, and mass spectrometry. 
Antibodies are traditionally used to study the hPTMs in different assays; they can be 
employed to analyse modifications at a single cell level (i.e. immunofluorescence, IF), or 
for the profiling of PTMs in different samples and/or conditions (western blot, WB). 
Antibodies can also be used in chromatin immunoprecipitation (ChIP) to map a specific 
modification, or a protein, at genome-wide level and with the resolution of a few 
nucleosomes (Barski, Cuddapah et al. 2007). ChIP is nowadays combined with massive 
DNA sequencing (ChIP-seq), which enables to observe that hPTMs are not uniformly 
distributed along the genome but tend to cluster within defined chromatin regions in 
distinct patterns. 
Despite their high specificity, antibodies have some limitations: they cannot determine the 
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modification status of different histones within the same nucleosome thus antibodies fall 
short in studying the combinatorial view of the code (Garcia, Shabanowitz et al. 2007); 
moreover, antibody binding may be reduced by steric effect of modifications occurring on 
adjacent or closely spaced residues, thus causing epitope-masking. 
In this context, MS has proved to be an effective alternative to characterise known 
modification but also to identify novel and unpredicted hPTMs. Furthermore, thanks to the 
development of high resolution MS-instruments, it allows distinguishing between nearly 
isobaric modifications and mapping very complex combinatorial patterns of hPTMs, thus 
overcoming antibodies limitations (Beck 2010). Finally, the use of chemical and metabolic 
labeling strategies has enabled the accurate quantification of modifications in a relative and 
absolute manner. However, the major limitation of MS lies on the fact that it has been 
employed mainly for the analysis of bulk chromatin, which provides only a global view of 
the modification state of a system, with no locus-specific information. An important 
implementation would therefore consist in the characterization of hPTMs pattern 
specifically associated with defined chromatin landscapes. 
 
2.2 Mass Spectrometry analysis and MS based-proteomics 
In the last decade, technological improvements generated mass spectrometers 
characterized by constantly higher resolution, sensitivity and performance. Nowadays, the 
most widely used approach for proteomic analysis is the liquid-chromatography coupled 
with tandem mass-spectrometry (LC-MS/MS).  
The classical workflow for the identification and characterization of complex mixture of 
proteins is the so-called “bottom-up” approach, a peptide-centric strategy where proteins 
are eventually separated and then digested with proteases into peptides. The most common 
protease used in bottom-up approach is trypsin, which cleaves at the C-terminus of lysine 
and arginine residues unless they are followed by proline residue. The large use of this 
Introduction 
 
8 
enzyme in bottom-up is due to the fact that it generates peptides about 10-12 amino acids 
long, which are then easily detectable by MS. 
In order to decrease the complexity of the mixture, peptides are separated by liquid 
chromatography typically in reversed phase mode (RP-LC), according to their 
hydrophobicity. Moreover, in RP-LC the polar and volatile mobile phase favors the ion 
transferring in the mass analyzer which measures the mass-to-charge ratio (m/z) of freely 
moving gas-phase ions in electric and/or magnetic fields. In the mass spectrometer 
precursor peptides are isolated and scanned (full scan MS or survey scan MS or MS or 
MS1) to identify the m/z that provides information on the elemental composition of the 
peptide. The most intense of these precursors are then fragmented in the constituent 
fragment ions through tandem MS events (MS/MS or MSn) to retrieve their amino acid 
sequence. 
Peptide identification is achieved by comparing the tandem mass spectra derived from 
peptide fragmentation with theoretical MS/MS spectra generated form in silico digestion of 
a protein database. Protein identification is then inferred by assigning peptide sequences to 
proteins (Fig. 4). 
 
 
Fig. 4: Classical workflow for bottom-up MS analysis. A protein mixture from a biological 
sample is separated by SDS–PAGE and enzymatically digested in the corresponding 
peptides, which are separated by HPLC. Peptides are then ionized and analysed by tandem 
mass spectrometry generating MS and MS/MS spectra. MS/MS spectra are searched 
against protein databases to obtain the protein identification. (Adapted from 
www.biochem.mpg.de) 
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A mass spectrometer consists of three main parts:  
1. The ion source: it converts the peptides into gas-phase ions.  
2. The mass analyzer: it separates the ions according to their mass/charge ratio (m/z).  
3. The detector: it records the number of ions at each m/z value.  
 
1. Ion Source and ionization of peptides  
Proteins and peptides are non-volatile and polar compounds as such their 
transferring into the gas phase without causing extensive degradation, required special 
vehicles.  
Mass spectrometers can measure m/z values of ionized molecules in gas-phase but since 
proteins and peptides are non-volatile and polar molecules, their analysis require an 
ionization method to transfer them into the gas-phase. One of the most important 
developments in instrumentation has been the introduction of “soft-ionization” technology, 
which allows for the ionization of proteins and peptides without causing extensive 
degradation. Two techniques are very widely used in the modern bench-top MS devices: 
matrix-assisted laser desorption ionization (MALDI) (Hillenkamp and Karas 1990; 
Hillenkamp, Karas et al. 1991) and electrospray ionization (ESI) (Fenn, Mann et al. 1989). 
In a MALDI source, peptides are co-crystallized with a solid-phase matrix on a metal plate. 
The matrix typically consists of a small organic molecule and the most extensively used for 
the analysis of peptides and proteins are α-cyano-4-hydroxycinnamic acid and di-hydroxy 
benzoic acid (DHB). When laser pulses irradiate the resulting solid mixture, this absorbs 
the laser energy and transfers it to the acidified peptides. At the same time, the rapid 
heating causes desorption of both matrix and newly formed [M+H]
+ 
protonated peptides 
into the gas-phase (Fig. 5). This ionization process generates ions in packets rather than 
beam-type, thus it requires an MS analyzer capable either to acquire a wide range of 
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masses in a single scan or to trap all the ions simultaneously. MALDI ionization can 
support different types of mass analyzers, but the most common combination for 
proteomics studies is the MALDI/time-of-flight (TOF) setup (Song and Lee 2001); in this 
analyzer, ions generated in the source are accelerated to a fixed amount of kinetic energy 
and travel down a flight tube. Smaller ions will have a higher velocity and will be recorded 
by the detector before the larger ones. In a TOF spectrum the m/z value for a given analyte 
is proportional to the time required to reach the detector.  
 
 
Fig. 5: Schematic representation of sample ionization in MALDI ion source. Sample is co-
crystallized with matrix solution on a sample plate; laser irradiation transfer energy to the 
sample thus promoting its conversion in to gas-phase. Ions are then separated in the mass 
analyzer and detected by the detector. (Adapted fromhttp://www.tankonyvtar.hu) 
In contrast to MALDI, the peptides or proteins analysed by ESI source are in aqueous 
solution and their charge is controlled by the pH of the solution. Peptides contain 
functional groups and at acidic pH values, protonation of the amines confers an overall net 
positive charge to the analyte; on the contrary, basic pH causes de-protonation of the amine 
and carboxyl groups thus conferring a negative charge. ESI sources produce ions from 
solution; the electrospray phenomenon is driven by applying a high voltage (2-6kV) 
between the emitter at the end of the LC-column and the inlet of the mass spectrometer. 
This electrically charged spray is followed by creation and desolvation of analyte-solvent 
droplets aided by a heated capillary and in some cases by sheath gas flow at the inlet 
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(Fig.6). Different theoretical models were formulated to explain the mechanism of ions 
formation in ESI source, but the features of this ionization technique are: the formation of 
multi-charged ions and the sensitivity to analyte concentration and flow rate. 
Typically, ESI source are usually coupled “on-line” with the LC instruments to achieve 
continuous analysis; an important development in ESI includes the micro and nano-ESI 
source where the flow rates are lowered to nanoliter/min, in order to improve the 
sensitivity (Griffin, Coffman et al. 1991; Emmett and Caprioli 1994) and increase the 
concentration of the analyte. 
 
Fig. 6: Schematization of electrospray-ionization process. Peptides eluted from the 
chromatographic column are ionized by applying a high voltage between the capillary and 
mass spectrometer. Charged liquid forms a cone shape (known as Taylor cone) and the 
analyte-solvent droplets burst away in to a spray. (Adapted from 
http://www.lamondlab.com) 
 
2. Mass Analyzer and dissociation methods  
The mass analyzer corresponds to the central core of the mass spectrometer and 
they can store ions and separate them based on the m/z. Common mass analyzers that have 
proven useful for peptide analysis from complex mixture are the linear ion trap (LIT), the 
Orbitrap, the FT-ICR, the quadrupole (Q) and the TOF above-mentioned. Since each 
analyzer isolates and measures peptides masses using different mechanisms, each mass 
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spectrometer represents a balance between sensitivity speed and accuracy. These mass 
analyzers fall in two broad categories: the scanning and ion-beam mass spectrometers like 
the TOF and Q; and the trapping mass spectrometers such as IT, Orbitrap and FT-ICR. 
Although these mass analyzers differ in the details of how they work, they all select a 
single m/z species from a mixture of peptide ions generated by the source and fragment 
them to obtain the MS/MS spectrum.  
In proteomics, one of the most frequently used fragmentation techniques is the 
collision-induced dissociation (CID) (Shukla and Futrell 2000) that breaks the peptide 
bond in fragment ions by multiple collisions with rare gas atoms. Upon fragmentation the 
characteristic b- and y-ions (at N- and C-terminus, respectively) are generated which are 
then used for the univocal peptide identification. In addition to these standard backbone 
ions, MS/MS spectra contain also other fragment ions like internal ions, immonium ions or 
neutral losses of thereof.  
In the last few years the higher energy collisional dissociation (HCD) has been adopted to 
high-resolution mass analyzers (Olsen, Macek et al. 2007). This dissociation resembles all 
the characteristics of CID and the combination with orbitrap analyzer allows for the in-
time analysis of ion beams generated by the ESI source; moreover both the full MS and the 
MS/MS scans may be acquired at high resolution and with high mass accuracy (“high-
high” acquisition mode) (Mann and Kelleher 2008) thus helping the peptide identification. 
In light of the type of dissociation, HCD ion spectra cover a wide mass range and are 
therefore particularly useful for the inspection of immonium ions as well as reporter ions 
resulting from isobaric-tag labeling strategies (see paragraph 2.3). 
These dissociation methods generate limited information for peptide longer than 15 
amino acids coming from the digestion with other proteases such as Glu-C and Asp-N that 
cut at less frequent amino acids. This limitation has been addressed by ad-hoc dissociation 
strategies to carry out peptide fragmentation through electron transfer to multi-protonated 
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longer peptides enabling their sequencing: electron capture dissociation (ECD) (Kelleher, 
Zubarev et al. 1999), electron transfer dissociation (ETD) (Syka, Coon et al. 2004) and ETD at 
HCD (hcETD) (Frese, Nolting et al. 2013). 
In a typical shot-gun proteomics workflow, peptides are analysed in a data-
dependent acquisition mode (DDA) (Sandhu, Hewel et al. 2008) where the mass analyzer 
selects the most intense ions in a time-window and subject them to fragmentation; the 
analyzer then automatically switches back to the full scan MS mode and selects the next 
most intense to be fragmented. DDA is therefore biased towards the most abundant 
species, thus more recently have been employed other acquisition methods that in a time 
window tend to generate as many MS/MS spectra as possible without intensity threshold 
(named data independent acquisition or DIA) (Gillet, Navarro et al. 2012) or methods that 
alternate different CID and ETD dissociation strategies according to the charge state of the 
precursor ion (data-dependent decision tree or ddDT) (Swaney, McAlister et al. 2008). 
 
3. Detector  
The role of the detector, as “Channeltron” or “Electron multiplier tubes (EMT)”, is 
to record the number of ions at each m/z value, thus it is placed at the end of mass 
spectrometer. “Channeltron” is a dynode coated with semiconductor material. The ions that 
strike the inner walls cause the emission of electrons, which are recorded in a counting 
system. “EMT” consists in a series of dynodes that cause the same effect of “Channeltron”, 
but it is able to amplify the signal of electric current until it is quantifiable.  
 In the last years the combination of linear ion trap with orbitrap analyzer has 
become very popular in bench-top instruments giving rise to the Orbitrap family of hybrid 
mass spectrometers. More recently the linear trap quadrupole (LTQ) Orbitrap Velos 
instrument has been developed; this devise has a linear geometry constituted by the s-lens 
for the ions transmission, the LTQ for isolation but also fragmentation and scanning at low 
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resolution, the c-trap for the ion transferring to the HCD collision cell or to the orbitrap 
analyzer. This instrument allows both CID and HCD fragmentations and MS acquisition at 
high resolution while MS/MS can be acquired at high or low resolution.  
Nowadays a new hybrid instrument has become popular in mass spectrometry-based 
proteomics, the Q Exactive. This instrument combines the selectivity and the speed of the 
quadrupole mass filter with the high resolution of the orbitrap analyzer. Thanks to the 
implemented instrument geometry and the presence of the quadrupole, Q Exactive selects 
virtually instantaneously the ions and is able to fragment them in HCD allowing the so-
called “hi-hi” acquisition modality in a very short duty cycle (Fig. 7).  
 
Fig. 7: Scheme of Q Exactive geometry. Construction details of the hybrid instrument constituted 
by the quadrupole mass filter HCD collision cell and orbitrap mass analyzer closely interfaced by 
the c-trap (Adapted from Michalski et al 2011).  
 
2.2.1 Protein identification from MS data 
 In shotgun proteomics, the identification of a protein is reduced to the identification 
of the constituent peptides generated by enzymatic digestion. In MS, the analysis of 
peptides has some advantages: first they are easily eluted compared to intact proteins; 
second MS has a higher sensitivity for small molecules in respect to proteins and finally 
peptides are easily fragmented (Rappsilber and Mann 2002). 
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The identification of a peptide is performed by using its tandem MS-spectrum; several 
MS/MS databases have been developed but they all follow a similar procedure. Briefly, 
every ion MS/MS spectrum is scored against a database containing all the theoretical 
fragmentation patterns constructed for peptides from the searched database. User-specified 
criteria like the mass tolerance, the proteolytic enzyme adopted and the post-translational 
modification allowed, restrict the pool of candidate peptides. The output results is a list of 
fragment ion spectra matched to the peptide, ranked according to the search score; this 
value measures the similarity between the experimental and the theoretical spectrum and 
allows a first separation between true or false identifications (Fig. 8). 
 
Fig. 8: Protein identification by MS/MS database searching. Classical workflow for protein 
identification. (Adapted from Nesvizhskii A.I. et al. 2007). 
 
2.2.2 Biochemical enrichment strategies and mass spectrometry-based identification of 
post translational modifications 
Generally, the workflow for proteins identification is also applicable to PTMs 
although this analysis is more difficult due to three characteristics of post-translation 
modifications: first PTMs are typically low abundant, hence high sensitivity of detection is 
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required; second the covalent bond between the PTM and the amino acid side chain of the 
peptide is frequently labile, thus it is difficult to maintain the peptide in its modified form 
during sample preparation and ionization. Third, some PTM are often transient, thus their 
capture is extremely difficult.  
Due to this complexity, common strategies for the enrichment of modified peptides have 
been developed; examples of these approaches are: immunopurification (IP), immobilized 
metal affinity chromatography (IMAC), titanium dioxide (TiO2) metal-based 
chromatography, ion exchange (strong cation/anion exchange, SCX/SAX) chromatography 
and hydrophilic interaction liquid chromatography (HILIC).  
Immunopurification relies on the use of specific antibodies able to recognize specifically a 
certain modification to enrich for it prior to MS analysis. SCX and SAX are separation 
strategies orthogonal respect to the RP (Giddings 1984) and are used in highly complex 
samples to decrease the complexity. The other three methods, namely IMAC (Ficarro, 
McCleland et al. 2002), TiO2(Pinkse, Uitto et al. 2004) and HILIC (McNulty and Annan 
2008) are all widely used in phosphoproteomics studies and are based on the principle of 
chelating phosphate group of phosphopeptides by using different metals like Fe3+ or 
TiO2+.  
Conceptually, the identification of a post-translational modification by MS is rather 
straightforward, since each PTM generates a positive or negative delta mass (Δ mass) 
relative to the unmodified form of the same peptide. However, the identification of post-
translational modifications is particularly challenging because the search engine has to take 
into account all the different modified forms that might exist. Computational methods for 
PTM annotation analyse MS and MS/MS spectra taking into account both the delta-mass 
produced by the modification of interest and neutral losses or other diagnostic ions like the 
immonium ions (Matthiesen, Trelle et al. 2005). The statistical approaches can be broadly 
clustered in two groups: in the first, the user selects a priori a list of modification that will 
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be matched during the sequence database search; in this step, PTMs are assigned to the 
specific amino acid of a candidate peptide sequence. In a very large dataset, the number of 
modifications specified is exponentially correlated with the complexity of the search, thus 
a restriction is usually imposed in order to reduce the rate of false-positive assignments. 
The second approach is based on a “blind” attribution of PTMs and it is composed of 
two sequential steps. In the first one, only unmodified peptides or recurring forms of 
thereof are searched, such as oxidation of methionine residues; the search of these standard 
modifications avoids the false-positive assignments of other PTMs later on. Due to the fact 
that every PTM correspond to a Δ mass, in the second step unidentified MS/MS spectra are 
inspected as modified forms of an already assigned peptide by using a list of naturally 
occurring known modifications (Marshall and Hendrickson 2008). 
The false-positive identification rate is in any case higher for computational methods that 
search for PTMs; in this regards, the development of high-resolution instruments have 
helped to partially address this issue, in fact they generate MS and/or MS/MS spectra with 
higher mass accuracy thus allowing the distinction between PTMs with similar delta-mass. 
 Some false-positives might also come from in vitro artifacts that are wrongly 
assigned as in vivo enzymatic modifications. A classic example is the di-glycine (-GG) tag 
on lysine amino acid: this delta-mass is used to determine ubiquitination of this residue but 
iodoacetamine (IAA), commonly used in shotgun proteomics for cytosine alkylation, has 
the same elemental composition (Nielsen, Vermeulen et al. 2008). Other examples of false 
assignment are amino acids substitutions that generate and identical delta-mass 
corresponding to PTM, like serine to glutamine substitution and glycine to alanine 
substitution that have the same ∆ mass as acetylation (+42.010) and mono-methylation 
(+14.015), respectively. 
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2.2.3 Analytical implementation to boost hPTMs identification 
In the identification of PTM on histones, the peculiar amino acid composition of 
these proteins represents a further challenger: histones are in fact highly rich in arigine and 
lysine residues, especially at the N-terminus where the majority of the hPTMs are located; 
for this reason, trypsin digestion generates peptides too short to be retained by the HPLC 
and to be efficiently analysed via MS (Bonaldi, Imhof et al. 2004).  
Another peculiarity of hPTM that affect MS-characterization is the fact that they often co-
exist on the same histone, thus the PTMs combinatorics must be taken into consideration 
during the identification procedure.  
In order to overcome these limitations, one way is to enzymatically digest histones 
with ArgC protease that cleaves at the C-terminus of arginine residues, thus generating 
longer and more ionizing histone peptides compared to trypsin (Bonaldi, Imhof et al. 2004; 
Jufvas, Stralfors et al. 2011). Moreover, these peptides will have a well-defined y-ions 
series due to the fact that they retain a positive charge on the C-terminus of arigines 
(Smith, Haimberger et al. 2002; Bonaldi, Regula et al. 2004; Garcia, Mollah et al. 2007). 
Alternatively, histones can be first chemically derivatized with deutered acetyl anhydride 
(D6-acetic anhydride [(CD3CO)2O]) and then digested with trypsin; this combination leads 
to an ArgC-like digestion because alkylated lysines are not digested (Shevchenko, Tomas 
et al. 2006). This approach has the same advantages as the classical ArgC strategy, 
furthermore can be employed in in-gel digestion which ensures the separation of histone at 
the level of individual molecules (Trelle, Salcedo-Amaya et al. 2009). An additional 
advantage of ArgC-like digestion is that the derivatization labels both unmodified and 
mono-methylated lysines by adding a deuterated acetyl moiety (delta mass or Δ mass + 
45.0294 Da) while this reaction does not occur at di-/tri-methylated or acetylated lysines, 
thus leading to a better distinction of peptides bearing isobaric modifications. Finally, the 
chemical alkylation slightly increases the retention time of the peptide, thus contributing to 
Introduction 
 
19 
the unambiguous assignment of the modifications to specific residues. 
Improved approaches for hPTM identification include also the optimization of LC-MS 
strategies for a better separation and site-specific attribution especially of hyper-modified 
histone peptides. Very recently we could demonstrate that ultra-high performance liquid 
chromatography (UHPLC) separation outcompetes the classical high performance liquid 
chromatography (HPLC) in separation efficiency and this effect is particularly important 
for hyper-modified histone peptides bearing isobaric modifications (Soldi, Cuomo et al. 
2014). Indeed, the use of columns packed with 1.9μm C18 beads in ultra-high-pressure 
regime confers very high peak capacity, thus increasing the peptide separation (Shen, 
Zhang et al. 2005; Nagaraj, Kulak et al. 2012).  
A second improvement is represented by the Q Exactive mass spectrometer that -being 
very selective and fast- allows a very high identification rate (Michalski, Damoc et al. 
2011). The Q Exactive fragments peptides in HCD mode, thus allows a “high-high” 
acquisition that helps the hPTMs assignment.  
The platform that combines UHPLC and Q Exactive mass spectrometer out-competes 
previous analytical strategies (e.g. the HPLC coupled with LTQ Velos Orbitrap system) 
and boosts the dissection of hyper-modified peptides bearing isobaric modifications. ArgC-
like digestion contributes to the better dissection of hPTMs, even though in solution Arg-C 
digestion may represent the ideal choice in peptides containing multiple lysines where the 
chemical alkylation can induce an “isobarization effect” (peptide 4 – 17 of histone H4) 
where peptide naturally acetylated at different degrees are equalized by the chemical 
acetylation (Soldi, Cuomo et al. 2014). 
 
2.3 Relative quantitation strategies in MS-based proteomics 
In the last few years, the concept that the mere qualitative data in not sufficient to 
describe the dynamics of the proteome is raising; thus, the quantitative information is 
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needed, especially for the comparative analysis of proteins among distinct functional 
states.  
Mass spectrometry is not intrinsically a quantitative technique for different reasons: first, 
the ion intensity is proportional to its amount but it is also dependent on its chemical-
physical properties like molecular composition, charge and hydrophobicity. Second, the 
comparative analysis between two different LC-MS/MS runs is influenced by external 
variations like temperature and chromatography reproducibility. In order to overcome this 
limitation, two conceptually distinct solutions are adopted: strategies based on a posteriori 
comparison among samples (label-free approaches) and quantification techniques that rely 
on peptide/protein isotopic labeling (Fig. 9). 
Label-free strategies take advantage of peptide intrinsic characteristics and the 
quantification is made post-acquisition. These approaches can be grouped in: 1) intensity-
based, where the quantification relies on the comparison of one or more peptide intensities 
of the same protein in different samples and 2) spectra counting quantification strategies, 
based on the number of MS/MS spectra for the same protein in different samples.  
The intensity-based approaches rely on the concept that the extracted ion chromatography 
(XIC or area under the curve, AUC) for a given peptide is linearly correlated with its 
abundance. XICs of the same peptide in different samples are extracted and compared for 
the peptide quantification. These approaches require extremely reproducible 
chromatography among multiple runs and ad hoc software capable to perform retention 
time realignment and peptide intensity normalization over the global intensity. 
Spectral counting strategies use MS/MS spectra both for identification and quantification; 
these approaches are based on the rational that more abundant proteins are identified with a 
higher number of peptides. Limits of these techniques are that both the length and the 
amino acid composition influence this linear correlation; furthermore, a high number of 
spectra are needed for accurate protein quantification.  
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Label-free strategies offer the great advantage that can be extended to a theoretically 
infinite number of conditions and can be applied to every type of samples (cell lines, 
primary cells, tissues, etc.). Limits of these approaches are: the requirement of highest 
technical and experimental reproducibility and an overall lower accuracy in protein 
quantification in respect to isotope-based techniques. 
 All the different isotope-based quantification strategies follow an overall similar 
rationale: create a delta-mass that distinguishes peptide derived from different samples in a 
single MS analysis. In a classical workflow, samples isotopically light-(L) or heavy-(H) 
labeled are mixed and the H/L intensity ratio allows for an accurate peptide and protein 
relative quantification in the two samples. The isotopic tag can be introduced in the peptide 
at different stages during the sample processing and the general rule is that the early this 
step is performed, the less are the variations are introduced between the two samples to be 
compared, so the more accurate the quantification is.  
 
Fig. 9: Schematic representation of distinct relative quantitation strategies.The comparative 
analysis made by label-free or chemical/metabolic labeling approaches are summarized in the 
picture. Extracted proteins form cells are digested in to peptide before mass spectrometry analysis 
and quantification at MS1 or MS2 level. Labeling is represented by blue and red colors, scissors 
mean protein digestion and 1:1 the sample mixing. XIC = extracted ion chromatography, I = 
intensity, A and B refer to the corresponding samples 
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Based on how proteins or peptides are labeled, isotope-based approaches can be divided in 
chemical- and metabolic-labeling strategies. In the first group the tag is added covalently to 
the reactive side chains of amino acids before or after proteolysis, through a chemical 
reaction. The first example of chemical-labeling was the isotope-coded affinity tag (ICAT) 
(Gygi, Rist et al. 1999), where proteins are labeled with cysteine-specific tag; the principal 
limit of this approach is that only cysteine-containing proteins can be labeled and 
quantified at MS level. The isobaric tag for relative and absolute quantification (iTRAQ) 
(Ross, Huang et al. 2004) is the most successful example of chemical labeling. Side chains 
of lysine residues are labeled with an isobaric tag that allows the quantification at MS/MS 
level. The advantage of iTRAQ is the possibility to multiplexing, by using up to 8 different 
isobaric tags; however, this approach requires high-resolution instruments and possibly 
HCD fragmentation, due to the low m/z of the reporter ions of the tag.  
Both ICAT and iTRAQ can be applied to different types of samples, such as tissue or 
clinical biopsies; among the limitations we mention the variable labeling efficiency that 
depends on sample complexity and the less accurate protein quantification due to the rather 
late step of labeling throughout the sample preparation protocol.  
A valid alternative is the metabolic-labeling strategy, where stabile isotopes are 
added to the growing cell medium as metabolic precursors in order to be incorporated in 
the proteome during protein biosynthesis. Major advantages of metabolic labeling 
approaches are that they can be applied to in vivo studies and that samples can be mixed at 
the beginning of the sample preparation. These strategies are therefore compatible with 
complex purification procedures and allow accurate protein quantitation. A clear drawback 
of these techniques is that, they can be generally applied only to cultured cells. The most 
successful example of metabolic-labeling strategies is the stable isotope labeling of amino 
acids in cell culture (SILAC) (see paragraph 2.3.1). 
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2.3.1 SILAC-based approaches for the relative protein quantitation 
 SILAC is a powerful and accurate procedure based on the use of essential amino 
acids where the naturally isotopes 12C, 1H and 14N (or light, L) are substituted with heavy 
(or H) isotopes (13C, 2H and 15N, respectively). In a classical SILAC experiment two cell 
populations, representative of two different functional states, are grown in medium 
containing either light or heavy isotope-coded essential amino acids for a sufficient number 
of cell doublings in order to assure the full incorporation of the isotopes in the proteins. 
After complete labeling, two identical proteomes are generated that only differ for protein 
isotope composition; the two samples might be directly mixed in equal amounts, thus 
generating a unique proteome that is processed via LC-MS/MS. As readout, every peptide 
will be represented as a pair where the mass is dependent on both the number and the 
type of the amino acids incorporated in the sequence (Ong, Blagoev et al. 2002) (Fig. 10). 
In SILAC labeling are generally used arginine and lysine isotope-coded amino acids in 
combination with trypsin digestion because this set up allow for the labeling of virtually 
every peptide.  
 
Fig. 10: Schematic view of SILAC labeling and of a prototypic experimental design. SILAC 
experiment is composed of two different phases: in the adaptation phase cells are grown in 
medium containing either light- or heavy-isotope coded amino acids until fully 
incorporation (red star). In the experiment phase the two population are mixed, proteins are 
purified, digested and analysed by MS. (Adapted from Ong S.E. & Mann M., 2007). 
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The SILAC labeling has been successfully applied to a wide variety of studies: 
from protein expression profiling (de Godoy, Olsen et al. 2006) to global PTM analysis 
(Blagoev and Mann 2006), protein-protein and DNA-protein interaction analysis (Blagoev, 
Kratchmarova et al. 2003). 
As further implementation, triple-SILAC setup has been proposed to discriminate 
among three distinct conditions within a single LC-MS/MS analysis. In this labeling 
strategy, a heavy-medium deuterated form of the above-mentioned amino acids are 
employed; as result each peptide is represented by peak-a triplet in MS. Due to its 
versatility, triple-SILAC has been successfully adopted to determine the stimulus specific 
interactions in the Wnt pathway (Hilger and Mann 2012). Triple SILAC was also 
employed in pulsed-SILAC (pSILAC) experiments, to quantitatively profile protein 
translation dynamics (Schwanhausser, Gossen et al. 2009).  
The major limitation of SILAC is that can be applied only to cells growing in 
culture for a sufficient number replications that ensure the complete incorporation of the 
isotope-coded amino acids. A solution is offered by the SILAC spike-in strategy that 
allows the protein quantification of unlabeled samples by using a protein extract from 
SILAC-labeled cells as internal standard (Ishihama, Sato et al. 2005). This strategy has 
been further implemented in the super-SILAC approach that uses a mixture of isotopically 
heavy-labeled cell lines (super SILAC-mix) as internal standard. The super-SILAC mix is 
added as spike-in to samples of various origins, in order to quantify the protein amount 
through the H/L ratio(Geiger, Cox et al. 2010). 
SILAC labeling can also be used to directly label PTMs: the heavy-methyl SILAC 
(hmSILAC) strategy implies the use of methionine-free media to which light- or heavy-
labeled forms of this amino acid are added. In the cell, methionine is converted to S-
adenosyl methionine (SAM), which represents the only donor of methyl groups in 
enzymatic methylation reaction. Proteins that contain methylations are therefore 
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enzymatically light- or heavy-methyl labeled and upon mixture the corresponding peptides 
are identified as a peak pair. The MS analysis allows for the unambiguous identification 
and quantification of in vivo methylated sites (Ong, Blagoev et al. 2002; Bremang, Cuomo 
et al. 2013). 
 
2.4 Screening of hPTM readers by distinct qProteomics approaches 
Histone PTMs are one of the mechanisms to fine-tune gene expression; in particular 
hPTMs function as docking sites for the recruitment of readers that translate a distinct 
modification pattern into a specific biological outcome. Due to their biological relevance, 
an increasing number of quantitative proteomics approaches have been developed to screen 
hPTM readers. These approaches can be classified into two main strategies: those based on 
affinity pull-down screening and those based on the isolation of native chromatin domains.  
The first approach designed for the identification of hPTM readers relied on pull-
down strategies using peptides bearing a certain modification, followed by MS-analysis of 
single bands; in this type of experiment, the specificity was assessed by using unmodified 
peptide as control (Wysocka, Swigut et al. 2005; Wysocka, Swigut et al. 2006). A step 
forward was represented by the SILAC-based peptide pull-down where the labeling allows 
the robust identification and quantification of hPTMs readers (Vermeulen, Mulder et al. 
2007; Vermeulen, Eberl et al. 2010); as alternative the Cross-Linking-Assisted SILAC 
Protein Identification (CLASPI) approach adopts also the photo-cross-linking in order to 
stabilize the more labile interaction between hPTM and binders, to identify low affinity 
readers (Li, Foley et al. 2012). The SILAC Nucleosome Affinity Purification (SNAP) 
approach was developed to study the synergic contribution between DNA methylation and 
hPTMs in promoting the binding of chromatin factors; indeed recombinant nucleosomes 
bearing methylation on H3 residues, on DNA or combination of thereof were used to 
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assess the interplay between these epigenetic marks in recruitment or chromatin binders 
(Bartke, Vermeulen et al. 2010).  
All these in vitro strategies, allow a precise assessment of proteins interacting with a 
specific chromatin modification; however, they suffer from the artificial conditions in 
which interactions are investigated and can address only limited combination of PTMs.  
The second class of approaches includes techniques that try to reproduce more 
physiological conditions, through the proteomic characterization of enriched native 
chromatin regions.  
The first strategy designed to purify a specific chromatin landscape was exploited through 
a DNA sequence-specific enrichment: in the Proteomics of Isolated Chromatin (PICh) 
approach, a nucleic acid probe is employed to isolate telomeric DNA, thus allowing the 
proteomic characterization of determinants and proteins associated to these chromatin 
regions (Dejardin and Kingston 2009). Similarly, the Chromatin Affinity Purification with 
Mass Spectrometry (ChAP-MS) technique allows a more focused analysis of hPTMs and 
proteins associated with a single genomic locus. In this strategy the GAL1 locus was 
engineered in budding yeast, enriched and proteins co-associated were quantified through 
isotope labeling (Byrum, Raman et al. 2012). The implementation of ChAP-MS approach 
relied on the engineering of the transcription activator-like (TAL) protein A (TAL-PrA) in 
order to make amenable to recognize GAL1 promoter. The TAL-PrA was used for the 
affinity purification of the locus followed label-free quantitation of interacting proteins 
(TAL-ChAP-MS) (Byrum, Taverna et al. 2013). 
The enrichment of a specific chromatin region can be alternatively achieved by using a 
specific chromatin determinant as bait for the immunoprecipitation.  
In the Modified ChIP (mChIP) approach Figeys and colleagues endogenously expressed 
TAP-tagged version of histone H2A (Hta2p) and its variant Htz1p in S. cerevisiae. After 
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affinity purification, they were able to reconstruct the network of these chromatin-
associated proteins through identification via LC-MS/MS (Lambert, Mitchell et al. 2009).  
A similar approach is the Chromatin Interacting Protein-Mass Spectrometry (ChIP-MS) 
where male-specific lethal proteins (MSL2 and 3) were expressed as biotin-tagged in vivo 
in D. melanogaster. The streptavidin chromatin enrichment allowed to identify both the 
MSL-enriched hPTMs and to characterize proteins interacting with the MSL complex 
(Wang, Alekseyenko et al. 2013). 
An alternative is represented by the Chromatin Proteomics (ChroP) strategy, which was 
developed by our groups and combines SILAC-based quantitative proteomics together 
with ChIP technique. In this approach cells are first metabolically labeled and cross-linked; 
after that, markers of specific chromatin regions are used as bait in the ChIP, followed by 
SILAC-based quantitative proteomic analysis of the determinants at the enriched 
functional chromatin territories. The ChroP was successfully employed for the 
characterization of hetero-chromatin and eu-chromatin regions using as bait H3K9me3 and 
H3K4me3, respectively (Soldi and Bonaldi 2013). As future perspective, a very interesting 
development would be the dissection of more focused chromatin domains with a proved 
relationship between protein composition and function; in this view, ChroP could be used 
to analyse in-depth the proteomic composition of a very restricted chromatin regions. We 
elaborated on this concept in the work discussed in this thesis, using ChroP to dissect the 
structure of enhancers  
 
2.5 Enhancers’ elements and transcriptional regulation as prototype for 
dynamically regulated biological process 
In biology there is a strong interest in understanding the mechanisms through which 
gene expression is established and fine-tuned at cellular level and specifically orchestrated 
in a time-specific fashion. The fundamental importance of this tight regulation relies on the 
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fact that deregulation of this process often leads to disease, such as cancer. Eukaryotic 
genes’ transcription is a biological process controlled at different steps from transcription 
initiation, elongation, to transcriptional termination. However, most of the regulation is 
believed to occur at the level of transcription initiation. RNA polymerase II transcribed 
genes, are indeed controlled by two families of regulatory elements acting in cis: proximal 
and distal regulatory elements. In the first group we find promoter elements and 
transcription start sites (TSSs), while in the latter category there are enhancers, silencers, 
insulators and locus control regions (LCR), which all contain binding sites for both 
transcription activators and suppressors, to fine tune gene transcription.  
Enhancers are defined as genomic regions approximately few hundreds of base 
pairs long, which are able to increase the transcription of target genes and to regulate the 
transcription in a cell-specific and temporal-specific manner (Banerji, Rusconi et al. 1981): 
in fact, the same promoter can be activated by distinct enhancers in different times or 
tissues, or in response to different stimuli, thus regulating the time-and-space- specific 
gene expression. 
Enhancers are characterised by two main features: first, they function in an orientation-
independent manner relative to the promoter of the target gene. Enhancers are composed of 
clusters of transcription factor binding sites (TFBSs) and the feature of independency of 
orientation only applies to the enhancer as whole, indeed the organization of the TFBSs is 
tightly linked to precise enhancers’ regulation. 
TFs may bind enhancers in different ways: they can be recruited in clusters with no 
apparent protein-protein interaction (PPI) among them (enhanceosome model); 
alternatively, they may first interact with co-factors that promote enhancer binding 
(cooperative model). Otherwise, specific TFs, named pioneer TFs, may compete with 
nucleosomes for the binding to target enhancer regions, thus generating a nucleosome-
depleted region (NDR) which allow the subsequent recruitment of other transcription 
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factors. Pu.1 and AP1 are two examples of pioneer transcription factors able to bind their 
target motives within a closed chromatin environment and to function as cell-specificity 
determinants and master regulators (Heinz, Benner et al. 2010; Serandour, Avner et al. 
2011). 
The second characteristic of enhancers is that they show a long-distance activity; 
indeed, they can be found frequently several hundreds of kilobases from the corresponding 
TSS. Moreover they can be located upstream or downstream to the promoter gene, and 
both in extragenic and intragenic regions. One of the most extreme examples is the 
enhancer of the Sonic hedgehog (Shh) gene, which is located more than 1 Mbp from its 
gene promoter (Lettice, Heaney et al. 2003). Due to this long-distance activity, the key 
question is how enhancers and promoters communicate and synergize to activate the 
transcription of the joint target gene; currently a widely accepted model proposes the 
existence of a chromosomal looping between these two transcriptional regulatory elements 
that allows their physical interaction and thus promotes transcription initiation (Fig. 11).  
 
Fig. 11: Regulatory chromosomal looping.The enhancer region is marked by mono-methylation 
of H3K4 while promoter region is enriched in H3K4me3. The promoter – enhancer 
chromosomal looping is mediated by sequence-specific TFs that -together with the 
mediator complex- stabilize this long-range interaction. Pre-iniziation complex (PIC) and 
positive transcription-elongation factor b (p-TEFb) regulate the transcription initiation and 
elongation of the nascent RNA. Enhancer RNA (eRNA) and other lincRNA) are 
transcribed and may help stabilize these structure, even if their precise function is still 
controversial. (MLL complex: MLL, WDR5, RbBP5, Ash2L). (Adapted from Flynn R.A. 
and Chang H. Y., 2011).  
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The interaction can also involve different components of the basal transcriptional 
machinery, as well as components of the mediator complex that acts as transcriptional co-
activator (Koch, Fenouil et al. 2011). Also the cohesin complex seems to play an important 
role in the stabilization of the bridging between enhancers and promoters. The 
development of new technologies based on chromosome conformation capturing (3C) 
(Dekker, Rippe et al. 2002) and microscopy (Lieberman-Aiden, van Berkum et al. 2009) 
have allowed studying the physical interactions between enhancers and promoters, 
facilitating the understanding on this long-range communication. Interestingly, recent data 
showed that the formation of new enhancer loops precedes the transcription activation in 
the β-globin locus (Krivega, Dale et al. 2014), suggesting the pre-existence of a high-
ordered structure, which is then dynamically remodeled in response to gene activation. 
These findings are in line with earlier data showing the co-localization of genes regulated 
by common TFs in nuclear foci termed “transcription factories” (Schoenfelder, Sexton et 
al. 2010; Razin, Gavrilov et al. 2011), even though with exceptions, since not all the genes 
in these clusters resulted to be active at the same time, which implies that other regulatory 
processes may exist.  
At the molecular level, enhancers were initially defined as genomic regions 
hypersensitive to the DNase digestion due to more open chromatin conformation caused by 
the TFBSs; for this reason, techniques like the micrococcal nuclease (MNase) digestion 
and the formaldehyde-assisted isolation of regulation elements (FAIRE) can be used for 
the identification of these cis-regulatory regions.  
The application of genome-wide strategies has added further knowledge on enhancers’ 
molecular signature and suggested a characteristic enrichment of the mono-methylation of 
lysine 4 of histone H3 in the absence of tri-methylation of the same residue 
(H3K4me1Hi/H3K4me3Low) (Heintzman, Stuart et al. 2007) to these cis-regulatory regions. 
More recently, by using ChIP-based approaches, the repertoire of enhancers has been 
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further subdivided in distinct functional types: active, poised or inactive cis-regulatory 
regions, marked by different and diagnostic hPTMs.  
In recent years a new feature of enhancers has emerged: the presence of 
transcription at these cis-regulatory by RNA polymerase II producing long non-coding 
RNAs, named enhancer RNAs (eRNAs) (De Santa, Barozzi et al. 2010; Heinz, Benner et 
al. 2010; Kim, Hemberg et al. 2010). Many of these eRNAs are short, bidirectional, lack a 
poly-A tail and are present at very low copy number in the cell. The function of these non-
coding transcripts is still not completely understood; in the past different models have been 
proposed to explain their activity, in line with that of other non-coding RNAs (lncRNAs).  
 
 
Fig. 12: Dynamics of chromatin determinants at enhancers.The collaborative binding of pioneer 
TFs and lineage-determining TFs (LDTFs) to closed chromatin (1) determine nucleosome 
remodeling and increased chromatin accessibility (2). This binding triggers mono-
methylation of K4 of histone H3 (H3K4me1, blue circle) and the recruitment of RNA 
polymerase II (3). Upon stimulation, signal-dependent TFs (SDTFs) bind to recognition 
sequence at enhancers and recruit co-activator complexes leading to further epigenetic 
modifications (histone acetylation, red cicles) and eventually activation of transcription at 
enhancers (eRNA). (Adapted from Lam M. T. Y., et al 2014). 
LncRNAs have in fact been proposed to act as decoy molecules, by binding and 
displacing TFs or repressor from their target DNA region; alternatively they can play a role 
as scaffold by tethering together proteins in a complex. A third model proposes a bridging 
function between proteins and DNA, which favors the recruitment of specific factors to the 
DNA. Finally, a fourth hypothesis is a structural model where, they can bind and stabilize 
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the chromosomal looping 3D structures. In addition to all above-mentioned models that 
apply to lncRNAs in general and could be hypothesized to work also for eRNAs, these 
specific set of transcripts may contribute to gene expression regulation in a time- and cell-
specific manner (Fig. 12). 
Gene expression regulation plays crucial roles in different biological processes 
from the control of cell differentiation during embryonic development, to response to 
external stimuli. This tight regulation is achieved through the interplay among different 
chromatin determinants that modify enhancers’ structure and composition to enforce 
specific transcriptional programs (Fig. 13). 
In embryonic stem (ES) cells enhancers can be divided in three classes based on 
their functional state: poised, active and inactive. The first group is composed of enhancers 
of genes not actively transcribed but with the potential to be. They are marked by the 
enrichment of H3K4me1 and tri-methylation of lysine 27 of histone H3 (H3K27me3), 
together with the presence of polycomb repressive complex 2 (PRC2), Brg1 protein (also 
known as Smarca4), p300 and the RNA polymerase II elongation factor ELL3. During 
differentiation, the poised enhancers of newly expressed genes become active; the active 
state is characterized by the loss of PRC2 and H3K27me3, paralleled by the gain of 
acetylation of H3K27 (H3K27Ac) (Creyghton, Cheng et al. 2010; Rada-Iglesias, Bajpai et 
al. 2011). Pluripotency genes get instead inactivated during differentiation; this inactive 
state is features by the loss of all enhancers’ hallmarks except for the ELL3 which is 
retained (Fig. 13).  
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Fig. 13: Hallmarks of enhancers of ES and macrophages cells at different developmental stages. In 
embryonic stem (ES) cells enhancer regions in a poised state are marked by the presence of 
the four DNA binding protein (ELL3, BRG1, p300 and PRC2) and two hPTMs (H3K4me1 
and H3K27me3). Upon activation enhancers acquire H3K27Ac and loose both PRC2 and 
H3K27me3; while one inactivated lose all the enhancer determinants but ELL3. In 
macrophages inactive enhancers are marked by H3K4me1 and Pu.1; active enhancers 
acquire H3K27Ac and p300 while the latent enhancers seems to not express any 
determinant (Adapted from Plank J. L. and Dean A., 2014)  
Gene expression is dynamically regulated in a very plastic fashion also in fully 
differentiated cells, like the macrophages. In response to inflammatory stimuli 
macrophages undergo a global gene expression reorganization, which included the 
activation of genes coding from effectors of the inflammatory response and the parallel 
inactivation of other sets of genes, for example the ones coding for proteins involved in 
proliferation.  
Hallmarks of macrophages’ enhancers are high H3K4me1/H3K4me3 ratio and enrichment 
of the master regulator pioneer TF Pu.1 (Fig. 13), which is constitutively expressed at high 
levels to induce and maintain the differentiated state. This TF binds almost all the genomic 
enhancer regions associated with H3K4me1 (about 35.000 – 40.000 genomic sites) 
(Ghisletti, Barozzi et al. 2010; Heinz, Benner et al. 2010) and is important for the local 
deposition of this mark.  
Macrophages can be stimulated in vitro by lipopolysaccharide (LPS) to a pro-inflammatory 
commitment state (M1 macrophages). LPS is a constituent of the outer membrane of gram-
negative bacteria and it stimulates a strong immune response in immune-competent cells, 
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indeed upon LPS treatment, enhancers of inflammatory genes rapidly acquire the histone 
acetyl-transferase p300 that mediates H3K27 acetylation (Creyghton, Cheng et al. 2010) 
and other stimulus-specific TFs. 
Recently a new class of enhancers has been characterized in macrophages, the so-
called “latent enhancers”. They correspond to a very minor fraction of the total and do not 
display the classical markers of all other macrophage enhancers, at basal conditions. Only 
upon inflammation they acquire Pu.1, H3K4me1 and H3K27Ac, which promote a 
chromatin conformation prone to the transcriptional activation of target genes (Ostuni, 
Piccolo et al. 2013) (Fig13). 
All these evidences suggest that there is a strong link between the enhancers’ 
composition in term of both binding proteins and hPTMs and their functional state.  
However, in spite of this limited set of determinants well-characterised, many more 
molecular hallmarks remain to be identified; thus a more comprehensive dissection of 
these cis-regulatory regions will allow for a better understanding of the mechanism through 
which gene expression is regulated in time and space. 
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AIM OF THE WORK 
Chromatin architecture is dynamically regulated by associated proteins and 
histones and DNA modifications that synergize to create distinct “chromatin landscapes”, 
with regulatory effects on the functional state of the underlying genes.  
In recent years a number of MS-proteomics approaches have been developed to 
study the protein composition of physically or functionally distinct chromatin regions. In 
particular, our laboratory optimized the Chromatin Proteomics (ChroP) approach (Soldi, 
2013), which combines chromatin immunoprecipitation (ChIP) and SILAC-based 
proteomics for the characterization of both protein binders and modifications specifically 
clustering at distinct chromatin regions. 
The aim of my PhD project was to implement the pre-existing protocol into a new 
version of the ChroP method, which was used to study a more restricted chromatin region 
namely enhancers. I decided to focus on these cis-regulatory regions because they are 
characterized by a strong link between their molecular composition and the functional state 
of the corresponding target genes. Furthermore, while the definition of the molecular 
signature enabling large-scale identification of enhancers is an appealing goal, their 
characterization is largely unexplored. 
Based on these considerations, we reasoned that ChroP approach could provide a valid 
analytical tool to expand the knowledge on their molecular composition and the 
consequent mechanism of regulation. To this aim, I worked to adapt ChroP strategy to the 
different model system under investigation and to better answer new open questions. As 
such, I employed a different cell line (RAW 264.7 macrophage-like cell line), I optimized 
the protocol to use a transcription factor that directly binds to nucleosome–free regions 
(NFR) as bait in the preparative ChIP and performed temporal analysis of the enhancers’ 
chromatome by coupling ChroP with triple-SILAC labelling. Results are illustrated in the 
following sections.
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MATERIALS AND METHODS  
4.1 General biochemistry and molecular biology buffers  
1. Phosphate-Buffered Saline (PBS), pH 7.4:  
137 mM NaCl  
2.7 mM KCl  
8.1 mM Na
2
HPO
4
(7H
2
O)  
1.76 mM KH
2
PO
4 
 
 
2. Tris-Buffered Saline (TBS):  
150 mM NaCl  
2.7 mM KCl  
25 mM Tris base  
 
3. Tris-Buffered Saline (TBS)-Tween:  
150 mM NaCl  
2.7 mM KCl  
25 mM Tris base  
0.1% Tween 20 
 
4. Tris-EDTA (TE): 
10 mM Tris-HCl pH 8.0 
1 mM EDTA pH 8.0  
 
5. Tris-Acetate-EDTA (TAE): 
40 mM Tris acetate  
1 mM EDTA pH 8.0  
 
6. RIPA lysis buffer 
20 mM Tris-HCl (pH 7.5) 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1% NP-40 
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1% sodium deoxycholate 
7. Urea lysis buffer:  
20 mM Hepes, pH 7.5  
8 M Urea  
 
8. Running gel mix (1 gel at 12%):  
Acrilamide/Bis-acrylamide solution 30: 0.8 ratio (2.52 mL and 3.48mL for 17.5% 12% 
gel)  
Tris-HCl, pH 8.8 (1.5 mL)  
ddH
2
O (1.92 mL)  
SDS 10% (60 μL)  
APS 10% (60 μL)  
TEMED (3 μL)  
 
9. Stacking gel mix (1 gel):  
Acrilamide/Bis-acrylamide stock solution - 30: 0.8 ratio at 30% (0.52 mL)  
Tris-HCl, pH 6.8 (1.25 mL)  
ddH
2
O (3.10 mL)  
SDS 10% (50 μL)  
APS 10% (50 μL)  
TEMED (5 μL)  
 
10. Laemmli loading buffer (5X): 
100mM Tris-HCl pH 6.8 
20% Glycerol  
2% SDS 
5% β-mercaptoethanol 
 
11. LDS sample loading buffer (1X):  
10% Glycerol  
1% Lithium dodecyl sulfate (LDS)  
1% Ficoll-400  
0.2 M Triethanolamine-Cl pH 7.6  
0.00625% Coomassie G250  
0.5 mM EDTA disodium  
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12. SDS-PAGE running buffer:  
192 mM Glycine  
25 mM Tris base  
2% SDS  
 
13. NuPAGE ® MES SDS running buffer:  
50mM 2-(N-morpholino) ethanesulfonic acid (MES) 
50 mM Tris base  
0.1% SDS  
1mM EDTA 
 
14. Fixing gel solution:  
50% Methanol  
10% Acetic acid  
 
15. Coomassie staining gel solution 
2.5g Coomassie brilliant blue R/250  
10% Acetic acid 
50% Methanol 
 
16. Colloidal Blue Coomassie Staining gel solution (Invitrogen Kit):  
20% Methanol  
20% Stainer A (Colloidal Blue Stain Invitrogen Kit)  
5% Stainer B (Colloidal Blue Stain Invitrogen Kit)  
17. Western blot transfer buffer:  
25 mM Tris base  
192 mM Glycine  
20% Methanol  
 
18. Western blot Stripping buffer:  
62.5 mM Tris-HCl, pH 7.6  
2% SDS  
100 mM β-mercaptoethanol  
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19. HEPES-buffered solution (HBS) pH 7.4 
25mM HEPES 
145 mM NaCl 
1.25 mM CaCl2 
2.6 mM KCl 
1.2 mM MgCl2 
1.2 mM KH2PO4 
 
4.2 Cell Culture, SILAC and triple-SILAC labeling of cells 
RAW 264.7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS, Invitrogen 10270-
106), 2mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin and cultured at 
37°C in a 5% CO2 humidified atmosphere.  
SILAC-labeled RAW 264.7 cells were grown in “Light”,  “Medium” and “Heavy” SILAC 
media prepared supplementing SILAC DMEM (EuroClone B7511L), depleted of lysine 
and arginine, with 10% dialyzed FBS (Invitrogen, 26400-044) and isotope encoded amino 
acid with different stable isotopes composition More specifically: Light isotope-coded 
medium contains 12C614N2 L-lysine (Lys 0, Sigma L8662) and 12C614N4 L-arginine (Arg 0, 
Sigma A6969); 12C614N2-d4 L-lysine (Lys 4, Sigma 616192) and 13C614N4 L-arginine (Arg 
6, Sigma 643440) were added to the medium isotope-coded medium; while Heavy medium 
is supplemented by 13C615N2 L-lysine (Lys 8, Sigma 68041) and 13C615N4 L-arginine 
(Arg10, Sigma 608033) always at a concentration of 146 mg/L and 84 mg/L, respectively. 
RAW 264.7 cells were grown in SILAC media for 8 generations at 37°C in a 5% CO2 
humidified atmosphere. Careful monitoring of growth rate, viability and overall 
morphology demonstrated no alteration from physiology compared to cells cultured in 
standard medium. 
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Cells were eventually frozen in freezing solution at 5x106 cells/mL in cryovials, let for o.n. 
at -80°C in isopropanol cryobox and then stored in liquid nitrogen.  
Freezing solution: 10% DMSO 
90% FBS serum (Invitrogen 10270-106 or Invitrogen, 26400-044 for 
unlabeled or SILAC labeled cells, respectively) 
 
4.3 Bone marrow-derived macrophages in vitro differentiation 
Bone marrow (BM) cells were isolated from either Fvb/Hsd (C57BL/6-129P2) mice. Red 
blood cells were lysed by osmotic shock (1 min in 2 ml NaCl 0.2% followed by addition of 
the same volume of NaCl 1.6% to reconstitute the physiological osmotic pressure). BM 
cells were then washed twice in cold PBS, resuspended in BM medium and plated 3x106 
cells in 5.5 ml of BM-Medium per 100 mm petri dish. Differentiating cells were harvested 
at day 7-8 of differentiation (or as otherwise stated). 
BM medium: DMEM supplemented with 30% L929-conditioned medium, 20% FBS, 2 
mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.5% sodium 
pyruvate, 0.1% β-mercaptoethanol 
 
4.4 Cell treatment with lypopolysaccharides 
Lypopolysaccharide treatment has been performed by direct injection in the medium of 
100ng/mL of LPS from E. coli serotype 055:B5 (Sigma) for the 1h or 4hrs. 
 
4.5 Cross-linking Chromatin immunoprecipitation (X-ChroP)  
X-ChroP protocol applied to this cell line was very similar to the recently published one 
(Soldi and Bonaldi 2013), with minor modifications regarding cross-linking conditions and 
antibody concetration.  SILAC-labelled RAW 264.7 cells were harvested and cross-linked 
in 1.5% formaldehyde for 10 min at room temperature (RT) on the orbital shaker in order 
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to stabilize protein-DNA and protein-protein interactions. Formaldehyde was quenched 
adding 125 mM Tris-HCl pH 7.6 for 5 min. After three washes with cold PBS, cells were 
suspended in Lysis Buffer1 (see above) for 10 min at 4°C. After centrifugation the nuclear 
pellets were washed once with Washing Buffer and then re-suspended in ChIP Incubation 
Buffer. Chromatin from nuclei was sonicated for 20 cycles (30 sec “on” and 1 min “off”) 
in a cooled water bath sonicator Bioruptor UCD 300 plus (Diagenode). After sonication, 
1% of Triton-100 was added to sonicated chromatin to pellet debris. Nucleosomes were 
solubilized through centrifugation at 13000 rpm for 10 minutes at 4°C, soluble fraction 
was then immunoprecipitated by adding 20 μg of the H3K4me1 (AbCam 8895) or Pu.1 
(sc-352 X) antibody. The reaction was carried out overnight on a rotating wheel. In 
parallel, 200 μl of G protein-coupled magnetic beads (Dynabeads, Invitrogen 100.04D) for 
each sample, were blocked in BSA 0.5% PBS for an overnight. Blocked beads were 
washed and added to chromatin and incubated for 3 h at 4°C on the wheel. Beads were 
washed with 20 mM Tris-HCl pH 7.6, 2 mM EDTA, 0.1% SDS, 1% Triton-100 and 
increasing NaCl concentration (150 and 300 mM). To reverse the crosslinking and elute 
the immunoprecipitated proteins, SDS-PAGE sample buffer (250 mM Tri-HCl pH 8.8, 
0.5M β-mercaptoethanol, 2% SDS) was added to the beads for 25 min at 95 °C. Proteins 
were resolved on 4-12% Bis-Tris acrylamide SDS-PAGE pre-cast gradient gels Invitrogen 
system and visualized by Colloidal Comassie staining kit (Invitrogen). 
Buffers for X-ChIP:  
1. Lysis Buffer1: 50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% 
glycerol, 0.5% NP-40, 0.25% Triton-100, 0.5 mM PMSF, 5 mM NaF, 5 
mM Na
3
VO
4
, 5mM NaButyrate, 5 mg/ml Aprotinin, 5 mg/ml Pepstatin 
A, 5 mg/ml Leupeptin.  
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2. Washing Buffer: 10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 
0.5 mM PMSF, 5 mM NaF, 5 mM Na
3
VO
4
, 5mM NaButyrate, 5 mg/ml 
Aprotinin, 5 mg/ml Pepstatin A, 5 mg/ml Leupeptin.  
3. ChIP Incubation Buffer: 10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.1% sodium deoxycholate, 0.5% sodium 
lauroylsarcoside, 0.5 mM PMSF, 5 mM NAF, 5 mM Na
3
VO
4
, 
5mM NaButyrate, 5 mg/ml Aprotinin, 5 mg/ml Pepstatin A, 5 
mg/ml Leupeptin.  
 
4.6 Native Chromatin immunoprecipitation (N-ChroP) 
4.6.1 Native chromatin immunoprecipitation (N-ChIP) followed by MNase digestion 
Eighty millions RAW 264.7 cells were homogenized in Lysis Buffer2 and nuclei were 
separated from cytoplasm, by centrifugation at 3750 rpm (4°C) for 30 minutes, putting 
cellular lysate on sucrose cushions. Nuclear pellets were washed in PBS, re-suspended in 
Digestion Buffer and digested with micrococcal nuclease (MNase, Roche) at a final 
concentration of 0.005 U/ml, at 37 °C for 70 minutes. The reaction was stopped by adding 
1 mM EDTA and chilling on ice. The soluble fraction of chromatin (S1), enriched in 
mono-nucleosomes, was collected as the supernatant obtained after centrifugation of re-
suspended nuclei at 10000 rpm (4 °C) for 10 minutes. DNA extracted by Qiaquick 
columns (QIAGEN) was run on 1% agarose gel to evaluate fractions of chromatin. The S1 
fraction was used as input for the immunoprecipitation with 10 μg of H3K4me1 (AbCam 
8895). Antibody was incubated overnight with chromatin; in parallel, 100 μl of G protein-
coupled magnetic beads (Dynabeads, Invitrogen 100.04D) were blocked in BSA 0.5% PBS 
for an overnight. Blocked beads were washed and added to chromatin and incubated for 3 
h at 4°C on a rotating wheel. Beads were washed four times (50 mM Tris-HCl pH 7.6, 10 
mM EDTA) at increasing salt concentration (75, 125 and 175 mM NaCl). LDS Sample 
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Buffer (InvitrogenNP0007) supplemented with 50 mM DTT was added to the beads for 5 
min at 70 °C to elute the immunoprecipitated proteins from the beads. Proteins were 
resolved on 4-12% Bis-Tris acrylamide SDS-PAGE pre-cast gels (Invitrogen 
NP0335BOX) on an Invitrogen system and visualized on the gel using Colloidal Comassie 
staining Kit (Invitrogen LC6025).  
Buffers for N-ChIP:  
1. Lysis Buffer2: 0.32 M saccharose, 0.5 mM EGTA pH 8.0, 15 mM NaCl, 60 mM KCl, 15 
mM HEPES, 0.5% Triton, 0.5 mM PMSF, 1 mM DTT, 5 mM NaF, 5 mM 
Na
3
VO
4
, 5mM Na-butyrate, 5 mg/ml Aprotinin, 5 mg/ml Pepstatin A, 5 
mg/ml Leupeptin.  
2. Digestion Buffer: 0.32 M saccharose, 50 mM Tris-HCl pH 7.6, 4 mM MgCl
2
, 1 mM 
CaCl
2
, 0.1 mM PMSF.  
3. Dialysis Buffer: 10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.5 mM PMSF, 5 mM NaF, 5 
mM Na
3
VO
4
, 5mM NaButyrate and protease inhibitors cocktail 
(complete EDTA-free, Roche, Cat. No. 11 873 580 001).  
 
4.6.2 Cross-linked chromatin immunoprecipitation (X-ChIP) followed by MNase digestion 
and sonication to use a transcription factor as bait in ChroP experiment 
 Chromatin was first fixed with formaldehyde at a final concentration of 0.75% on 
an orbital shaker, the reaction was then quenched by adding 125 mM Tris-HCl pH 7.6 for 5 
min. Cells were washed twice with cold PBS and centrifuged at 1000 rpm for 5min. Pellet 
from one hundred million cells was first resuspended in 5 mL of Buffer A, then one 
volume of Lysis buffer3 was added and the sample was put in ice for 5 min. After 
centrifugation the nuclear pellet was washed with 10mL of buffer B to remove any residual 
detergent, then resuspended into 500 uL of MNase digestion buffer and digested with 6 U 
MNase (Roche, Catalog No. 10107921001) for about 1h at 37 °C in order to obtain a 
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fraction enriched in mono-nucleosomes. Reaction was stopped with 50 mM EDTA, DNA 
was than de-crosslinked at 65 °C for some hours and loaded onto 1% agarose gel. Three 
mL of lysis buffer 4 were added to the lysate and 1.5mL aliquots of the input were 
sonicated for 3 pulses (30 sec “on” and 1 min “off”) in a cooled water bath sonicator 
Bioruptor UCD 300 plus (Diagenode) to break the nuclei. NP-40 1% final was added and 
the sample was then pelleted at 13000 rpm for 10 min. The supernatant was then used as 
input for the immunoprecipitation with Pu.1 antibody (sc-352 X); the reaction was carried 
out overnight as already described for X-ChroP. Blocked beads were washed and added to 
chromatin and incubated for 3 h at 4°C on the wheel. Beads were washed with 20 mM 
Tris-HCl pH 7.6, 2 mM EDTA, 0.1% SDS, 1% NP40 and increasing NaCl concentration 
(150 and 300 mM). Protein decrosslinking - likewise the elution of immunoprecipitated 
proteins, the SDS-PAGE separation and the Coomassie staining of the gel, were carried out 
similarly as for X-ChroP (see paragraph 4.5). 
 
Buffers for X-ChIP + MNase and sonication:  
1.Buffer A: 15 mM NaCl, 15 mM Tris-HCl pH 7.6, 60 mM KCl, 2 mM EDTA, 0.5 mM 
EGTA, 300 mM saccharose, 1 mM DTT, 0.2 mM spermine, 1 mM 
spermidine, 0.5 mM PMSF. 
2. Lysis buffer3: 15 mM NaCl, 15 mM Tris-HCl pH 7.6, 60 mM KCl, 2 mM EDTA, 0.5 
mM EGTA, 300 mM saccharose, 0.4% NP40, 1 mM DTT, 0.2 mM 
spermine, 1 mM spermidine, 0.5 mM PMSF. 
3. Buffer B: 15 mM NaCl, 15 mM Tris-HCl pH 7.6, 60 mM KCl, 300 mM saccharose, 1 
mM DTT, 0.2 mM spermine, 1 mM spermidine, 0.5 mM PMSF. 
4. MNase digestion buffer: 20 mM Tris-HCl pH 7.6, 5 mM CaCl2, 1 mM DTT, 0.2 mM 
spermine, 1 mM spermidine, 0.5 mM PMSF. 
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5. Lysis Buffer 4 : 10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 
0.1% Na-deoxycholate, 0.5% Na-laurylsarcosine, 1 mM DTT, 0.2 mM 
spermine, 1 mM spermidine, 0.5 mM PMSF. 
 
4.7 Protein co-immunoprecipitation from nuclear soluble extract 
RAW cells were collected, washed twice with cold PBS 1% and resuspended in Lysis 
buffer5. After 5 min on ice and centrifugation the pellet was re-suspended into a Nucleosol 
extraction buffer. The supernatant was diluted to decrease NaCl concentration for the 
subsequent immunoprecipitation. After overnight incubation of the antibody with the 
nuclear extract, 100 μl of G protein-coupled magnetic beads (Dynabeads, Invitrogen 
100.04D), previously blocked with BSA 0.5% in PBS and washed three times with PBS 
were added and incubated for 3h on a rotating wheel at 4°C. After incubation, beads were 
pelleted, washed for four times (50 mM Tris-HCl pH 7.6, 10 mM EDTA) at increasing salt 
concentration (75, 125 and 175 mM NaCl) and finally incubated with LSD Sample Buffer 
-supplemented with 50 mM DTT- for elution of the co-immunoprecipitated proteins, which 
were then either resolved on a 4-12% Bis-Tris acrylamide SDS-PAGE pre-cast gel and 
visualized with Colloidal Coomassie staining Kit, or loaded on hand-made linear SDS-
PAGE gels for western blot immunodetection. 
Lysis buffer5: 2 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 0.1% NP-40 and 10% 
glycerol).  
Nucleosol extraction buffer: 250 mM NaCl, 0.2 % NP-40, 50 mM Tris-HCl, 0.5 mM 
EGTA and 0.5 mM EDTA 
 
4.8 In-gel chemical alkylation and digestion of histones prior to MS analysis  
This protocol was specifically modified in order to maximize histone protein coverage and 
hPTMs detection (Bonaldi, Imhof et al. 2004, Soldi and Bonaldi 2013). 
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Bands corresponding to the core histones were excised from the gel, de-stained with 
repeated washes in 50% acetonitrile (ACN) in ddH2O, alternated with dehydration steps in 
100% ACN. Gel pieces were in-gel chemically alkylated as previously described, by 
incubation with D
6
-acetic anhydride (Sigma 175641) 1:9 in 1 M NH
4
HCO
3 
and 
CH
3
COONa solution as catalyzer (Bonaldi, Imhof et al. 2004). After 3h at 37 °C with 
strong shaking in a thermo mixer, gel slices were washed with buffer at increasing ACN 
concentration (50% and 100% ACN in water). In-gel digestion was performed with 100 
ng/μl trypsin (Promega V5113) in 50 mM NH
4
HCO
3 
at 37 °C overnight; the alkylation of 
lysine residues in combination with trypsin digestion generates an “in-gel” ArgC-like 
digestion because the enzyme will cleave only at the amide bond C-terminal of arginine 
residues. This digestion produces histone peptides with optimal length for MS analysis. 
Digested peptides were extracted, desalted and concentrated using a combination of 
reverse-phase C18/Carbon “sandwich” system and strong cation exchange (SCX) 
chromatography, on hand-made nano-columns (StageTips) (Rappsilber, Mann et al. 2007): 
digested peptides loaded on C
18
/C and SCX StageTips were then eluted with high organic 
solvent (80% ACN) and NH
4
OH, respectively. Eluted peptides were lyophilized, re-
suspended in 0.1% TFA in ddH2O, pooled and subjected to LC-MS/MS.  
 
4.9 Standard protein in-gel digestion for MS-based protein identification 
Processing of gel-separated proteins prior MS analysis was carried out as previously 
described, with minor modifications (Shevchenko, Tomas et al. 2006). About ten gel slices 
per lane were cut from gel and de-stained in 50% v/v acetonitrile (ACN)/50 mM 
NH
4
HCO
3
. Cysteine residues were reduced with 10 mM DTT in 50 mM NH
4
HCO
3
 and 
were alkylated with 55 mM iodoacetamide in 50 mM NH
4
HCO
3
 to avoid disulphide bond 
formation. Proteins were subjected to in-gel digestion with 12.5 ng/μL trypsin (Promega 
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V5113) in 50mM NH
4
HCO
3
 for overnight at 37 °C. Digested peptide were first extracted 
from the gel with 3% TFA, 30% ACN and finally with 100% ACN; peptides were then 
lyophilized, desalted and concentrated on C
18 
Stage Tips (Rappsilber, Mann et al. 2007). 
Samples were loaded in 1% TFA and 5% ACN and eluted with high organic solvent (80% 
ACN). Eluted peptides were lyophilized, re-suspended in 0.1 % TFA in ddH2O and 
subjected to LC-MS/MS analysis.  
 
4.10 Nano Liquid Chromatography and Tandem Mass Spectrometry  
Two different methods were adopted for either proteome analysis of protein interactors or 
for the MS-analysis of histone peptides, indeed the latter takes into account the peculiar 
chemical-physical properties of these proteins such as the basic composition of the 
peptides. To this aim different gradients were employed in the run. 
Peptide mixtures were analyzed by online nano-flow liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using an EASY-nLC™ 1000 (Thermo Fisher Scientic, Odense, 
Denmark) connected to a Q Exactive (Thermo Fisher Scientific) through a nano 
electrospray ion source. For nUHPLC, the nano LC system was operated in one column 
set-up with a 25 cm analytical column (75 μm inner diameter, 350 μm outer diameter) 
packed with C18 resin (ReproSil, Pur C18AQ 1.9 μm, Dr.Maisch, Germany) configuration.  
For the analysis of peptides from interactome studies solvent A was 0.1% FA, 2% ACN in 
ddH2O and solvent B was 80% ACN with 0.1% FA. Samples were injected in an aqueous 
1% TFA solution at a flow rate of 500 nl/min and they were separated with a gradient of 5-
30% solvent B over 90 min followed by a gradient of 30-60% in 5 min and 60-95% over 5 
min at a flow rate of 250 nl/min in the EASY-nLC 1000 system.  
For the analysis of histone peptide the solvent A was 0.1% FA in ddH2O and solvent B was 
80% ACN with 0.1% FA. These samples were injected in an aqueous 1% TFA solution at 
a flow rate of 500 nl/min and they were separated with a gradient of 0-40% solvent B over 
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100 min followed by a gradient of 40-60% in 5 min and 60-95% over 5 min at a flow rate 
of 250 nl/min in the EASY-nLC 1000 system.  
The Q Exactive instrument was operated in the data-dependent mode (DDA) to 
automatically switch between full scan MS and MSMS acquisition. Survey full scan MS 
spectra (from m/z 300-1150) were analysed in the Orbitrap detector with resolution 
R=35,000 at m/z 400. The ten most intense peptide ions with charge states ≥2 were 
sequentially isolated to a target value of 3e6 and fragmented by Higher Energy Collision 
Dissociation (HCD) with a normalized collision energy setting of 25%. The maximum 
allowed ion accumulation times were 20 ms for full scans and 50 ms for MSMS while the 
target value for MSMS was set to 1e6. The dynamic exclusion time was set to 20s. 
Standard ESI conditions for all experiments were: spray voltage, 2.4 kV; no sheath and 
auxiliary gas flow. 
 
4.11 Analysis of Mass Spectrometric data  
Acquired Raw data were analyzed by the integrated MaxQuant software v.1.3.0.5, using 
the integrated Andromeda search engine (Cox, Neuhauser et al. 2011). This software was 
designed for the analysis of experiments performed in SILAC, therefore was optimized for 
the quantification SILAC pairs. The MOUSE 1401 database (51195 entries) was used for 
peptide identification. Enzyme specificity was set to Arg-C for in-gel chemical alkylation 
followed by trypsin digestion (“Arg-C-like” mode), while for the interactome studies we 
set trypsin as enzyme which cleaves at the C-terminus of lysine and arginine residues 
unless they are followed by proline residue. In MaxQuant, we fixed the estimated false 
discovery rate (FDR) of all peptide identifications at a maximum of 1%. The main search 
was performed with a mass tolerance of 6 ppm. A maximum of 3 missed cleavages were 
permitted, and the minimum peptide length was fixed at 6 amino acids.  
 
Material and Methods 
 
 
50 
4.11.1 Identification and quantitation of hPTMs 
In the search, variable modifications included: lysine D3-acetylation (+45.0294 Da), lysine 
mono-methylation (+59.045 Da) from the sum of D3-acetylation mass (+45.0294) plus the 
mass of mono-methylation (+14.016 Da)], arginine mono-methylation (+14.016 Da), 
lysine and arginine di-methylation (+28.031 Da), lysine tri-methylation (+42.046 Da), 
lysine acetylation (+42.010 Da), lysine crotonylation (+68.026 Da) and lysine 
ubiquitination (+118.127 Da or +383.228 Da). MaxQuant search results were exported and 
peptides with Andromeda score less than 60 or localization probability score less than 0.75 
were removed, as identified with low-confidence.  
MaxQuant is not an unbiased search tool as the user selects a set of PTMs of interest prior 
to employ the bioinformatic tool for peptide and protein ID. This option is applied during 
the sequence database search, when PTMs are assigned to the relevant amino acid of a 
candidate peptide sequence. Histones are characterized the co-occurrence of different 
modifications on the same peptide, but the increase of the number of modifications in the 
search enhances the complexity of the search itself; for this reason for very large datasets 
the search has to be restricted to a limited number of PTM. In our searches we used a 
maximum of five different modifications in each search and we run different MaxQuant 
jobs in parallel in order to cover theoretically all the possible different combinations among 
them. For peptides form ArgC-like digestion, we applied as constant modification the D3-
acetylation on lysine residues in every MaxQuant job.  
Filtered data were subjected to manual inspection and validation using QualBrowser 
version 2.0.7 (ThermoFisher Scientific) where theoretical mass of a specific modification 
and its MS profile are used to reconstruct the eXtracted Ion Chromatogram (XIC), while 
MS/MS spectrum is used for the robust identification and the assignment of the 
modification. XICs were constructed for each precursor based on the m/z value, using a 
mass tolerance 10 ppm and a mass precision up to 4 decimals. Histone PTMs were first 
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quantified by calculating the area under the curve (AUC) of each peak corresponding to 
every specific modified peptide. Then, their relative abundance was estimated by dividing 
the area under the curve (AUC) of each peptide by the sum of the areas corresponding to 
all observed modified forms of that peptide, in percentage as already described in (Jung, 
Pasini et al. 2010, Soldi and Bonaldi 2013). For the same modifications, we also calculated 
the relative enrichment as the ratio between the relative abundance of the same 
modification in the ChIP and in the corresponding chromatin input. 
 
4.11.2 Visualization of hPTMs 
hPTMs in basal state we represented through barr charts where we divided the analysis in 
H3, H4 and H2A peptides generated upon ArgC-like digestion. We expressed the log2 of 
the relative enrichment for all the modifications robustly identified on the same peptide.  
Visualization of hPTMs clustering was performed using Perseus program 
(http://www.perseus-framework.org/). Here we represented in a heat map the log2 value of 
the different hPTMs robustly identified in the histone H3 and H4 peptides ordered 
according to peptide and histone they belong to. Maximum and minimum relative 
enrichment values are used as extremes in the colour code. 
 
4.12 Analysis of SILAC data for interactome and dynamic study  
Carbamidomethylation of cysteine was selected as a fixed modification whereas oxidation 
of methionine, and acetylation of protein N-terminus were included as variable 
modifications. The modifications corresponding to arginine and lysine labeled with heavy 
and medium stable isotopes were treated as fixed modifications in the Andromeda search. 
Additional peptides were identified by "the match between run" option in MaxQuant, 
which matches precursor masses in a 2-min retention time window (after realignment of 
the runs) based on the accurate mass measurement. Proteins were accepted if identified 
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both in forward and reverse experiments with two peptides, at least one of which unique. 
For the quantification, were accepted proteins with at least 1 ratio count (RC>0) in forward 
and reverse experiments. Proteins that pass these filtering criteria in both H3K4me1 and 
Pu.1 ChIPs were subjected to statistical analysis and visualization using the open-source 
software package R and Perseus software (http://www.perseus-framework.org/). Based on 
the SILAC ratio distribution generated through R-script, we defined the statistical 
threshold to distinguish between real binders and background proteins for forward and 
reverse experiments; the two dataset were then visualized in a scatter plot (H/L ratio and 
L/H ratio for forward and reverse experiment, respectively) where we identified as specific 
binders only those proteins significantly enriched in both experiments (tops) that are 
represented in the upper right quadrant. To define the genuine enhancers’ binders we 
intersect the tops subset of proteins from H3K4me1 and Pu.1.  
For the dynamic analysis we generate SILAC ratio distribution plot for every time point 
(1hr/UT, 4hr/UT) and for both the experiments (forward and reverse) performed with the 
two baits, namely H3K4me1 and Pu.1. For all these ratio distributions we build a 
theoretical distribution of 90% of the entire set which correspond to proteins that are 
supposed to do not change upon the stimulus. We calculated the standard deviations (s.d.) 
of these 90% distributions e we applied them to the corresponding entire datasets to define 
proteins recruited (SILAC ratio > +s.d.) or evicted (SILAC ratio <- s.d.) in that specific 
time point. We profiled in time the list of genuine enhancers’ determinants and we defined 
as recruited or evicted only those proteins that showed that specific trend in at least 3 out 
of 4 dataset (H3K4me1 forward, H3K4me1 reverse, Pu.1 forward, Pu.1 reverse) thus 
taking into account different kinetics of recruitment of eviction between the two baits used 
in the ChIP. 
The list of newly recruited proteins at enhancers is composed of proteins showing a 
positive trend in at least 3 out of 4 abovementioned datasets taking into account different 
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kinetics of recruitment between H3K4me1 and Pu.1. 
 
4.13 Quantitative RT-PCR of immunopurified DNA  
DNA from ChIP-ed material was eluted in TE (Tris-HCl pH 7.5, EDTA) containing 2% 
SDS for 15minutes at 65°C (for X-ChIP experiments DNA was also de-crosslinked at 
65°C overnight) and DNA was then purified through Qiaquick columns (QIAGEN). 1μl of 
purified DNA was used for substrate for amplification on Applied Biosystems 7500 Fast 
Real-time PCR system applying Biosystem Sybr-green.  
 
4.14 RNA extraction and cDNA synthesis 
Total RNA was extracted using RNeasy kit (Qiagen), according to manufacturer 
instruction. RNA was quantified by ND-1000 spectrophotometer (NanoDrop 
Technologies) and its quality was assessed by measuring A260/A280 and A260/A230 
ratios.  
Complementary DNA (cDNA) was obtained by reverse transcription with the following 
protocol: 0.5 μg of RNA were mixed with 0.5ug/reaction of Oligo(dT) and 0.5 ug/reaction 
of Random primers into a final volume of 5uL. Then were added 4uL of 5x Reaction 
buffer, 1.5 mM final concentration of MgCl2, 0.5mM/dNTP of dNTP mix, and 1uL of 
Reverse Transcriptase, in a total volume of 20 μl. Enzymatic reactions were performed in 
the shaking termoblock: 10 min 25°C (annealing), 60 min 42°C (elongation) and 5 min 
95°C (enzyme inactivation).  
 
4.15 Immunoblot analysis  
Input chromatin and immuno precipitated histone octamers were separated in 12% or 
17.5% SDS-PAGE and transferred to PVDF membranes (Millipore). Membranes were 
blocked 1 h in 5% BSA in TBS-T. After blocking, membranes were incubated at 4°C for 
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an overnight with primary antibodies diluted in TBS-T 5% BSA. After three washes in 
TBS-T, binding was revealed by ECL western blot detection reagent and hyperfilm ECL 
(GE Healthcare) or by Clarity western blot ECL Substrate and Chemidoc XRS with Image 
Lab software (Biorad). For Western blot analysis the following antibodies were used, 
according to the manufacturer’s instructions: H3K4me1 (Abcam, dilution 1:2000), Pu.1 
(Santa Cruz Biotechology, dilution 1: 1000), H3K27Ac (Active Motif, 1:2000), Mpeg1 
(Genetex, dilution 1:1000), MafG (SantaCruz Biotechnology, dilution 1:1000),  H3K9me3 
(Abcam, dilution 1:2000), vinculin  (Upstate Millipore 06-866, dilution 1:10000), H3 
(Abcam, dilution 1:5000).  
 
4.16 Retroviral vector oligonucleotide cloning 
4.16.1 Retroviral Constructs and Production of Retroviruses 
All shRNA constructs were prepared in the MSCV-based pLMP retroviral vector (Dickins, 
Hemann et al. 2005). The sequences of the shRNAs used in the experiments are: 
- KD1-Mpg1: GCTTAATTGTCTCCAAAGGAAA 
- KD2-Mpg1: TGCATTTAGTCTGAATTTGAAA 
Phoenix-ECO packaging cells were plated  into producer cell growth media (DMEM, 10% 
heat-inactivated FBS, 2mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin) 
co-transfected with 2.8 μg pCLEco and 10 μg of either LMP empty vector or the same 
vector carrying the directed shRNA sequences, using the CaCl212.2 mM and Hepes 
Buffered Saline (HBS). After 15 min 20 uM final of cloroquine was added to inhibit 
lysosomal degradation of exogenous DNA.After few hours the medium of phoenix-ECO 
packaging cells was replaced with target cell medium. Supernatants from transfected 
Phoenix-Eco were collected at 48 hours post-transfection and used for BM infections. 
Material and Methods 
 
 
55 
 
4.16.2 Retroviral Transduction of Bone Marrow-Derived Macrophages 
On day 0, bone marrow cells were isolated and 3x106 cells/dish were seeded on 10 cm 
plates in BM medium. Infection was performed on day 1. In details, cells were first spun at 
2500 rpm for 5 min, the BM medium was removed, and the retroviral supernatants, 
supplemented with 8 μg/ml polybrene and 8 μl/ml of 1 M HEPES pH 7.5, were added. 
After 12 hours the virus-containing medium was gently removed and replaced by fresh BM 
medium. Puromycin selection (3 μg/ml) started on day 3. Assays were carried out at days 
7–8. 
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RESULTS 
5.1 Employment of X-ChroP approach in RAW 264.7 cells 
For the interactome dissection, we needed to grow the cells in the appropriate 
medium for seven to nine replications (see below), thus we used as model system a cell 
line, namely the murine macrophage cell line RAW 264.7. These cells were obtained by 
transformation of mouse macrophages from male BALB/c mice with Abelson murine 
leukemia retrovirus (Ab-MLV) and Moloney MLV (M-MLV) as helper virus (Raschke et 
al. 1978). RAW 264.7 cells are macrophage-derived, therefore they respond to 
inflammatory stimuli like interferon-gamma (IFN-γ) and lipopolysaccharide (LPS), 
mounting inflammatory response and producing pro-inflammatory cytokines. The LPS-
induced activation of RAW 264.7 cells is a very well characterized mechanism thus 
making this macrophage-like cell line the most widely employed model to study the 
inflammatory response (Chang et al 2010, Shih et al 2010, Min et al 2012, Ying et al 
2013). Two complementary processes characterize their activation: macroscopically, they 
stop growing and acquire a macrophage-like morphology characterized by the formation of 
the cellular protrusions; at the molecular level they activate different pathways, such as the 
toll-like receptor (TLR) pathway and the tumor-necrosis factor (TNF) receptor pathway, 
that in turn elicit a massive transcriptional activation of inflammatory genes, like those 
coding for chemokines and cytokines. 
In order to dissect the enhancers’ determinants at both basal and inflamed states, we 
set up the Chromatin Proteomics (ChroP) approach, recently developed in our laboratory 
(Soldi and Bonaldi 2013), in this model system.  
The cross-linked ChroP (X-ChroP) approach has been developed to dissect the 
interactors and histone variants specifically associated with a chromatin region of interest, 
the so-called chromatin interactome. Following this approach, a specific histone PTM is 
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used as bait in the chromatin immunprecipitation (ChIP) and the proteins co-enriched 
together with the chromatin stretch are analysed by mass spectrometry (MS) (Fig.14).  
The X-ChroP approach takes advantage of SILAC metabolic labeling in order to 
discriminate between the background proteins and the specific interactors: chromatin is 
prepared from heavy- and light- labeled cells and fragmented in nucleosome stretches of 
chosen length by sonication; poly-nucleosomes are used as input for the ChIP. In the 
immunoprecipitation step, the antibody against the modification used as bait is added in 
both light and heavy SILAC channels, whereas in only one of the two chromatin 
preparations (es. light channel in the forward experiment) an excess of soluble peptide 
bearing the epitope is added, to compete the native mark and displace it from the antibody. 
Upon H/L cells mixing in 1-to-1 ratio, proteins are eluted from the beads and analysed by 
LC-MS/MS. Due to the competition with the soluble peptide, the bait is displaced from the 
antibody together with all the co-associated interactors, thus generating a specific SILAC 
ratio different from 1 (H/L > 1 in the forward experiment). The binding of the unspecific 
contaminants is instead unaffected by the competition, leading to a SILAC H/L ratio equal 
to 1 (Fig. 14). 
 
Fig. 14: Experimental design of the SILAC-based X-ChroP strategy. Purified nuclei 
from SILAC-labeled and formaldehyde fixed RAW 264.7 cells are fragmented through 
sonication and the chromatin inputs are subjected to ChIP. An excess of soluble peptide 
displaces partially the antibody in the light SILAC channel so that, upon mixing in 1to1 
H/L ratio, separation of eluted proteins via SDS-PAGE and LC-MS/MS analyses, 
interactors will show a high H/L SILAC ratio while contaminants will have an H/L ratio 
equal to 1. (Light = blue, heavy = red). 
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5.1.1 SILAC labeling of RAW 264.7 cells 
 We cultured RAW 264.7 cells in parallel, in normal and in SILAC DMEM medium 
to assess whether the different composition between them may affect cell growth. The 
SILAC medium contains heat-inactivated and dialyzed fetal bovine serum (FBS), to ensure 
that the isotope-coded light (Arg0, Lys0) and heavy (Arg10, Lys8) amino acids added 
represent the only source of the amino acids used for new protein synthesis. Growth curves 
of RAW264.7 cells cultured in SILAC medium containing light or heavy amino acids are  
 
Fig. 15: Establishment of the SILAC labeling in RAW 264.7 cells. A) Comparison of 
the growth curves between RAW 264.7 cells cultured in DMEM (black) or SILAC 
medium (both light and heavy isotope coded media, blue and red, respectively. B) 
Evaluation of the morphology in RAW 264.7 cells cultured in DMEM or in SILAC 
medium through phase contrast microscopy. C) Incorporation rate of RAW 264.7 cells 
grown in heavy SILAC medium (Arg10, Lys8). Table summarizes the number of peptides 
identified and the incorporation percentages of arginine- or lysine-containing peptides. 
 
identical to the one of cells cultured in normal DMEM, thus indicating that the growth is 
not affected by the poorer composition of the SILAC medium (Fig. 15A). 
To assess whether the SILAC serum induces an inflammatory state, we evaluated 
the morphology of RAW 264.7 cells cultured in both conditions, which represent an early 
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prognostic feature of macrophage activation (Fig. 15B). We did not appreciate any 
significant change in the morphology of the cells culture in the two conditions, thus we 
concluded that RAW 264.7 cells are not induced or activated by the SILAC serum. 
We cultured RAW 264.7 cells in heavy SILAC medium for eight replications to 
determine the incorporation rate; upon cell lysis, we separated the total extract on SDS-
PAGE gel and evaluated by quantitative MS the percentage of heavy peptides from 2 slices 
of the gel lanes. We identified 4215 peptides in total and estimated that the incorporation 
rate of arginine- and lysine- containing peptides was 96 and 96.4%, respectively. In fact, 
we identified 10 peptides existing in the only-light form, which corresponds the 0.23% of 
the whole peptide population; the peptides present as H/L doublets were 364, 
corresponding to about 8% and their average SILAC H/L ratio was 18 (Fig. 15C), while all 
remaining 3843 peptides were present only in the heavy-labeled form, accounting for 92% 
of the total. Altogether these results demonstrate that we could reach an almost complete 
incorporation of heavy Arg10 and Lys8 in RAW 264.7 cells. 
 
5.1.2 Optimization of chromatin cross-linking conditions for the characterization of 
inflammatory genes’ enhancers 
 We carried out ChIPs for ChroP experiments with two well-described markers of 
enhancers: one is a histone post-translational modification namely the mono-methylation 
of lysine 4 of histone H3 (H3K4me1) and the other is a transcription factor and 
macrophage master regulator Pu.1, which binds specifically to enhancers of inflammatory 
genes. 
The cross-linking conditions and the length of the DNA stretch are the two critical 
aspects of the protocol for the preparation of the chromatin input for ChIP.  
Formaldehyde is used in ChIP to stabilize DNA-protein and protein-protein interactions 
(PPI): while too low concentration of formaldehyde only traps the more stable interactions, 
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but missing the more dynamic ones, an excess of formaldehyde may mask the epitope. As 
such, an optimal concentration of this reagent should be defined to ensure the right balance 
between PPI stability and the efficiency of the immunoprecipitation of the bait (Fig. 16A). 
Also the length of the chromatin stretch must be defined precisely: we chose a stretch of 2 
– 3 nucleosomes that corresponds to an overall DNA length between 300bp and 500bp.  
 
Fig.16: Balance between formaldehyde cross-linking and DNA fragmentation to 
reach the optimal DNA length. A) Schematic representation of the effect of the increase 
of cross-linking percentage on the ChIP efficiency. B) Comparison among DNA from 
0.75%, 1%, 1.5% and 2% formaldehyde cross-linked chromatin upon 10, 15, 18 and 24 
cycles of sonication (30sec ON/60secOFF), respectively. C) DNA from 0.75% and 1.5% 
of formaldehyde cross-linked chromatin upon 10and 20 cycles of sonication, respectively. 
 
Such nucleosomal stretch can be used as input for both immunoprecipitations, since the 
transcription factor binds to the nucleosome-free region (NFR) in-between two 
nucleosomes. 
We tested different concentrations of formaldehyde and we tried to balance the 
concentration with the number of sonication cycles needed to reach the chosen DNA 
length, taking into account that increasing sonication cycles can lead to overheating of the 
sample and protein denaturation.  
As expected, at increasing formaldehyde concentrations, a higher number of sonication 
cycles were needed to reach a fixed and established nucleosome length (Fig.16B). We 
could obtain an optimal DNA length using 1.5% formaldehyde cross-linked chromatin 
with 20 cycles of sonication, thus we focused our investigation around this percentage of 
cross-linking agent (Fig.16C). 
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We analysed by qPCR the DNA from 0.75 or 1.5% formaldehyde cross-linked 
chromatin in the input and in ChIPs using H3K4me1 as bait. We then evaluated the fold 
enrichment of three genomic regions with enhancer function (GAS7, PU.1, RGL) and one 
hetero-chromatin region as negative control (NEG) in the ChIP and in the respective input, 
in order to test whether the increase of formaldehyde reduced the epitope accessibility (Fig. 
17A). The three target regions were 2 to 5 fold more enriched in the H3K4me1 ChIP, 
normalised over the input, then the negative control; we also observed a slightly higher 
efficiency upon 1.5% formaldehyde cross-linking, suggesting that this experimental 
condition increases the binding and immunoprecipitation yield (Fig. 17).  
 
Fig. 17: Optimization of cross-linking percentages for H3K4me1 X-ChroP 
experiment. A) qPCR measures the level of target genomic regions and negative region in 
the ChIP using 0.75% (red) or 1.5% (blue) formaldehyde cross-linked chromatin input. B) 
WB validation of H3K4me1 enrichment in the ChIP compared to the input, using 0.75% or 
1.5% formaldehyde cross-linked chromatin; total histone H3 level is used as normalizer. 
C) Quantification of WB in B) obtained by calculating H3K4me1 enrichment in the ChIP 
over the input; total H3 used as normalizer for fold enrichment calculation 
[H3K4me1(ChIP/Inp)/H3(ChIP/Inp)]. 
 
We also measured the amount of immunoprecipitated H3K4me1 by western blot, 
estimating the enrichment of the signal for mono-methyl K4 normalized over the total H3 
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amount in ChIP and input (Fig. 17B). Fig. 17C shows that the enrichment of the bait is 
comparable between the experiment carried out with 0.75 or 1.5% formaldehyde cross-
linking, confirming similar efficiency in the immunoprecipitation of the bait. We therefore 
carried out ChroP protocol with 1.5% formaldehyde with the aim of increasing the 
stabilization of more dynamic DNA-protein and protein-protein interactions. 
 
5.1.3 Optimization of the antibody/peptide ratio and of the peptide competition in the 
H3K4me1 X-ChroP 
We next optimized the ratio between chromatin input and the amount of antibody 
to be used in the ChIP in order to immunoprecipitate a representative proportion of the 
bait. We can extrapolate this by evaluating the depletion of bait in the unbound fraction 
(flow-through, FT). Chromatin isolated from 100 million RAW 264.7 cells was used as 
input in ChIPs carried out with increasing ratios of antibody/input, starting from 5μg of 
anti-H3K4me1 per 100 million cells up to 20μg (Fig. 18A). As expected, the increase of 
antibody/input ratio is mirrored by a progressive H3K4me1 depletion in the corresponding 
FT; in Fig. 18B the relative amount of bait in the input compared to the FT is plotted at 
increasing antibody/input ratio. It is worth mentioning that we immunoprecipitated only 
about 65% of H3K4me1 even when we use the highest antibody/input ratio; this is likely 
due to the relatively high abundance of this modification in bulk RAW 264.7 chromatin. 
Based on MS data, we estimated that about 20% of peptide H3 (3 – 8) is mono-methylated 
at lysine 4 (see also below and paragraph 5.4.1), therefore is quite difficult to completely 
deplete this modification; in any case, we consider that 65% of the total will allow 
achieving a good representation of the composition of H3K4me1-bearing chromatin. 
We compared the lowest and the highest antibody/input ratio in a Coomassie-stained SDS-
PAGE to assess whether the amount of histone octamer immunoprecipitated is sufficient 
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for the MS-analysis: the highest ratio yields an amount of stoichiometric histone octamer 
sufficient for the subsequent mass spectrometry investigation (Fig. 18C). 
Based on all these tests we concluded that our optimal experimental conditions were the 
following: 80 million RAW 264.7 cells as starting material, 1.5% formaldehyde 
concentration and 20μg of anti-H3K4me1 antibody. 
 
 
Fig.18: Optimization of antibody/input ratio and peptide fold excess for H3K4me1 X-
ChroP experiment. A) H3K4me1 levels in input, flow-through and ChIP using different 
antibody/input conditions (chromatin from 100*106 cells and 5ug of antibody, 100*106 
cells and 10ug of antibody or 50*106 cells and 10ug of antibody); Ponceau staining of the 
histone octamer is shown as normalizer. B) WB quantification of flow-through (FT) 
depletion calculated as Input/FT in H3K4me1 and normalized on the same ratio in histone 
octamer ponceau staining. C) Coomassie staining of SDS-PAGE showing the ChIP 
efficiency using either 5ug (left) or 20ug (right) of H3K4me1 antibody on the same 
chromatin input. D) H3K4me1 levels in the inputs and in the ChIPs not competed (NO) or 
competed with 60, 80 or 160 fold molar excess of peptide bearing H3K4me1; Ponceau 
staining of histone octamers used as loading control for normalization of the bait PTM over 
the total histone amount.  
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In the X-ChroP experiment, the combination of the ChIP with a SILAC-based 
peptide competition assays allows to robustly distinguish between specific and unspecific 
chromatin interactors. A molar excess of a peptide bearing the epitope recognized by the 
antibody is added in one of the two SILAC-ChIP channels, to displace the bait with all co-
associated proteins, thus generating a H/L ratio differing form 1; background proteins 
maintain a H/L ratio equal to 1. The excess of soluble peptide added in the light channel 
must be titrated to reach an optimal SILAC H/L ratio; the rationale is in fact to get the 
highest SILAC ratio for the bait without reaching the point of a complete loss of the signal 
in the competed channel, which would generate an infinite ratio. A high SILAC ratio 
enables to better discern the specific binders from background. 
For the competition, we employed the same commercial peptide used as epitope to 
generate the antibody; we performed four ChIPs in parallel, using the same number of cells 
and the same amount of antibody but with increasing doses of soluble peptide: 60, 80, 160 
fold molar excess (Fig. 18D). As expected, the bait is enriched in the non-competed ChIP 
compared to the input but the efficiency of the ChIP significantly drops when the excess of 
peptide is added. In particular, 60-fold peptide molar excess decreases the bait of about 
50%, while with 80-fold molar excess the ChIP efficiency is about 20%. At 160-fold 
peptide molar excess, we abolished the binding of H3K4me1 in the ChIP. Hence, we chose 
120-fold molar excess of the peptide as a compromise to ensure strong competition of the 
bait without abolishing completely the binding; this setting is expected to produce an 
optimal H/L SILAC ratio of the bait and co-associated proteins. 
 We thus performed a forward X-ChroP experiment using 80 million RAW 264.7 
cells 1.5% formaldehyde cross-linked and 20μg of antibody against H3K4me1 for each 
heavy and light chromatin input, plus a 120-fold molar excess of soluble peptide in the 
light SILAC channel. After protein separation in SDS-PAGE, we excised the histone bands 
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from both the H/L 1-to-1 mix input and from the ChIP (Fig. 19A) and processed them 
using an ArgC-like in-gel digestion protocol (see material and methods for details).  
Upon LC-MS/MS analysis we focused the analysis on the peptide H3 (3 – 8) and 
calculated the extracted ion chromatography (XICs) for all the hPTMs on this peptide 
based on their exact mass, for both heavy and light sample, (see also 5.4.1) (Fig. 19B). We 
then calculated the percentage relative abundances (RA%) of each modification as the XIC 
of the specific modification over the sum of all the XICs of all the modifications on the 
same peptide expressed in percentage. Next, we estimated the relative enrichment (RE) of 
each modification as the ratio between its relative abundance in the ChIP and in the 
corresponding input.  
As expected, the H3K4me1 RA% increases upon ChIP (80% vs. 25% in ChIP and input, 
respectively) which corresponds to 3.2-fold relative enrichment (1.7 fold in log2) (Fig. 
19C). Such enrichment is less marked after competition with the soluble peptide (RA: 53% 
vs 23% in ChIP and input, respectively) leading to about 2 fold RE (Fig. 19D). Of note, the 
abundance of this modification in bulk chromatin (around 20%) limits the efficiency of the 
enrichment; as a matter of fact, 5 folds is the maximum enrichment that we can expect. The 
MS-readout shows a H/L SILAC ratio of 32 fold between the H3K4me1 in the heavy, 
relative to the light channel, thus confirming that the peptide competition works efficiently 
(Fig. 19E). 
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Fig. 19: Readout of H3K4me1 X-ChroP SILAC experiment. A) Coomassie staining of 
SDS-PAGE of X-ChroP experiment; in blue boxes histone octamers analyzed. B) Survey 
scan (left) and XIC visualization (right) of peptide 3 – 8 of histone H3 in the chromatin 
input (up) or in the ChIP (bottom). C) Relative abundance of peptide 3 – 8 in the input and 
in the ChIP (left) and its relative enrichment (right) in heavy not competed chromatin. D) 
Relative abundance of peptide 3 – 8 in the input and in the ChIP (left) and its relative 
enrichment (right) in light peptide-competed chromatin. E) MS validation of peptide 
competition between not competed (heavy) and competed (light) ChIPs.(Blue = light; red = 
heavy). 
 
The results obtained by mass spectrometry were also validated by western blot; Fig. 
20 shows the amount of H3K4me1 in the input as well as in the ChIP before the 1-to-1 H/L 
mixing. As expected, the bait is enriched in the heavy ChIP (ChIP H) over its input, while 
the competed light ChIP (ChIP L) does not show a similar enrichment (Fig. 20A).  
Furthermore the heavy FT (FT H) is more depleted compared to light one (FT L). We also 
validated these results by qPCR analysis of the DNA extracted from the same samples: a 
strong enrichment the genomic regions with enhancer function (GAS7, PU.1, RGL) is 
observed in the heavy, not-competed ChIP but not in the light, competed channel. The 
negative control (NEG) did not show enrichment in any of the ChIPs (Fig. 20B). 
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Fig. 20: WB and qPCR validation of peptide competition in H3K4me1 X-ChroP 
experiment. A) WB analysis of Input, flow-through (FT) and ChIP in heavy and light 
SILAC channels in forward X-ChroP experiment. B) qPCR validation of the enrichment of 
the mRNA of positive (PU.1, GAS7 and RGL) and negative (NEG) regions in forward X-
ChroP experiment. (Red boxes = ChIP light channel forward experiment, blue boxes = 
ChIP heavy channel forward). 
 
5.1.4 Setup of Pu.1 X-ChroP 
Following the same strategy as for H3K4me1, we optimized the 
immunoprecipitation for the transcription factor Pu.1, which binds enhancers’ chromatin at 
the level of the NFRs. We compared the immunoprecipitation efficiency of the bait in the 
ChIP performed using either 0.75% or 1.5% of formaldehyde cross-liked chromatin. 
Western blot analysis indicated that the immunoprecipitation was not impeded by the 
higher concentration of cross-linking agent (Fig. 21A), as Pu.1 was immunoprecipitated in 
both conditions with similar efficiency. Hence, we adopted 1.5% formaldehyde cross-
linked chromatin as input, to better stabilize the DNA-protein interactions. As such, we can 
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use the same chromatin input in the two X-ChroP experiments carried out with H3K4me1 
and Pu.1 as baits. 
We then optimized the input/antibody ratio by comparing three different conditions tested: 
100x106 cells as input for the ChIP and 5μg of antibody against Pu.1 and increasing 
twofold or fourfold the ratio (Fig. 21B). The progressive increase in the antibody to input 
ratio leads to a more efficient immunoprecipitation of the bait (Fig. 21B, lower exposure), 
mirrored also by its more pronounced depletion in each corresponding FT (Fig. 21B, 
higher exposure). Based on these findings, we chose as experimental conditions for the 
Pu.1 X-ChroP: 150x106 RAW 264.7 cells and 20μg of antibody, a setting that could 
efficiently immunoprecipitate a representative portion of the bait.  
We performed two parallel ChIPs using as input chromatin cross-linked with either 0.75% 
or 1.5% of formaldehyde and the chosen input/antibody ratio (Fig. 21C). Upon SDS-PAGE 
and coomassie staining, we observed that the immunoprecipitation efficiency of the histone 
octamer and the general pattern of the bands in the two ChIPs were comparable; since 
1.5% formaldehyde does not seem to hamper IP efficiency and it is supposed to better 
stabilize the dynamic interaction, we chose 1.5% formaldehyde cross-linking as working 
condition. 
The peptide fold excess in the Pu.1 X-ChroP was then optimized employing the 
commercial peptide used as epitope for the generation of the polyclonal anti-Pu.1 antibody. 
We tested four different peptide concentrations to evaluate the right molar excess capable 
of producing the optimal Pu.1 H/L ratio. Fig. 21D shows that a 25-fold molar excess of the 
Pu.1 peptide abolishes the immunoprecipitation of the bait; therefore we tested slightly 
lower fold molar excess: the effect of adding 18-peptide fold molar excesses was 
investigated by mass-spectrometry in a SILAC forward experiment, where the competition 
was carried out in the light channel. Fig. 21E shows the SILAC pair for the C-terminal 
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Fig.21: Optimization of the X-ChroP conditions using Pu.1 as bait. A) Pu.1 ChIP 
efficiency over the input using either 0.75% or 1.5% formaldehyde cross-linked chromatin; 
global histone H3 level shown as normalizer. B) Pu.1 levels in input, flow-through and 
ChIP using different antibody/input ratios (100*106 cells and 5ug of antibody, 100*106 
cells and 10ug of antibody or 50*106 cells and 10ug of antibody) (exp. = exposure). C) 
Coomassie stained SDS-PAGE showing Input, flow-through (FT) and ChIP using either 
0.75% or 1.5% cross-linked chromatin input. D) Pu.1 enrichment in the not-competed 
ChIP (NO) over the input and decreased ChIP efficiency upon increasing Pu.1 peptide 
folds excess. E) MS validation of peptide competition between not-competed (heavy) and 
peptide-competed (light) ChIP. 
 
peptide (GTFQFSSK) of Pu.1 with a H/L SILAC ratio of 31, which we evaluated adequate 
for the subsequent interatomics experiments. 
MS-results were also validated by western blot; Fig. 22 shows the amount of Pu.1 
in the input as well as in the ChIP before the 1-to-1 H/L mixing. The bait is enriched in the 
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not competed ChIP (ChIP H) over its input, while Pu.1 does not show a similar enrichment 
in the light competed ChIP (ChIP L) (Fig. 22A). These results are confirmed by a higher 
depletion of the heavy FT (FT H), relative to the light one (FT L). QPCR analysis of the 
DNA extracted from the same samples displays a strong enrichment of the genomic 
regions with enhancer function (GAS7, PU.1) in the heavy, not-competed ChIP but not in 
the light, competed channel. The negative control (NEG) does not show enrichment in any 
of the ChIPs (Fig. 22B). 
 
Fig. 22: qPCR and WB validation of peptide competition in Pu.1 X-ChroP 
experiment. A) WB analysis of Input, flow-through (FT) and ChIP in heavy and light 
SILAC channels in forward X-ChroP experiment. B) qPCR validation of the enrichment of 
the mRNA of positive (PU.1 and GAS7) and negative (NEG) regions in forward X-ChroP 
experiment. (Red = ChIP light channel forward experiment, blue = ChIP heavy channel 
forward). 
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5.2 Dissection of enhancers’ determinants in resting macrophages by X-
ChroP 
 We started by characterizing the proteins co-associated with the H3K4me1-bound 
chromatin. We performed forward and reverse X-ChroP experiments by swapping the 
SILAC channel in which the peptide competition was carried-out. We mixed the two 
SILAC-labeled channels in a combined sample that was then separated by SDS-PAGE. We 
excised 10 slices for gel lane and subjected them to trypsin digestion, followed by MS-
analysis on Q Exactive instrument (Thermo Fisher Scientific) (see material and methods 
for details). Proteins were identified and quantified by using the MaxQuant software suite 
(Cox and Mann 2008; Cox, Neuhauser et al. 2011) setting a confidence level of 99% 
(protein and peptide FDR equal 1%).  
 
Fig.23: Dissection of the H3K4me1 interactome. Venn diagram shows the overlap 
between forward (Fwd) and reverse (Rev) X-ChroP experiments using H3K4me1 as bait. 
The scatterplot shows the log2 SILAC distribution (H/L ratio and L/H ratio for the forward 
and reverse experiment, respectively) of common proteins. The zoom underlines 
significantly enriched proteins belonging to the top 30% distribution of both Fwd and Rev 
experiment. The table summarises proteins identified and quantified in the experiments. 
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We quantified 1335 and 1339 proteins in the forward and reverse experiment, respectively, 
of which 1152 were quantified with at least one ratio count in each experiment (Fig .23).  
Based on the protein ratio distributions (log2 of H/L and L/H ratio for the forward and the 
reverse experiment, respectively) we defined as putative interactors those proteins within 
the Top 30% (70th percentile) of both distributions, which are located in the upper-right 
section of the scatterplot. Zooming into this area, we observed proteins specifically 
associated with H3K4me1-bound chromatin such as Pu.1 itself, several subunits of the 
RNA polymerase II complex, the facilitating of chromatin transcription (FACT) complex, 
components of diverse chromatin remodeling complexes and H3.3 and H2A.Z, two histone 
variants, traditionally associated with active chromatin (Fig. 23, zoomed upper panel). 
 
Fig.24: Dissection of the Pu.1 interactome. Venn diagrams show the overlap between 
forward (Fwd) and reverse (Rev) X-ChroP experiments using Pu.1 as bait. The scatterplot 
shows the log2 SILAC distribution (H/L ratio and L/H ratio for the forward and reverse 
experiment, respectively) of common proteins. The zoom underlines significantly enriched 
proteins belonging to the top 45% distribution of both Fwd and Rev experiment. The table 
summarizes proteins identified and quantified in the experiments. 
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 The geLC-MS/MS analysis of the forward and reverse X-ChroP experiments using 
the Pu.1 as bait produced 1255 and 1262 proteins in the forward and reverse experiments, 
respectively, of which 950 were in common and they were identified with at least one ratio 
count in each experiment (Fig. 24).  
Based on the log2 of the two protein ratio distributions, we set as putative interactors of 
Pu.1-marked chromatin those proteins within the Top 45% (55th percentile) of both 
distributions (in the upper-right quadrant of the scatterplot). As expected, Pu.1 was the top 
scoring protein among them, but other interesting proteins such as the RNA polymerase II 
subunit Rbp1, the histone variant H2A.Z, the protein arginine methyl-transferase 1 (Prmt1) 
and the transcription activator Pura were found in this group (Fig. 24, zoomed upper 
panel). 
 
5.2.1 Characterization of enhancers’ composition by the intersection of H3K4me1 and 
Pu.1 interactomes. 
 We intersected the data coming from the two interactome studies (Fig. 25A) and 
identified 764 proteins in common (displayed in the heat map in Fig. 25B). Among these, 
we selected as genuine enhancers’ determinants only those proteins belonging to the top 
distribution of each interactome, namely the Top 30% and Top 45% for H3K4me1 and 
Pu.1, respectively. Upon this filtering criterion, 148 proteins were selected, of which a 
subset, organized in distinct functional classes, is listed in Fig. 25C (see also Appendix 1).  
In this group we identified two core subunits (Smc1a and Smc3) and one accessory subunit 
(Pds5a) of the cohesin complex, important for chromatin structural stabilization and two 
enhancers binding proteins, namely the far upstream-elements binding protein 2 (Khsrp) 
and matrin3 (Matr3). Interestingly, matrin3 has been recently shown to be required for the 
effective enhancer’s activation and subsequent transcription of the homeodomain 
transcription factors target genes (Skowronska-Krawczyk, Ma et al. 2014).  
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Among the potential enhancers’ determinants we identified components of the RNA 
polymerase II complex, like the B-TFIID transcription factor associated protein (Btaf1), 
the general transcription factor II B (Gtf2b) and IIE (Gtf2e2) and the RPB1 subunit of the 
RNA polymerase II (Polr2a). Moreover, we also identified proteins associated with this 
complex like the Ccar2 protein and the scaffold attachment factor B1 (Safb), core 
components of the Dbc1-Zird (DBIRD) complex and the transcriptosomal complex, 
respectively, that both coordinate transcript elongation and RNA processing.  
In the group of transcription factors or co-activator identified, interestingly we cite the 
histone acetyl-transferase p300 (Ep300) that is a key-mark of the LPS-inducible enhancers 
in macrophages (Ghisletti, Barozzi et al. 2010) and the Brg1-associated polybromo protein 
(Pbrm1), whose expression is a prognostic marker in renal cell carcinomas (Poirier, de 
Murcia et al. 1982). 
At enhancers we also identified transcriptional regulator proteins that can play both a 
positive or negative role on transcriptional control, depending on the distinct set of binding 
partners associated: among those some subunits of the SWI/SNF ATP-dependent 
chromatin remodelers family (Smarcc1, Smarcc2 and Smarcd2); the Non-POU domain-
containing protein (Nono, also known as p54(nrb)), which interact with both Matr3 and 
RNA-binding proteins; some ATP-dependent RNA helicases (Ddx17, Ddx21, Dhx9) 
already described to play important role in transcription as co-activator or co-repressors 
(Fuller-Pace 2006) and Parp1 that plays a dual role in transcription (Poirier, de Murcia et 
al. 1982). 
Interestingly, we also identified as enhancers’ determinants some transcriptional repressors 
like the protein Sin3a, the p66 alpha protein (Gatad2a) and the C-terminal binding proteins 
(Ctbp) 1 and 2. 
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Fig. 25: Dissection of the basal enhancers’interactome. A) Venn diagrams show the 
overlap between H3K4me1 and Pu.1 interactomes. B) Proteins in common between the 
two interactomes are subjected to hierarchical cluster analysis and represented as heatmap; 
dotted lines show proteins in the Top of both H3K4me1 and Pu.1 experiments. C) Subset 
of new potential enhancers’ determinants classified according to their molecular function. 
 
 To understand whether these enhancers’ determinants belong to specific complexes 
we used the "g:Profiler" tool (Reimand, Kull et al. 2007). This web-based toolset generates 
functional descriptions of gene lists derived from large-scale experiments, such 
descriptions include the presence of experimentally-characterized protein complexes, 
described in the CORUM database (Ruepp, Waegele et al. 2010). Using this feature, we 
were able to assign a statistical significance to a set of protein complexes through a 
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comparison of our list of proteins enriched at enhancers with a background that included 
the complete list of proteins identified and quantified in input (Fig. 26). 
The results showed an enrichment of transcription regulator complexes associated with 
SWI/SNF family proteins and involved in both transcription activation and repression. 
Thanks to the identification of specific subunits, we were able to discern among different 
SWI/SNF-containing complexes.  
Among the most significant complexes identified, we determined the locus control region 
(LCR)-associated remodeling (LAR) complex which fine-tunes the transcription of the. 
β-globin locus through long-range interactions involving the enhancer region DNase 
hypersensitive 2 (HS2) and the beta β-globin promoter (Mahajan, Narlikar et al. 2005). 
This complex consists of 18 subunits comprising components of the SWI/SNF family and 
the nucleosome remodeling and deacetylase (Mi2/NuRD) complex like Chd4, Mta2 and 
Rbbp4. Moreover, the heterogeneous nuclear ribonucleoproteins (hNRNPs) confer to the 
LAR complex the sequence-specific DNA recognition.  
 
Fig.26: Protein complexes significantly enriched at enhancers’ of resting 
macrophages. Visualization of transcriptional regulators and RNA processing protein 
complexes found significantly enriched at enhancers, using the entire set of proteins 
robustly identified in the chromatin input as background for the p-value calculation. (p-
value reported in to parenthesis). 
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Thanks to the identification of the Sin3a protein, we could also confidently identify the 
Brg1-Sin3a complex (Sif, Saurin et al. 2001); this complex has been recently shown to 
regulate transcription in a context-dependent manner and to mediate efficient signal 
transducer and activator of transcription (STAT)-dependent transcriptional activities 
(Icardi, Mori et al. 2012).  
As above-mentioned, in the cluster of the transcription co-activators we identified the 
polybromo protein 1, which is a unique component of the Polybromo, Brg1-Associated 
Factors (PBAF) complex. PBAF is the only SWI/SNF-containing complex that potentiates 
transcription and its role in gene transcriptional regulation during stress response in 
Caenorhabditis elegans has been recently described (Kuzmanov, Karina et al. 2014). 
Moreover, this complex is necessary for ligand-dependent transactivation via nuclear 
hormone receptor (Lemon, Inouye et al. 2001). Very interestingly PBAF is recruited to 
active chromatin through the bromo-domains of the Pbrm1 that recognize a specific pattern 
of lysine acetylation on the H3 tail (Chandrasekaran and Thompson 2007). 
We identified as robustly associated with enhancers also two other SWI/SNF-related 
complexes, namely the p300-CBP-SWI/SNF complex and the RNA polymerase II 
complex. The p300-CBP-SWI/SNF complex brings together the histone acetyl-transferases 
activity of p300 and CBP with the chromatin remodeling function of SWI/SNF complex, 
thus representing a model of transcriptional activation function through histone acetylation 
(Dallas, Cheney et al. 1998). The RNA polymerase II complex was identified in our 
dataset by the specific enrichment of both the Polr2a protein and the general transcription 
factor II B (Gtf2b) (Cho, Orphanides et al. 1998). It promotes the activation of 
transcription by coupling chromatin remodeling and RNA polymerase II activities. 
Noteworthy, at enhancers we identified both the acetyl-transferase p300 and the RNA 
polymerase II which form the transcription initiation complex when the c-terminal domain 
(CTD) of the RNA polymerase II is non-phosphorylated.  
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We also identified the MASH1 promoter-co-activator complex, which promotes 
transcription via Parp1-dependent co-repressor displacement (Ju, Solum et al. 2004). 
At enhancers, the presence of two RNA binding complexes, namely the Emerin complex 
24 and the p54(nrb)-PSF-matrin3 complex was also observed; while the former is 
associated with RNA processing (Holaska and Wilson 2007), the latter is involved in RNA 
binding (Zhang and Carmichael 2001) and it is composed by Matrin3 and Nono proteins, 
both previously described also as transcriptional regulators. 
Interestingly, the spliceosome complex (Zhou, Licklider et al. 2002) seems enriched at 
enhancers; this finding corroborates the model that proposes co-occurrence between 
transcription and mRNA editing in both time and space. 
The role of the minichromosome maintenance (MCM) complex in DNA replication is well 
established since about two decades (Ishimi, Ichinose et al. 1996); however more recently, 
it has been described that some subunits of this complex interact with histones and the 
RNA polymerase II (Holland, Gauthier et al. 2002) and that MCM complex may 
participate in the Stat1 target gene activation and RNA polymerase II-mediated 
transcription (Snyder, He et al. 2005). Our findings indicate a clear enrichment of this 
complex at enhancers thus corroborate the hypothesis of a novel function of MCM 
complex in transcriptional regulation. 
Putting all our findings in a common view, at enhancers we observed the specific 
enrichment of chromatin-modifying co-factors associated with transcriptional regulation, 
together with mRNA binding proteins, transcription factors, enhancer binding proteins, 
RNA polymerase II complex, p300, components of the pre-initiation complex (PIC) and 
the cohesin complex. These data are reminiscent of a model whereby the enhancer-
promoter chromosomal looping bridges together transcriptional regulator complexes and 
chromatin remodelers in order to tightly regulate the expression levels of relevant genes at 
the correct time and in the specific cellular context (Fig. 27). 
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Fig. 27: Enrichment of players of the enhancer/promoter looping in the basal 
enhancers’ interactome Transcription regulators, chromatin modifiers and Cohesin 
complex, bridge together enhancer and promoter regions establishing a chromosomal 
looping that modulates the formation of the pre-initiation complex (PIC) and transcription 
by RNA polymerase II.(Adapted from Maston G A et al. Annu Rev Gen Hum Gen 2012). 
 
5.3 Profiling chromatin determinants of enhancers during inflammatory 
stimulus 
5.3.1 Triple SILAC labeling, for time-course X-ChroP analysis 
 Having determined the set of proteins that constitute the basal enhancers’ proteome, 
we then want to profile the changes in chromatin composition in response toan 
inflammatory stimulus, such as LPS. In fact RAW 264.7 cells react to LPS by eliciting a 
massive transcriptional activation of inflammatory genes, accompanied by a global 
rearrangement of chromatin architecture.  
We set up an X-ChroP experiment using triple SILAC labeling, to carry out the temporal 
analysis at three time-points during the inflammatory response. 
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Fig. 28: Schematic representation of triple-SILAC labeling combined with X-ChroP. 
Experimental design of time-course X-ChroP e (tc-ChroP); cells are labeled in light, 
medium and heavy SILAC amino acids and left untreated, treated for 1h and 4hrs with 
LPS, respectively. Formaldehyde-fixed cells are lysed and fragmented and chromatin is 
used as input for ChIP, using H3K4me1 and Pu.1 as baits. Eluted proteins are mixed in a 
1:1:1 H:M:L ratio, separated and analyzed by LC-MSMS. Proteins stably associated, 
evicted and recruited to chromatin during the inflammatory response will display, a stable, 
decreasing or increasing protein ratio passing from light to medium up to heavy, 
respectively. 
 
Cells were grown in SILAC medium containing light, medium or heavy isotope-coded 
lysine and arginine amino acid. In the forward experimental design, light, medium and 
heavy labeled cells were left untreated or treated for 1 or 4hrs with LPS, respectively; these 
two intervals of treatment recapitulate the early (1h) and acute (4hrs) phase of activation of 
the inflammatory genes. Cells were cross-linked and lysed and then chromatin from each 
preparation was fragmented through sonication to obtain 300-500bp nucleosomal stretches. 
This was used as input for three parallel ChIP experiments. The eluted proteins were mixed 
in a 1-to-1-to-1 ratio, de-cross-linked and separated via SDS-PAGE. Upon geLC-MS/MS 
analysis, proteins were identified and quantified by MaxQuant software (Cox and Mann 
2008; Cox, Neuhauser et al. 2011). The final SILAC readout enables to discern proteins 
recruited, evicted or stably associated with enhancers during inflammation, as schematized 
in Figure 28. More specifically: proteins stably associated with these cis-regulatory regions 
are expected to display a similar intensity in all the three SILAC channels; while proteins 
evicted or recruited to enhancers, will show a progressive decrease or increase, 
respectively, in the intensity of the corresponding peaks from the medium and heavy 
channels relative to the light one, which represents the basal state. 
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Fig. 29: Incorporation rate of RAW264.7 cells in heavy and medium SILAC media. 
Density distributions show the percentages of incorporation of medium (left) or heavy 
(right). The table summarizes the peptides identified (at list 2 peptides, 1 of which unique) 
and the incorporation rate of arginine- and lysine containing peptides in both medium and 
heavy samples. 
 
We evaluated the incorporation efficiency of RAW 264.7 cells cultured in SILAC 
DMEM containing Medium amino acids (Arg 6, Lys 4); upon 8 passages, we obtained 
95% and 96% incorporation for Arg6- and Lys4-containing peptides, respectively (Fig. 
29).  
We performed four tc-ChroP replicate experiments, two in the forward and two in 
the reverse setups (Fig. 30A); we evaluated the global correlation of protein ratios among 
the input of the experiments, focusing on the H/L and M/L ratios for forward and reverse 
experiments respectively, which correspond to 4hrs of LPS treatment over the untreated 
state. The forward 2 (fwd2) and reverse 2 (rev2) experiments showed the highest 
correlation (Fig. 30B) and where selected as reference dataset for the analysis of the 
dynamic profiling of enhancers’ determinants. We clusterized the proteins based on their 
SILAC ratio during the inflammatory stimulus, carrying out an unsupervised hierarchical 
clustering analysis of protein ratios in the fwd2 and rev2 chromatin inputs. Only a subset of 
proteins resulted up-regulated (SILAC ratio greater than +2 s.d.) during the stimulus (Fig. 
30C), precisely 26 out of 2532 proteins.  
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Fig. 30: Analysis of the inputs from tc-ChroP experiments. A) Experimental design of 
forward and reverse tc-ChroP experiments. Untreated cells (UT, blue) are always light-
labeled; in forward experiment, medium (orange) and heavy-labeled (red) cells are treated 
for 1h and 4hrs with LPS, respectively (these correspond to 4hrs and 1hr treatment 
respectively in reverse experimental design). B) Multi scatterplot visualization of 4hrs/UT 
ratio in the inputs (red dotted-lines = threshold for significantly up-regulated proteins). C) 
Heat map representing the hierarchical unsupervised clustering of proteins enriched upon 
LPS in forward 2 (Fwd2) and reverse 2 (Rev2) experiments (red = enriched, green = 
depleted; white = within ± 2 standard deviations). D) Protein description and log2 SILAC 
ratio of enriched proteins in Fwd2-Rev2 experiments. 
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The majority of these proteins have been previously described as involved in the 
inflammatory response, such as the transcription factor JunB (Fujihara, Muroi et al. 1993), 
the interferon-induced proteins (Ifit1, Ifit2, Ifit3, Ifih1) (Lee, Jenkins et al. 1995; Smith and 
Herschman 1996), the interleukin-1 beta (Il1b) (Wu, Chen et al. 2009) as well as proteins 
important for the toll-like receptor 4 (TLR4) and NF-kB cascades, like the Nod-like 
receptor (NLR) family member, Nlrp3. 
The up-regulation of all these positive markers, suggested us that the model system 
adopted efficiently responds to the inflammatory stimulus and that the experimental 
approach and the technique employed are sensitive enough to reveal such biological 
effects. 
Each tc-ChroP experiment was carried in duplicate using both H3K4me1 and Pu.1 
as baits (see Fig. 28 for the scheme of the experimental design). In H3K4me1 tc-ChroP we 
identified and quantified 953 proteins and 1420 proteins in the forward and reverse 
experiments, respectively; in the Pu.1 tc-ChroP, we quantified 863 proteins in the forward 
and 1166 proteins in the reverse experiment. Upon intersection of the technical replicates 
we robustly identified 847 and 769 proteins in H3K4me1 and Pu.1 dataset, respectively 
(Fig. 31A).  
The M/L and H/L SILAC ratios in the forward experiment correspond to the difference 
between the peak intensity of a given protein in the 1hr-stimulated sample (medium 
channel, M) and in the 4hrs-stimulated sample (heavy channel, H) respectively, relative to 
the untreated state (light channel, L). These ratios correspond to H/L and M/L in the 
reverse experiment. We applied an unsupervised hierarchical clustering based on the 
protein SILAC ratios, to classify proteins based on similar trends of response upon the 
inflammatory stimulus; these clusters are represented in the heatmaps in Fig. 31B and 31C, 
for H3K4me1 and Pu.1 respectively. Each cluster displays specific dynamics, represented 
as a profile plot (Fig. 31B and Fig. 31C, right).  
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Fig.31: Analysis of tc-X-ChroP forward 2 and reverse 2 experiments upon LPS 
stimulus. A) Venn-diagrams show the overlap between forward and reverse experiment 
for both H3K4me1 (right) and Pu.1 (left); table summarises protein identified and 
quantified in the experiments. B) Heatmap visualization of the unsupervised hierarchical 
clustering analysis of proteins in common between forward 2 (Fwd2) and reverse 2 (Rev2) 
H3K4me1 tc-ChroP experiments (left), line-trend visualization of protein with similar 
behaviors during inflammation (right). C) Heat map visualization of the unsupervised 
hierarchical clustering analysis of proteins in common between forward 2 (Fwd2) and 
reverse 2 (Rev2) Pu.1 tc-ChroP experiments (left), line-trend visualization of protein with 
different behavior at enhancers, during inflammation (right). (Red = recruited, green = 
evicted, white = within ±1 s.d. of 90% distribution). 
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As expected, some proteins were not influenced by the LPS stimulus and their association 
with enhancers remains constant during inflammation, with a “Pu.1-like” behavior; other 
proteins were dynamically recruited to- or evicted from-enhancers upon LPS, with 
different kinetics. 
Using these data, we wanted to profile the dynamic behavior of the proteins 
identified as specific macrophage enhancers’ determinants at basal conditions. We thus 
intersected the temporal protein profiles with the initial list of 148 static enhancer’s 
determinants (See also Appendix 2). Interestingly, we observed a specific recruitment at 
enhancers of the Smarcc2 protein and the Pbrm1 protein, two subunits of the SWI/SNF-
related complex PBAF. As already mentioned, this complex is associated with 
transcriptional activation; indeed while the SWI-SNF subunits mediate the ATP-dependent 
chromatin remodeling activity, the bromo-domains of Pbrm1 regulate the site-specificity 
for the binding of the PBAF complex (Fig. 32). 
In addition to PBAF, we observed the recruitment of Nono and Sfpq proteins, both 
involved in RNA processing and in the androgen receptor-mediated transcription 
(Kuwahara, Ikei et al. 2006). Safb protein was also specifically recruited at enhancers; 
interestingly, this protein is a component of the transcriptosomal complex that couples 
transcription to RNA processing. 
In parallel we observed the eviction from enhancers of some interesting proteins: the DNA 
(cytosine-5) methyl-transferase 1 (Dnmt1) protein, which promotes the methylation of 
hemi-methylated CpG islands at promoter regions, a well-established mechanism through 
which transcriptional silencing is achieved (Mohn, Weber et al. 2008); the eviction of 
Dnmt1 from enhancers upon LPS, is in accordance with the concept of a more accessible 
chromatin state which promotes TFs binding to DNA. 
Upon LPS stimulus some proteins related to the processes of DNA replication and cell 
proliferation, like the Proliferating Cell Nuclear Antigen (PCNA) protein and the Marker  
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Fig.32:Dynamic profiling of enhancer’ determinants during LPS stimulus and 
proteins newly recruited at these cis-regulatory regions. (Adapted from Maston G A et 
al. Annu Rev Gen Hum Gen 2012). Recruitment of PBAF complex at enhancers during the 
inflammatory stimulus, as well as Nono, Sfpq, Fus and Snrnp70. Displacement of Dnmt1, 
Mki67, Pcna and Ubc from enhancers along the LPS treatment. A class of proteins newly 
recruited at enhancers is displayed. 
 
of proliferation Ki-67 (Mki67) protein, are evicted from enhances; thisresult is in line with 
the evidence that activated macrophages stop dividing and focalize their activity on 
mounting the immunological response, to counteract the infection. 
 Our analysis also enables to identify those proteins which were undetectable at 
basal condition but resulted as newly recruited at enhancer only upon LPS (See also 
Appendix 3). In this class we found the CCAAT/enhancer binding protein zeta (Cebpz) that 
is a transcription factor important for myeloid differentiation (Zhang, Hetherington et al. 
1996) and Junb, a transcription factor already proposed to be inducer of pro-inflammatory 
cytokines during LPS-dependent inflammation (Gomard, Michaud et al. 2010). 
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Interestingly, we also identified some transcriptional regulators involved in the response to 
inflammatory stimuli, such as the Signal Transducer and Activator of Transcription 1 
(Stat1) protein, whichactivates genes involved in the inflammatory response (Luu, 
Greenhill et al. 2014) and two components of the HIN-200 family, namely the Myeloid cell 
Nuclear Differentiation Antigen-Like (Mndal) and the Interferon-activable protein 204 
(Ifi204), both acting as transcriptional regulators (Dauffy, Mouchiroud et al. 2006; Zhang, 
Kagan et al. 2009). Furthermore, two proteins crucial for transcriptional activation were 
also newly recruited: the Staphylococcal Nuclease and tudor Domain containing 1 (Snd1) 
and the Suppressor of Ty6 Homolog (Supt6h).Snd1 is a DNA-binding protein, co-activator 
of Stat6 and bridging factor between this signal transducer and the basal transcription 
factor (Yang, Aittomaki et al. 2002); Supt6h is a member of the polymerase associated 
factor 1 (PAF1) complex, required for efficient transcriptional elongation (Willmann, 
Milosevic et al. 2012). 
This temporal profiling highlighted a somehow expected dynamics of enhancers upon LPS 
illustrated by the recruitment of chromatin remodelers and the displacement of a DNA 
methyl-transferase enzyme, which together stimulate gene expression. Based on these 
findings, during the inflammatory response the majority of enhancers’ determinants are 
stably associated, suggesting that enhancers are constituted by an overall high-ordered 
structure that pre-exist the transcription activation; after the LPS treatment, specific 
proteins are recruited in a time-specific fashion and serve to fine-tune gene expression. 
 
5.3.2Follow-up validation of Mpeg1 protein as a novel enhancer determinant  
In addition to chromatin determinants dynamically recruited or evicted from 
enhancers during the inflammatory response, we also identified a set of proteins that are 
stably associated with these regions, like Pu.1. They are potentially very interesting as they 
may either synergize with Pu.1, or act independently as novel transcription factors to 
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regulate the expression of inflammatory genes in macrophages. Within this list of 
candidates, we focused our attention on the Macrophage-Expressed gene 1 (Mpeg1) 
protein, because of its macrophage-specific expression and it functional dependence on 
Pu.1 (Zakrzewska, Cui et al. 2010). As a matter of fact Mpeg1 has been identified in mice 
and human as macrophage-specific, with an increasing expression during macrophages 
differentiation (Spilsbury, O'Mara et al. 1995). The mpeg1 gene is evolutionary conserved 
from invertebrates to vertebrates; Mpeg1 is structurally composed of a N-terminal 
Membrane-Attack Complex and Perforin (MACPF) domain and a C-terminal region 
containing a single-pass transmembrane domain. Proteins belonging to the MACPF super-
family are involved in different biological functions, but almost all of them play crucial 
roles in the immune defense against both extracellular and intracellular infections by 
means of two different mechanisms: either they form pores in the outer membrane of Gram 
negative bacteria or they deliver cytotoxic granzyme into target cells, thus inducing cell 
death.  
Mouse embryonic fibroblasts induce mpeg1 expression in response to infection and their 
ability to kill the pathogen is lost upon mpeg1 depletion (McCormack, de Armas et al. 
2013). In human and murine cells, Mpeg1 is described to be either up- or down-regulated, 
depending on the different inflammatory stimulus; while in zebrafish two isoforms exist, 
Mpeg1 and Mpeg1.2, originated by gene duplication and typically regulated in opposite 
directions upon the same stimulus. The specific function of these two isoforms is still 
poorly characterized (Benard, Racz et al. 2014). 
The reproducible enrichment of Mpeg1 in X-ChroP experiments carried out using both 
Pu.1 and H3K4me1 as baits was quite surprising and intriguing, because there were neither 
evidences in the literature concerning the involvement of this protein in the macrophage 
transcriptional response to inflammation, nor indication of its localization in the nucleus. 
In order to validate the ChroP finding, we assessed Mpeg1 subcellular localization in RAW 
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264.7 cells. By western blot we observed that Mpeg1 is present both in cytosol and in the 
nucleus in a 60% to 40% ratio; moreover, the slightly lower molecular weight of the 
nucleosolic band of Mpeg1 compared to the cytosolic one would be compatible with the 
possible loss of the signal peptide, present at the N-terminus (Fig. 33A). Unexpectedly, we 
detected two distinct bands for Mpeg1: one at about 72kDa, in line with the predicted 
molecular weight, and a specific band around 50kDa which shows the same above-
mentioned molecular shift between cytosolic and nucleosolic fraction. These two bands are 
specific, since both of them decrease upon Mpeg1 knock-down by shRNA (see below). We 
can exclude that the smaller band represents a splicing variant because mpeg1 is 
constituted by only one exon; thus, we speculated that Mpeg1 might be subjected to 
cleavage by a still uncharacterized protease, which would generate the shorter isoform 
observed and a cleavage product of about 20kDa. By western blot we could not detect band 
around 20kDa reactive with the Mpeg1 antibody in use. Thus it is possible that either only 
the N-terminal region is stable upon cleavage, or that the 20kDa remnant is not recognized 
by the antibody. MS data did not help in understanding this mechanism, because we could 
only detected Mpeg1 peptides around the MACPF domain. To prove the protease cleavage 
hypothesis, it would be interesting to test a panel of protease inhibitors, to possibly identify 
the enzyme cleaving Mpeg1 and to characterize the functional differences between the full-
length protein and the shorter isoform. 
To confirm the interaction between Pu.1 and Mpeg1 and assess whether it occurs 
only on chromatin, we carried out a Pu.1 co-immunoprecipitation (co-IP) experiment by 
using RAW 264.7 nucleosolic fraction as input and IgG IP as negative control (Fig. 33B). 
We confirmed that the interaction exists and we observed that it is chromatin-independent: 
both bands recognized by the anti-Mpeg1 antibody were specifically immunoprecipitated 
in the nucleosolic co-IP using ant-Pu.1. This interaction was further assessed by label-free 
quantitative (LFQ) MS-proteomics analysis (Fig. 33C): the box-plot shows the specific  
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Fig. 33: Characterization of Mpeg1 localization and dissection of chromatin-
independent Pu.1 interaction. A) WB analysis on cytosolic and nucleosolic localization 
of Mpeg1 (up), positive control for the subcellular fractionation (bottom). B) Chromatin-
independent specific interaction between Pu.1 and Mpeg1 in Pu.1 nucleosolic IP; IgG IP 
and Ezh2 as negative controls for IP and WB, respectively. C) Coomassie-stained SDS-
PAGE and MS-analysis of nucleosolic Pu.1 IP. Box-plots show the log2 of the label-free 
quantitation (LFQ) value for Pu.1 and Mpeg1 proteins and for the general population of 
other proteins in Pu.1 IP, IgG IP and in the chromatin input; IgG IP is used as negative 
control. 
 
enrichment of Mpeg1 in Pu.1 IP relative to the input, while the same enrichment is not 
observed in the IgG control IP.  
All these experiments do not demonstrate a direct interaction between Pu.1 and 
Mpeg1; in order to test this hypothesis we are currently expressing a GST-tagged version 
of both the N-terminal and the C-terminal domains of Mpeg1.  
We already have available an expression vector containing Pu.1 cDNA that may be used 
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for the in-vitro translation and S35-methionine labeling of this transcription factor. The 
two recombinant products, namely N- or C-terminal GST-tagged Mpeg1 and S35-labelled 
Pu.1 will then be mixed and assayed in pull-down experiment to reveal the direct 
interaction between these two proteins.  
We have also started the Mpeg1 knock-down experiments in primary bone marrow-
derived murine macrophages (BMDMs), using short interfering RNAs (siRNAs) in order 
to assess the functional role of Mpeg1 in the expression of macrophage inflammatory 
genes, at basal state and upon inflammation. We designed and tested five different short 
hairpin RNAs (shRNAs), reported in Fig. 34A, in comparison with the empty vector and 
selected two shRNAs based on their increased knock-down efficiency assessed both at the 
mRNA and at protein level. These two shRNAs induce very efficient depletion of Mpeg1 
after 48hrs, in both resting and activated BMDMs (Fig. 34B and C). We then screened a 
panel of 20 among macrophage-specific and inflammatory genes in both Mpeg1-depleted 
and control (empty vector transfected) BMDMs and observed a significantly decreased 
expression for FMS and Cd68 genes, two macrophage-specific genes coding for surface 
proteins important for macrophages recruitment and differentiation (Fig. 34D). This 
preliminary result could suggest a role of Mpeg1 in macrophage differentiation; we did not 
notice a significant delay in the differentiation of BMDMs in absence of Mpeg1 upon an 
initial assay; however this aspect deserves more in-depth investigation.  
Remarkably, we also observed a decreased mRNA expression of some very interesting 
inflammatory genes, such as IP10 and Tnf-α (Fig. 34E), which are both involved in 
chemokine and cytokine secretion, respectively, upon the inflammatory burst. 
Based on these encouraging but preliminary results, we have just started the RNA-
seq analysis of BMDMs upon shRNA-depletion of Mpeg1 at both basal and inflamed state, 
to expand our investigation on the function of this protein in the regulation of development 
and inflammation.  
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Fig. 34: Functional characterization of Mpeg1 depletion in macrophages. A) Western 
blot analysis of the screening of shRNAs targeting Mpeg1 gene in bone marrow derived 
macrophages (BMDM) transfected with either empty vector (EV) or with shRNAs. B) WB 
analysis and C) quantitative PCR (qPCR) readout of BMDMs untreated (UT) or treated 
with LPS for 4hrs (4hrs) and transfected with either EV or the two shRNA constructs for 
Mpeg1 (sh1 and sh2). D) QPCR measurement of a set of macrophage-specific genes in UT 
BMDMs transfected with EV or sh1/sh2. E) Gene expression levels of LPS-responsive 
genes in BMDMs UT or LPS-treated and transfected with EV or sh1/sh2. 
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We are also setting ChIP-seq experiments in control and Mpeg1-depleted BMDMs to 
evaluate the genome-wide distribution and level of Pu.1, H3K4me1 and H3K27Ac in 
dependence of Mpeg1 in basal and stimulated condition. 
 
5.4 Dissection of hPTMs associated with enhancers of inflammatory genes in 
macrophages. 
 In order to reconstruct the enhancers’ chromatome in its completeness, we also 
investigated the histone post-translational modifications (hPTMs) associated with these 
cis-regulatory elements, the so-called “modificome”. We employed the native-ChroP (N-
ChroP) approach, recently established in our laboratory in HeLaS3 cells (Soldi and 
Bonaldi 2013). Similarly to X-ChroP, this strategy allows to comprehensively profile 
hPTMs co-enriching at distinct chromatin regions, biochemically immunopurified by ChIP 
using a defined mark as bait. The N-ChroP has the remarkable advantage of enabling the 
assessment of co-associating PTMs, not only at the intra-molecular level within the same 
histone, but also at the inter-molecular level, among the core-histones within the same 
intact mono-nucleosome, purified as a single entity. 
 
5.4.1 N-ChroP strategy to characterize the H3K4me1-modificome  
 We applied the standard N-ChroP strategy (Soldi and Bonaldi 2013) in RAW 264.7 
cells, using H3K4me1 as bait. 
The experimental approach is schematized in Fig. 35A: cells were first lysed and the nuclei 
were enriched by density centrifugation over a sucrose cushion. The purified nuclei were 
then digested using micrococcal nuclease S7 (MNase), monitoring the reaction over-time 
at fixed enzyme concentration (Fig. 35B) to obtain a chromatin fragment highly enriched 
in mono-nucleosomes (Fig. 35C). This fraction was used as input and incubated with anti-
H3K4me1antibody; the bound chromatin was then captured on magnetic beads and the  
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Fig. 35: The N-ChroP strategy for the characterization of the modificome of 
H3K4me1-chromatin. A) Schematic representation of the N-ChroP strategy. Unfixed 
cells are lysed and chromatin enzymatically fragmented prior to ChIP. Eluted proteins are 
separated via SDS and histones are ArgC-like digested and analysed by LC-MSMS. B) 
Small scale MNase test digestion of purified nuclei. C) MNase-digested input prior to 
H3K4me1-ChIP. D) Coomassie stained SDS-PAGE of input and ChIP: green boxes 
indicate the histone bands excised for LC-MS/MS analysis. 
 
eluted proteins were separated via SDS-PAGE (Fig. 35D). Core histones from both the 
ChIP-ed material and the input were excised and subjected to ArgC-like digestion, to 
ensure the generation of peptides of optimal length for the subsequent LC-MS/MS 
analysis. Samples were analyzed on a high-resolution mass-spectrometer and the raw files 
were subjected to hPTM search using the MaxQuant software (Cox and Mann 2008; Cox, 
Neuhauser et al. 2011). Identified hPTMs were validated through manual inspection of the 
corresponding MS/MS fragmentation spectra, for exact modification site assignment. 
 In order to quantify the relative abundance of each distinct modified isoform in 
both ChIP and input, we used the intensity-based label-free strategy already described 
(Jung, Pasini et al. 2010; Soldi and Bonaldi 2013). Briefly, for each modified peptide 
isoform we reconstructed an extracted ion chromatogram (XIC), based on the theoretical 
exact mass (See also Appendix 4). Fig. 36A illustrates the survey scan (left) and the XIC 
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(right) for peptide 3 – 8 of histone H3 in the chromatin input (upper panels) and in the 
ChIP (bottom panels), when H3K4me1 is used as bait. The relative abundance of all the 
modified forms of a peptide is determined as the XIC of each modified peak over the sum 
of the XICs of all the modifications occurring on the same peptide, expressed as 
percentages (RA%). Then we determined the hPTM relative enrichment in the ChIP as the 
ratio between its RA% in the ChIP and the corresponding one in the input (Fig. 36A). 
The relative abundances of the different modified forms of peptide H3 (3-8) were 
measured (Fig. 36B): in the input, 87% of K4 is unmodified, 12% is mono-methylated, 
while the di- and tri-methylated species account for 0.6% and 0.07% of the total, 
respectively. In the ChIP-ed material, 39% of K4 is unmodified, while 60% is mono-
methylated and the di-/tri-methylated species still remain around the 1% in total (1.28% 
and 0.03%, respectively). The calculated relative enrichment indicates that mono-
methylated K4 increases of about 5 fold (2.32 fold in log2) upon H3K4me1-N-ChroP. 
Importantly, both unmodified and tri-methylated K4 are depleted, suggesting that we could 
specifically enrich for enhancers (H3K4me1Hi/H3K4me3Low) (Heintzman, Stuart et al. 
2007) and deplete the promoter regions, marked by H3K4me3. Di-methylation on lysine 4 
is increased in the ChIP of about 2 fold (1 fold in log2); however its overall abundance 
remains around 1% (Fig. 36C).  
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Fig.36: Intensity-based quantification of peptide 3 – 8 of histone H3 in H3K4me1 N-
ChroP. A) Survey scan (left) and XIC (right) for peptide 3 – 8 of H3 in the input (up) and 
in ChIP (bottom). This peptides contains Lys 4 that can be unmodified (blue), mono- (red), 
di- (green) or tri-methylated (orange); the relative abundance and the relative enrichment 
of a hPTM are calculated according to the shown formulas (AUC = area under the curve). 
B) Pie-charts representing the relative abundance of peptide H3 (3 – 8) forms in the input 
(left) and in ChIP (right). C) Log2 relative enrichment of peptide 3 – 8 forms in H3K4me1 
N-ChroP experiment. D) WB validation of H3K4me1 enrichment in the ChIP over the 
input; total H3 was used as normalizer for the fold enrichment calculation as 
H3K4me1(ChIP/Inp)/H3(ChIP/H3). 
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We validated the enrichment of H3K4me1 in the ChIP relative to the input also by western 
blot (Fig. 36D), confirming about 5 fold enrichment of the bait, normalized on the total 
level of H3. These results suggest that the N-ChroP works efficiently also in RAW 264.7 
cells using H3K4me1 as bait. 
In addition to the expected enrichment of the bait and the depletion of the tri-
methylated K4 (Fig. 37A) in H3K4me1 IPs, we observed a general decrease of H3K9me3, 
alone or in combination with acetylated K14 (K9me3 and K9me3/K14Ac, respectively), in 
accordance with the fact that this modification is a well-established mark of 
heterochromatin (Heard, Rougeulle et al. 2001; Peters, Kubicek et al. 2003). We also 
detected a depletion of H3K79me3, which has been associated with gene silencing (Barski, 
Cuddapah et al. 2007). Interestingly, the H3K79me2 was found enriched in our N-ChroP. 
This result confirms already published evidence suggesting that di-methylation of lysine 79 
is mutually exclusive with the tri-methylation on the same residue and that H3K79me2 is 
typically enriched at actively transcribed genes (Sawado, Halow et al. 2008). As expected, 
we confirmed a global increase of the di-acetylated form of peptide (9 – 17) 
(K9Ac/K14Ac) and both the mono- and the di-acetylated forms of peptide (18 – 26) 
(K18Ac and K18/K23Ac). These results are in accordance with the general view that 
histone hyper-acetylation positively correlates with a relaxed chromatin conformation at 
actively transcribed regions (Marushige 1976).All these results confirm the robustness of 
our approach.  
Due to their importance in enhancers’ functional regulation, we extended the analysis to 
H3K27me3 and H3K27Ac, two markers that should allow distinguishing between poised 
and active enhancers, respectively (Creyghton, Cheng et al. 2010). Lysine 27 is at the N-
terminus of peptide (27 – 40) produced upon ArgC-like digestion of histone H3; the 
unambiguous identification of modifications at this amino acid relies on the first y-ion (y1) 
and on all the b-ions produced upon fragmentation. Tri-methylation and acetylation 
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generate a very similar delta mass (+42.0469 Da and +42.0106 Da, respectively), that is 
however easily distinguishable by high-resolution mass-spectrometry. The use of Q 
Exactive allowed the correct modification assignment because of its “high-high” 
acquisition modality.  
We obtained good fragmentation spectra that enabled the robust identification and 
quantification of tri-methylation of lysine 27. We did not observe any significant increase 
in ChIP, probably suggesting that we are enriching a pool of distinctH3K4me1-enhancers 
in different functional states, such as active, poised and inactive. Instead the mass spectra 
for H3K27Ac were not of a quality sufficient for a reliable identification and accurate 
quantification of this mark. This might be the consequence of the overall low abundance of 
the mark; to overcome this problem, we are setting a targeted-MS strategy to increase the 
signal-to-noise of the peak corresponding to this modification.  
Surprisingly, within the same peptide we observed a strong increase of di- and tri-
methylation at K36, alone or in combination with K27 mono- or di-methylation. Both 
K36me2 and K36me3 correlate positively with gene expression and with RNA polymerase 
II transcription elongation, together with H3K79me2 and with mono-ubiquitination of 
lysine 120 of histone H2B (H2BK120ub1) (Fuchs, Hollander et al. 2014). The enrichment 
of H3K36me2/3 levels at enhancers can be explained with twofold models: either we are 
enriching intragenic enhancers that are actively transcribed by the RNA polymerase II; or 
small non-coding RNAs transcription may occur at enhancers (eRNA), leading to 
deposition of these marks at these regions. In murine macrophages, about 30 – 40% of 
enhancers are intragenic (Ghisletti, Barozzi et al. 2010): a significant enrichment of this 
class of enhancers could indeed explain the observed increase of H3K36me3.  
Interestingly, two new functions for H3K36me3 have been recently proposed: first, this 
mark could serve to distinguish, in combination with H3K4me1 and H3K27Ac, intragenic 
and extragenic active enhancers from inactive or poised ones (Zentner, Tesar et al. 2011). 
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Fig. 37: Relative enrichment of hPTMs in H3K4me1 ChIP. A) Relative enrichment of 
hPTMs in peptides 3-8, 9-17, 18-26, 27-40 and 73-83 of histone H3. B) Relative 
enrichment of hPTMs in peptide 4-17 of histone H4 and peptide 4-11 of histone H2A. 
Values of RE are expressed as log2 values. 
 
Second, H3K36me3 could work as good indicator for eRNA transcription in logistic 
regression model (Zhu, Sun et al. 2013).These considerations confirm that our result could 
be the consequence of the co-occurrence of both the two models. Additional ChIP-MS 
experiments could help to better dissect among these options. For instance, it could be 
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interesting to carry out N-ChroP experiments using H3K27Ac as bait to dissect active from 
poised enhancers. It would also be interesting to analyse the enhancers’ modificome upon 
RNase treatment to characterize eRNA role in H3K36me3 deposition. 
As anticipated above, the N-ChroP approach allows also characterizing inter-
molecular associations, namely hPTMs enriched on different histones within the same 
mono-nucleosome. By expanding our analysis we evaluated a general increase of multiply 
acetylated forms of the peptides 4 - 17 and 4 – 11 on histone H4 and H2A, respectively. 
This confirms the general enrichment of hyper-acetylated forms in H3K4me1-mono-
nucleosomes (Fig. 37B). 
To evaluate the dynamics of H3K4me1-modificome upon an inflammatory 
stimulus, we carried out three N-ChroP experiments in parallel, using mono-nucleosomes 
from RAW 264.7 cells which were untreated or treated with LPS for 1 or 4hrs (Fig. 38A). 
Upon ChIPs, proteins were eluted and separated by SDS-PAGE (Fig. 38B) and core-
histones were then analysed through geLC-MS/MS, as above described. Histone PTMs 
relative enrichments in the three different conditions were calculated and are illustrated in 
the heat map in Fig. 38C.  
In all the three experiments we confirmed a constant depletion of the heterochromatic 
marker H3K9me3, both alone and in combination with H3K14Ac. This effect is paralleled 
by a constant enrichment of the mono- and di-acetylated forms of the peptides (9 – 17) and 
(18 – 26) during the early inflammatory response. These trends were expected. 
Preliminary analysis of the data revealed PTMs showing a dynamic behavior during the 
inflammatory response: H3K79 mono- and di-methylated are partially enriched, in line 
with the expected activation of gene transcription. The H3K36me2/me3-containing 
peptides showed different dynamics: H3K36me2 is stably enriched in all the conditions, 
while the association of this modification with H3K27me2 (K27me2/K36me2) shows a 
linear enrichment from untreated cells to 4hrs treated cells. We can explain this result 
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Fig. 38: Histone PTMs within H3K4me1-regions profiled at basal conditions and 
upon inflammation. A) Chromatin input from untreated (UT) or treated for 1h (1h) or 
4hrs (4hrs) with LPS using the tc-N-ChroP approach. B) Coomassie-stained SDS-PAGE of 
the inputs and ChIPs from tc-N-ChroP using H3K4me1 as bait. C) Heat-map visualization 
of the relative hPTM enrichment for the marks identified in theH3K4me1-
mononucleosomes and quantified through the intensity-based label-free approach. (Red = 
positive enrichment, blue = negative enrichment; results shown as log2 of the relative 
enrichment). 
 
either hypothesizing a higher number of accessible intragenic enhancers’  
immunoprecipitated, or a higher rate of transcription occurring at these cis-regulatory 
regions upon LPS.  
Unexpectedly, we also observed the enrichment of H3K9me1, alone and in combination 
with K14Ac (H3K9me1 or H3K9me1/H3K14Ac), at 1h and, to a lesser extent, at 4hrsupon 
LPS treatment. The presence of this mark has been described in association with H3K4me1 
at the enhancers of genes activated during the differentiation of hematopoietic stem 
cells/progenitor cells into erythrocytes precursors (Cui, Zang et al. 2009). The increased 
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level of this mark in H3K4me1-regions could be explained by its specific deposition at the 
enhancer of very early-response genes, which are activated immediately after LPS 
stimulus, but already switched-off after 4hrs of LPS treatment. Such a model could also 
explain the observed depletion of H3K27me3, marker of poised enhancers, at the late time 
point. 
 We also observed a constant enrichment of the tri- and tetra-acetylated forms of 
peptide 4-17 of histone H4 during the inflammatory response; interestingly these 
enrichments seem to be slightly higher after 4hrs of LPS treatment, compatible with an 
accumulation of these marks in response to the further activation. Overall, additional 
analyses at shorter time-intervals are required to assess more in depth the dynamics of this 
model. 
 
5.4.2 Setup and initial assessment of a new strategy combining formaldehyde cross-linking 
with MNase digestion to analyse the modificome of Pu.1-chromatin 
To dissect the Pu.1-modificome, we modified the original N-ChroP protocol to use 
a transcription factor as bait, taking into account that TFs by definition bind in the 
nucleosome-free region (NFR). To achieve this goal we first stabilized with formaldehyde 
the interactions between the transcription factor and the underlying DNA, with the protocol 
already used in X-ChroP. Second, we combined the cross-linking with the MNase 
enzymatic digestion instead of sonication, to tightly regulate the DNA length and obtain a 
more homogeneous input for the Pu.1 ChIP. 
Briefly, RAW 264.7 cells were cross-linked with formaldehyde and then purified nuclei 
were digested with a high concentration of MNase to cut the fixed chromatin. The reaction 
was monitored over time on an agarose gel at fixed MNase concentrations and the 
digestion was stopped when the input was mainly represented by mono-/di-/tri-
nucleosomes. The input was incubated with antibody against Pu.1 and the eluted proteins 
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were separated by SDS-PAGE (Fig. 39A). Fig. 39B shows that we could successfully 
immunopurify an intact and stoichiometric histone octamer. Remarkably, this enrichment 
is specific, since it is abolished by competing the anti-Pu.1 antibody with the specific 
peptide used in X-ChroP experiment (for details se 3.2.2 and material and methods). The 
competition reflects the increase of the Pu.1 protein in the competed FT fraction relative to 
the non-competed one(Fig. 39C). All together these results indicate that we can enrich the 
chromatin fraction specifically associated with Pu.1. 
We then focused on the analysis of hPTMs by MS. Firstly, we evaluated the relative 
abundance and enrichment of modifications on peptide H3 (3 – 8). H3K4me1 represents 
the positive control because of its known association with Pu.1. The RA% calculation of 
the input recapitulates what we already found in the N-ChroP input: 90% of K4 is 
unmodified, 9% is mono-methylated, while the remaining di- and tri-methylated K4 
account for less than 1% (0.6% and 0.07%, respectively). Upon Pu.1 enrichment, K4me1 
increases up to 13%, while the unmodified K4 slightly diminishes (85%) and di- and tri-
methylated K4 account for 1.3 and 0.19% respectively (Fig. 39D).However, the relative 
enrichment of 1.4 fold for K4me1is not enough to conclude that the X-ChIP worked 
successfully using the present experimental conditions. In fact, we also observed a relative 
enrichment of about 2 fold for H3K4me2 and 2.5 fold for H3K4me3 (1 fold and 1.3 fold in 
log2, respectively), even though their overall percentage account for maximum 1% of the 
total modifications at this residue (Fig. 39E). 
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Fig. 39: X-ChroP/MNase combined strategy for the characterization of the 
modificome of Pu.1-mononucleosomes. A) Schematic representation of X-ChroP/MNase 
combined strategy. Formaldehyde-fixed cells are lysed and chromatin is enzymatically 
fragmented prior Pu.1 ChIP. Eluted proteins are de-crosslinked and separated via SDS-
PAGE; histone bands are ArgC-like digested and analysed through LC-MSMS. B) 
Coomassie stained SDS-PAGE shows the Input and ChIP from Pu.1 X-ChroP/MNase 
experiment. C) Coomassie stained SDS-PAGE shows that the 18X fold peptide 
competition completely abolishes the specific nucleosome enrichment in the competed 
ChIP (left).This effect is mirrored in the WB (right) by the increase of Pu.1 levels in the 
corresponding flow-through (FT). D) Pie charts representing the relative abundance of 
peptide 3 – 8 of histone H3 in the input (left) and in the ChIP (right). E) Log2 relative 
enrichment of peptide 3 – 8 in H3K4me1 X-ChroP/MNase combined experiment. 
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These observations suggest that the protocol needs further optimization to obtain a more 
efficient H3K4me1-enrichmentand a corresponding H3K4me3 depletion, to achieve a 
more faithful representation of enhancers. 
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DISCUSSION 
In this thesis I describe how I carried out the in depth characterization of enhancers’ 
protein composition in the macrophage-like cell line RAW 264.7 by using a combined 
approach based on biochemical methods for chromatin fractionation and enrichment and 
MS-based proteomics. We performed this analysis both in the basal and inflamed states, 
achieving a temporal analysis of the global transcriptional response elicited in 
macrophages by lipopolysaccharide.  
We investigated the enhancers’ chromatome based on the assumption that the 
protein composition and architecture of these regulatory regions strongly correlate with 
their functional state. Enhancers are well characterized functionally but information on 
their protein determinants is limited: they are defined as genomic sequences extensively 
bound by transcription factors thus leading to reduced nucleosome occupancy. Markers of 
these regions are hyper-sensitivity to DNase I and enrichment of mono-methylation of 
lysine 4 of histone H3 (H3K4me1), in the presence of low tri-methylation of the same 
residue (H3K4me1Hi/H3K4me3Low) [Heintzman et al 2007]. In macrophages, enhancers 
are further marked by the master regulator Pu.1, a pioneer TF that allows the recruitment 
of stimulus-specific transcription factors in response to distinct inflammatory stimuli, 
necessary for fine-tuning gene expression of different set of genes in time and space. 
To study the enhancers’ chromatome we employed the ChroP approach recently 
established by our laboratory. This strategy combines the ChIP technique and MS-based 
proteomics, thus allowing the characterization of both the hPTMs pattern (modificome) 
and the interactors (interactome) associated with a chromatin landscape marked by a 
specific hPTM. We enriched biochemically enhancers by using both H3K4me1 and Pu.1 as 
bait in the preparative ChIP.  
The setup of ChroP in this model system required the optimization of different 
steps, such as: the SILAC labeling of RAW 264.7; the appropriate cross-linking conditions 
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to stabilize TF-DNA interaction for the subsequent MS analysis; the setup of a time-course 
experiment for the temporal analysis of enhancers during the early inflammatory response.  
Based on the SILAC ratio distribution we defined statistical cut-offs to discern specific 
binders from background proteins. One of the top scoring proteins in the H3K4me1-
interactome was Pu.1 itself, thus demonstrating that in macrophages enhancer regions are 
truly marked by the co-occurrence of this hPTM and the master regulator. In genome-wide 
ChIP-seq analysis this information could only be addressed by carrying out sequential 
ChIPs, followed by sequencing and tracks’ alignment. 
We considered as genuine enhancers’ determinants proteins enriched in both 
H3K4me1 and Pu.1 interactomes, identifying enhancer-binding proteins, transcription 
factors/co-activators and well-characterized markers of macrophage enhancers’, such as 
the histone acetyl-transferase p300. Moreover, we observed an enrichment of the cohesin 
complex and of several SWI-SNF-associated complexes that may be involved in both 
positive transcription regulation (like the PBAF and the RNA polymerase II-associated 
complex) and negative transcriptional regulation (like the Brg1-Sin3a complex) or whose 
function may vary in dependence on the functional state (such as the LAR complex). 
Interestingly, we also identified two complexes related to RNA processing, namely Emerin 
24 complex and p54nrb-PSF-matrin3 complex, and the spliceosome complex. The 
presence of these complexes as intrinsic part of the enhancers’ architecture could be in 
accordance with the co-occurrence of gene transcription and mRNA processing. We also 
observed an unexpected enrichment of the MCM complex. In addition to an established 
function in DNA replication, some subunits of MCM have been recently described to 
associate with RNA polymerase II, thus suggesting a possible new role for this complex in 
the Stat1 target gene activation and RNA polymerase II-mediated transcription. In order to 
discern between enhancer-specific enrichment and chromatin-association of these 
unexpected complexes, it would be interesting to compare the data we have acquired with 
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experimental data coming from a completely unrelated landscape where we do not expect 
the presence of such complexes, such as the hetero-chromatic H3K9me3-marked 
chromatin. 
 In the time-course experiment, we profiled all these interactors during the early 
phases of the inflammatory response by treating RAW 264.7 cells for 1or 4 hrs with 
lipopolysaccharide. These analyses revealed three dynamic scenarios: proteins that remain 
stably associated with these chromatin regions, proteins recruited to enhancers and proteins 
evicted upon the stimulus. Through our proteomics analysis we could conclude that 
enhancers are composed by a high-ordered structure which is quite stable and maintained 
throughout the inflammatory response. However, we also identified some dynamic changes 
in the enhancers’ composition upon LPS treatment. Remarkably, Pbrm1 and Smarcc2 were 
both recruited during the inflammatory response; these proteins are subunits of the PBAF 
complex which is the only member of the SWI/SNF-related family that links chromatin 
remodeling activity with positive gene expression regulation. Pcna and Mki67 proteins are 
markers of DNA replication and were found to be dynamically displaced from enhancers 
during the inflammatory response, together with the DNA methyl-transferase Dnmt1, 
which is associated to gene silencing.  
 The time-course X-ChroP experiment also revealed a group of proteins newly 
recruited at enhancers upon LPS treatment. The induction of some of them during 
inflammation had been previously reported. This is for instance the case for the 
transcription factors Junb and Stat1, both of which promote activation of target 
inflammatory genes. Our finding suggests that the other newly recruited proteins may be 
involved in the activation of enhancers upon LPS treatment. Among them we found the 
enhancer binding protein Cebpz, the transcription elongation factor Supt6h and two 
PHYIN-domain-containing proteins (Mndal and Ifi204), involved in transcriptional 
regulation. To gain further insights into the role of these determinants in the regulation of 
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gene expression upon inflammation, we intend to carry out the ChIP-seq analysis of their 
genomic localization prior and during the inflammatory response; moreover, we will have 
available the genomic profiles of both the baits used in the tc-ChroP and of many other 
proteins with putative role as TFs from collaborators at IEO. We plan to compare the 
ChIP-seq profiles of these known and novel determinants, to confirm whether they localize 
at enhancers and to assess whether they synergize/cooperate with Pu.1 or other enhancers’ 
markers. 
Altogether our results suggest that macrophages respond to the inflammatory 
stimulus by stopping cell proliferation and committing towards a global gene 
transcriptional activation, which correspond to certain extent of chromatin remodeling and 
DNA de-methylation at enhancers. The finely-tuned gene expression regulation of 
inflammatory genes in time and space is achieved by the cell through the interplay between 
positive and negative transcriptional regulators. Moreover macrophages enhancers seem to 
be characterized by an overall stable higher-order structure, in line with a model that 
suggests the existence of a chromosomal-looping bridging together enhancer and promoter 
regions of corresponding genes. This higher-ordered structure seems to exist prior to the 
transcriptional activation induced by the inflammatory stimulus and is maintained 
throughout the inflammatory response, with only minor internal dynamics of specific 
factors. The plasticity of some chromatin determinants favors the activation of specific set 
of genes while the recruitment of distinct TFs and transcriptional co-activators serves to 
activate specific gene expression programs at the required time upon stimulus. Data from 
chromosome-conformation capturing (3C)-based sequencing technologies suggest a model 
where the majority of chromatin interactions, namely enhancers-promoter looping, are 
already formed within a cell and represent a stable architecture. Upon a specific stimulus, 
only some of these loops are reorganized while others maintain the previous structure; 
remarkably, this model is in perfect agreement with our findings.  
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The model of the chromosomal looping between enhancers and promoters as mechanism 
of transcription regulation is still under debate and our findings are not sufficient to prove 
or discard this model. To immunopurify enhancers, we used ChIP-grade antibodies against 
the two known markers that better define these cis-regulatory regions in macrophages, 
namely the H3K4me1 and the TF and master regulator of macrophages Pu.1. In the X-
ChroP approach, as in many other techniques used to study chromatin composition, we 
utilized formaldehyde-fixed chromatin to stabilize DNA-/ protein-protein interactions, 
therefore it would be difficult to discriminate between determinants associated with 
promoters or enhancers in a scenario of chromosomal looping where these two cis-
regulatory regions bridge together and appear as a unique and well-structured genomic 
entity that fine tunes gene transcription.  
The X-ChroP strategy allows the unbiased characterization of a specific chromatin 
region and in our analysis we identified expected and already known determinants that 
have a central role in the enhancer regulation, thus confirming the robustness of the 
approach itself; moreover we characterized novel and potentially very interesting 
determinants both in basal condition and during the transcriptional activation response. 
Currently, we are working on the validation and follow-up of some of these novel 
determinants and therefore these findings may expand the knowledge on enhancer 
composition as well as on their mechanism of action during inflammatory response. 
 Mass-spectrometry is a well-established and powerful tool also for the analysis of 
PTMs without a priori knowledge. Histone post-translational modifications (hPTMs) 
represent an additional layer of epigenetic determinants that act in concert with TFs and 
chromatin remodelers to regulate the functional state of the underlying DNA. We achieved 
the dissection of the enhancers’ modificome through the ChroP approach using H3K4me1 
and Pu.1 as baits. We applied to RAW 264.7 cells the already optimized N-ChroP protocol 
to purify of mono-nucleosomes enriched in H3K4me1 and analyzed by MS PTMs co-
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associations, not only within the same histone molecule but also among distinct core-
histones within the same mono-nucleosome.  
Through the analysis of three parallel N-ChroP experiments, we performed the 
dynamic dissection of the H3K4me1-modificome starting from cells untreated or treated 
for 1h or 4hrs with LPS. Chromatin regions marked by H3K4me1 revealed an overall 
enrichment for markers of active chromatin, like the hyper-acetylated forms of H3 and H4 
and H3K79me2; this enrichment was mirrored by a corresponding depletion of hetero-
chromatic marks, such as H3K9me3. Unexpectedly, we observed the enrichment of H3-
K36me2 and K36me3, two markers typically associated with transcription elongation, 
which were further increased upon induction of the inflammatory response. Twofold 
models may explain this result: first, in macrophages around 30 – 40% of enhancers are 
intragenic, thus correspond to regions highly transcribed that are enriched with these 
markers. A second possibility may be occurrence of lncRNAs transcription at enhancers, 
the so-called eRNAs, which are proposed to promote deposition of these marks at 
transcribed cis-regulatory regions. Although the transcription of lncRNAs at enhancers is 
extensively described, their precise function is still under debate. At present, we cannot 
distinguish between these two hypotheses; one possibility could be to carry out ChroP 
experiment in presence of RNase to impair eRNA production and then assess the stability 
of the higher-order structure characterized and the presence of the corresponding 
modificome. We also detected a very rapid enrichment of H3K9me1 after 1hr of LPS, 
followed by a decrease to almost basal condition at 4 hours, which is mirrored by a quick 
depletion of H3K27me3 at the same time point. These two observations may be explained 
by the activation of a class of very early enhancers, which loose very rapidly the poised 
mark and acquire the H3K9me1 mark to activate target genes quickly, and then return with 
the same fast kinetic to a basal state.  
A well-established marker of active enhancers in macrophages is represented by 
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H3K27Ac: in general, repressed genes loose this modification upon transcriptional 
activation, while active genes enhancers’ acquire it. This mark is typically investigated via 
antibody-based approaches, indeed the correct site-specific assignment of modifications is 
particularly challenging by MS, since this modification is located at the N-terminal of the 
peptide H3 (27 – 40) generated by ArgC-like digestion, thus its identification only relies on 
the first y-ion and on the b-ion series. High-resolution mass spectrometer allows 
distinguishing with high confidence between tri-methylation and acetylation on this 
residue; however the very low abundance of H3K27Ac hampers its identification and 
quantification. Due to the functional relevance of this mark especially in the context of 
enhancers, we are currently establishing MS-targeted strategies to better isolate the peptide 
bearing this modification, to increase its signal-to-noise and obtain a better-quality 
fragmentation spectrum. To quantify this modification more reliably, we plan also to 
synthesize isotopically-labeled peptides, such as AQUA peptides, bearing H3K27Ac alone 
or in combination with other modifications. The use of AQUA peptides as spike-in will 
help building the optimal targeted method for accurate quantification by following the 
elution profile and fragment ions of the synthetic peptide. 
Based on the data so far acquired, we envisage that an interesting next step will be 
to extend our analysis to other types of modifications co-occurring within the same 
enriched chromatin regions, such as arginine methylation and lysine ubiquitination, 
crotonylation and propionylation. The MS raw data already acquired in fact represent a 
valuable repository to gain information about more exotic PTMs and their possible 
combinations specifically enriched and functionally active at enhancers. 
 Interestingly, our temporal analysis of enhancers’ determinants revealed the 
dynamic recruitment of the Polybromo protein 1 (Pbrm1). This protein contains six 
different bromo-domains with high specificity for the acetylation of lysine residues on 
histone H3, namely K4, K9, K14, K18 and K23. Remarkably, we identified the enrichment 
Discussion 
 
 
116 
of 4 out of 5 of these acetylated residues during the inflammatory stimulus, which function 
as docking sites for the recruitment of the PBAF complex. As such this represents an 
emblematic case, where the combined analysis of N- and X-ChroP enables observing the 
enrichment of a certain histone mark that serves to recruit the corresponding “reader”, 
which finally promotes gene activation through chromatin remodeling. 
More in general, I foresee that the combination of ChroP and ChIP-seq can lead to the 
comprehensive characterization of a distinct chromatin region from two different but 
tightly complementary perspectives. While ChroP allows for a “blind” and unbiased 
characterization of known and unexpected chromatin determinants, their genome-wide 
localization can be then validated and investigated by a “targeted” ChIP-seq strategy. 
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APPENDIX 1. The enhancers’s basal chromatome: proteins identified upon the 
intersection of H3K4me1 and Pu.1 basal interactomes.Protein determinants of enhancers 
where identified based on their SILAC ratio and ratio counts (RC)in four X-ChroP 
experimental replicas (H3K4me1 Forward, H3K4me1 Reverse, Pu.1 Forward, Pu.1 
Reverse). (Fwd = Forward, Rev = Reverse). Fasta identifiers, gene names and protein 
names are given. 
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Fasta 
headers Gene names Protein names Ratio H/L  H/L RC  Ratio L/H H/L RC  Ratio H/L H/L RC  Ratio L/H H/L RC
P50247 Ahcy Adenosylhomocysteinase 1.65        58 2.02        32 13.46      23 32.21       24
E9Q3L4 AI607873 Interferon-Inducible Protein X 2.27        8 2.78        7 12.28      4 18.23       4
Q9DBR0 Akap8 A-kinase anchor protein 8 2.39        21 3.58        15 11.28      3 20.59       2
O35381 Anp32a Acidic leucine-rich nuclear phosphoprotein 32 family member A 1.98        31 2.84        25 14.16      18 47.36       19
Q9EST5 Anp32b Acidic leucine-rich nuclear phosphoprotein 32 family member B 2.31        21 3.06        18 9.10        12 49.08       7
P28352 Apex1 DNA-(apurinic or apyrimidinic site) lyase;DNA-(apurinic or apyrimidinic site) lyase, mitochondrial 4.82        22 8.79        9 10.60      10 28.57       4
O35841 Api5 Apoptosis inhibitor 5 1.86        21 2.71        21 7.27        7 37.24       7
E9QAE3 Btaf1 RNA polymerase II, B-TFIID transcription factor-associated 1.92        10 2.01        12 12.12      13 14.14       12
Q8CH18 Ccar1 Cell division cycle and apoptosis regulator protein 1 2.57        20 3.95        11 10.13      5 21.71       5
Q8VDP4 Ccar2 DBIRD complex subunit KIAA1967 homolog 1.55        37 2.43        24 12.23      10 26.79       8
P24788 Cdk11b Cyclin-dependent kinase 11B 2.00        18 2.74        16 10.24      2 18.74       7
Q9CXS4 Cenpv Centromere protein V 5.33        6 7.06        8 12.53      8 38.24       2
Q8BHG9 Cggbp1 CGG triplet repeat-binding protein 1 2.55        4 3.31        5 11.09      3 29.90       2
E9QAS5 Chd4 Chromodomain-helicase-DNA-binding protein 4 2.39        80 2.99        61 13.50      40 33.32       38
G5E8I8 Cherp Calcium homeostasis endoplasmic reticulum protein 1.61        8 2.41        4 9.47        5 19.96       5
O88712 Ctbp1 C-terminal-binding protein 1 2.15        4 3.08        3 14.06      6 38.23       5
P56546 Ctbp2 C-terminal-binding protein 2 1.83        17 2.65        14 14.07      9 28.55       11
Q9CWL8 Ctnnbl1 Beta-catenin-like protein 1 2.05        16 2.41        9 12.80      2 40.31       4
Q3U741 Ddx17 Probable ATP-dependent RNA helicase DDX17 2.21        41 3.49        33 12.98      9 19.11       16
Q9JIK5 Ddx21 Nucleolar RNA helicase 2 2.89        91 4.15        76 9.82        21 17.37       27
Q8BTS0 Ddx5 Probable ATP-dependent RNA helicase DDX5 2.04        158 3.53        139 10.36      70 30.50       70
E9QNN1 Dhx9 ATP-dependent RNA helicase A 2.14        163 3.42        127 12.25      54 35.10       62
H3K4me1_Fwd H3K4me1_Rev Pu.1_Fwd  Pu.1_Rev 
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Q9CSH3 Dis3 Exosome complex exonuclease RRP44 1.95        29 2.39        23 8.34        12 16.10       13
Q6NZB0 Dnajc8 DnaJ homolog subfamily C member 8 2.71        7 3.81        4 9.68        6 42.77       3
P13864 Dnmt1 DNA (cytosine-5)-methyltransferase 1 2.70        46 3.38        38 12.30      34 20.35       32
P70372 Elavl1 ELAV-like protein 1 1.81        49 2.63        37 13.04      20 15.05       15
B2RWS6 Ep300 Histone acetyltransferase p300 1.98        6 3.33        4 11.00      8 17.47       6
P35550 Fbl rRNA 2-O-methyltransferase fibrillarin 2.14        26 2.88        15 10.05      4 16.35       3
Q91Z50 Fen1 Flap endonuclease 1 2.50        33 3.60        15 12.60      15 35.92       10
P56959 Fus RNA-binding protein FUS 2.08        29 3.60        22 7.45        8 15.27       8
Q8CHY6 Gatad2a Transcriptional repressor p66 alpha 2.34        13 2.94        10 12.99      6 14.48       7
Q8VHR5 Gatad2b Transcriptional repressor p66-beta 2.13        13 2.74        9 8.22        2 18.23       9
P62915 Gtf2b Transcription initiation factor IIB 2.03        6 2.77        2 12.64      8 16.27       4
Q9D902 Gtf2e2 General transcription factor IIE subunit 2 2.42        4 2.88        5 11.75      3 26.49       2
Q9QZQ8 H2afy Core histone macro-H2A.1 9.45        44 19.37      31 9.87        6 25.61       4
P0C0S6 h2afz Histone H2A.Z;Histone H2A.V;Histone H2A 10.80      19 24.20      12 9.06        6 19.55       5
B1AUX2 Hcfc1 Host cell factor 1 2.09        26 2.66        20 12.95      17 22.46       22
P51859 Hdgf Hepatoma-derived growth factor 10.73      21 19.71      19 11.40      3 16.03       8
P43275 Hist1h1a Histone H1.1 8.68        22 18.29      19 9.12        5 19.40       6
P43276 Hist1h1b Histone H1.5 9.43        62 18.57      45 8.94        14 18.57       13
P63158 Hmgb1 High mobility group protein B1 3.84        45 5.69        33 10.66      14 41.08       17
P30681 Hmgb2 High mobility group protein B2 3.77        57 6.92        50 11.70      21 24.17       19
Q9CX86 Hnrnpa0 Heterogeneous nuclear ribonucleoprotein A0 2.10        64 3.38        47 13.56      19 34.86       23
Q5EBP8 Hnrnpa1 Heterogeneous nuclear ribonucleoprotein A1 2.10        85 3.56        74 11.92      36 32.47       29
O88569 Hnrnpa2b1 Heterogeneous nuclear ribonucleoproteins A2/B1 2.13        181 3.31        162 12.18      87 24.70       70
Q8BG05 Hnrnpa3 Heterogeneous nuclear ribonucleoprotein A3 1.84        130 3.08        105 12.16      42 27.44       34
Q20BD0 Hnrnpab Heterogeneous nuclear ribonucleoprotein A/B 2.42        47 3.39        48 12.82      24 35.82       27
Q9Z204 Hnrnpc Heterogeneous nuclear ribonucleoproteins C1/C2 2.43        73 3.61        66 12.25      25 34.41       24
Q60668 Hnrnpd Heterogeneous nuclear ribonucleoprotein D0 2.49        37 3.68        29 11.97      17 32.65       18
Q9Z2X1 Hnrnpf Heterogeneous nuclear ribonucleoprotein F 2.03        66 3.21        46 12.66      30 27.57       21
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Q8C2Q7 Hnrnph1 Heterogeneous nuclear ribonucleoprotein H 1.91        67 3.22        64 11.11      33 23.78       11
Q8R081 Hnrnpl Heterogeneous nuclear ribonucleoprotein L 1.85        106 2.99        73 9.92        26 32.55       30
Q9D0E1 Hnrnpm Heterogeneous nuclear ribonucleoprotein M 2.49        340 4.01        250 11.34      96 33.30       94
Q8VHM5 Hnrnpr Heterogeneous nuclear ribonucleoprotein R 2.01        68 3.05        63 11.10      12 24.87       16
Q8VEK3 Hnrnpu Heterogeneous nuclear ribonucleoprotein U 2.47        178 4.07        165 11.58      68 34.01       75
Q3TEA8 Hp1bp3 Heterochromatin protein 1-binding protein 3 10.71      61 24.69      45 7.81        7 21.14       5
Q5SWT9 Ikzf1 DNA-binding protein Ikaros 2.66        5 3.11        3 11.63      2 19.38       2
Q9CXY6 Ilf2 Interleukin enhancer-binding factor 2 2.32        15 3.44        15 13.66      6 39.30       5
Q60749 Khdrbs1 KH domain-containing, RNA-binding, signal transduction-associated protein 1 2.45        33 4.60        25 12.76      7 40.51       9
Q3U0V1 Khsrp Far upstream element-binding protein 2 2.12        86 3.70        57 9.87        23 26.51       31
P48678 Lmna Prelamin-A/C;Lamin-A/C 3.80        349 5.40        328 8.66        137 23.29       140
Q9CYI4 Luc7l Putative RNA-binding protein Luc7-like 1 2.05        7 2.83        4 7.51        2 14.64       1
Q7TNC4 Luc7l2 Putative RNA-binding protein Luc7-like 2 2.06        24 2.52        25 11.36      10 43.05       10
Q8K310 Matr3 Matrin-3 2.84        75 4.85        51 10.94      21 22.44       17
P97310 Mcm2 DNA replication licensing factor MCM2 2.12        58 2.74        44 11.72      27 15.92       31
P25206 Mcm3 DNA replication licensing factor MCM3 2.25        71 2.89        57 10.95      32 23.14       34
P49717 Mcm4 DNA replication licensing factor MCM4 2.25        52 2.86        42 11.57      23 15.68       27
Q52KC3 Mcm5 DNA replication licensing factor MCM5 2.19        60 2.94        48 10.42      21 34.83       18
P97311 Mcm6 DNA replication licensing factor MCM6 2.20        85 2.71        67 10.64      33 25.95       35
Q61881 Mcm7 DNA replication licensing factor MCM7 2.16        41 2.78        39 11.17      19 32.54       22
E9PVX6 Mki67 Marker of proliferation Ki-67 3.51        63 5.41        43 8.39        18 15.27       12
Q9JK91 Mlh1 DNA mismatch repair protein Mlh1 1.77        5 2.52        5 13.09      2 37.97       1
E9QN37 Mpeg1 Macrophage-expressed gene 1 protein 0.65        18 0.97        8 4.56        9 11.08       6
P54276 Msh6 DNA mismatch repair protein Msh6 1.94        25 2.68        19 8.83        17 14.65       14
Q9R190 Mta2 Metastasis-associated protein MTA2 2.20        45 2.75        37 13.09      18 19.90       31
Q7TPV4 Mybbp1a Myb-binding protein 1A 2.67        70 3.11        42 7.65        11 15.60       18
Q3UYV9 Ncbp1 Nuclear cap-binding protein subunit 1 2.00        16 2.51        12 13.53      6 28.91       7
P09405 Ncl Nucleolin 2.48        186 3.22        174 9.37        72 21.64       73
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Q9D0T1 Nhp2l1 NHP2-like protein 1 1.90        7 2.24        7 8.92        3 19.12       3
Q99K48 Nono Non-POU domain-containing octamer-binding protein 3.07        104 5.08        80 8.60        22 41.63       22
Q9D6Z1 Nop56 Nucleolar protein 56 2.36        26 2.77        13 7.89        1 14.12       5
Q9D6T0 Nosip Nitric oxide synthase-interacting protein 1.94        3 2.49        5 8.83        5 43.58       3
Q61937 Npm1 Nucleophosmin 2.34        65 2.78        53 9.50        26 20.74       26
Q9CPP0 Npm3 Nucleoplasmin-3 2.08        2 2.47        2 10.93      3 20.92       2
Q1HFZ0 Nsun2 tRNA (cytosine(34)-C(5))-methyltransferase 2.77        44 3.79        35 11.67      9 24.96       14
Q9CQF3 Nudt21 Cleavage and polyadenylation specificity factor subunit 5 2.58        8 4.01        11 18.10      4 15.46       3
E9Q7G0 Numa1 Nuclear mitotic apparatus protein 1 1.94        96 2.14        76 10.46      58 15.71       53
Q9DCE5 Pak1ip1 p21-activated protein kinase-interacting protein 1 2.73        9 3.97        2 13.52      4 24.98       2
Q921K2 Parp1 Poly [ADP-ribose] polymerase 1 2.82        58 3.83        47 10.35      27 17.85       39
F8VQD1 Pbrm1 Protein polybromo-1 3.82        9 5.35        9 13.71      19 17.61       18
P17918 Pcna Proliferating cell nuclear antigen 2.29        28 2.76        25 12.58      15 33.38       14
E9QPI5 Pds5a Sister chromatid cohesion protein PDS5 homolog A 3.17        50 4.30        35 10.03      27 19.67       22
P52431 Pold1 DNA polymerase delta catalytic subunit;DNA polymerase 1.77        15 2.36        14 11.93      9 14.80       12
P08775 Polr2a DNA-directed RNA polymerase II subunit RPB1 3.22        48 4.69        36 11.08      20 21.18       16
Q8CCF0 Prpf31 U4/U6 small nuclear ribonucleoprotein Prp31 1.72        14 2.29        8 13.54      5 16.61       9
Q99JF8 Psip1 PC4 and SFRS1-interacting protein 6.79        32 13.83      30 10.95      4 29.84       3
Q922I7 Ptbp1 Polypyrimidine tract-binding protein 1 1.67        70 2.64        71 12.31      43 32.08       22
Q64012 Raly RNA-binding protein Raly 2.40        52 3.48        45 12.72      23 35.78       23
P62827 Ran GTP-binding nuclear protein Ran 1.61        38 2.06        36 8.66        27 15.60       15
Q60972 Rbbp4 Histone-binding protein RBBP4 2.00        14 2.70        17 10.27      22 14.32       12
Q0VBL3 Rbm15 RNA binding motif protein 15 2.32        25 3.42        16 9.42        2 22.41       7
Q5SFM8 Rbm27 RNA-binding protein 27 1.65        7 2.15        7 8.83        7 17.86       7
Q9CWZ3 Rbm8a RNA-binding protein 8A 1.58        2 2.36        4 11.06      3 17.73       2
Q91VM5 Rbmxl1 RNA binding motif protein, X-linked-like-1 2.48        77 4.28        51 12.47      14 36.31       19
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P31266 Rbpj Recombining binding protein suppressor of hairless 2.81        20 3.83        23 8.70        4 23.91       9
Q6PFB2 Rcc1 Regulator of chromosome condensation 6.33        11 8.42        10 10.41      3 18.27       4
Q8BK67 Rcc2 Protein RCC2 4.66        68 6.62        73 8.57        22 28.55       15
Q9R1T2 Sae1 SUMO-activating enzyme subunit 1 2.44        15 3.39        8 12.00      5 41.46       2
D3YXK2 Safb Scaffold attachment factor B1 2.95        14 3.51        9 12.71      2 37.08       3
Q9JLI8 Sart3 Squamous cell carcinoma antigen recognized by T-cells 3 1.51        19 2.00        19 10.96      6 14.30       9
Q9EQU5 Set Protein SET 4.41        12 8.02        15 7.71        6 14.69       8
E9Q4Q2 Sf1 Splicing factor 1 2.42        22 3.73        17 21.45      2 15.66       7
Q8VIJ6 Sfpq Splicing factor, proline- and glutamine-rich 3.42        134 5.41        105 11.68      36 23.47       48
Q60520 Sin3a Paired amphipathic helix protein Sin3a 2.07        11 2.87        10 10.70      10 24.75       7
Q9CZU3 Skiv2l2 Superkiller viralicidic activity 2-like 2 1.63        27 2.06        26 11.17      13 15.08       14
Q3TKT4 Smarca4 Transcription activator BRG1 2.98        35 3.96        24 14.02      54 27.59       49
P97496 Smarcc1 SWI/SNF complex subunit SMARCC1 3.07        25 4.03        25 15.02      36 14.80       43
Q6PDG5 Smarcc2 SWI/SNF complex subunit SMARCC2 3.44        16 4.88        8 15.00      15 17.51       18
Q99JR8 Smarcd2
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily D 
member 2
2.94        8 4.27        9 8.99        19 28.52       17
Q9CU62 Smc1a Structural maintenance of chromosomes protein 1A 3.69        64 4.87        50 13.57      39 22.72       45
Q9CW03 Smc3 Structural maintenance of chromosomes protein 3 3.50        81 4.48        62 13.83      41 14.88       45
Q6P5D8 Smchd1 Structural maintenance of chromosomes flexible hinge domain-containing protein 1 3.75        36 5.25        24 11.95      29 21.48       28
Q62376 Snrnp70 U1 small nuclear ribonucleoprotein 70 kDa 2.08        30 2.98        28 12.25      2 26.56       8
Q62189 Snrpa U1 small nuclear ribonucleoprotein A 1.87        28 2.99        23 12.49      14 38.94       14
P57784 Snrpa1 U2 small nuclear ribonucleoprotein A 1.53        13 2.07        16 10.85      6 37.08       7
Q9CQI7 Snrpb2 U2 small nuclear ribonucleoprotein B 1.58        6 2.05        4 11.44      1 27.37       2
P17433 Spi1 Transcription factor PU.1 6.49        3 10.06      2 12.02      36 39.73       27
Q99MR6 Srrt Serrate RNA effector molecule homolog 1.95        52 2.73        41 16.90      32 25.71       36
H7BX95 Srsf1 Serine/arginine-rich splicing factor 1 1.86        35 2.80        30 12.33      13 29.20       14
Q62093 Srsf2 Serine/arginine-rich splicing factor 2 1.87        28 2.92        21 11.07      8 37.87       10
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Q9D8S5 Srsf5 Serine/arginine-rich splicing factor 5 1.97        8 2.73        7 7.87        1 25.30       3
Q3TWW8 Srsf6 Serine/arginine-rich splicing factor 6 1.67        35 2.38        38 12.51      13 29.02       11
Q8BL97 Srsf7 Serine/arginine-rich splicing factor 7 1.89        31 3.07        20 10.17      13 23.86       18
P32067 Ssb Lupus La protein homolog 2.30        46 3.46        39 12.79      23 27.28       15
Q08943 Ssrp1 FACT complex subunit SSRP1 3.11        25 4.10        22 10.27      11 36.82       12
P61957 Sumo2 Small ubiquitin-related modifier 2 2.92        16 3.73        11 8.18        9 40.94       8
O55201 Supt5h Transcription elongation factor SPT5 3.06        34 3.97        30 10.46      13 15.45       13
Q93092 Taldo1 Transaldolase 3.28        31 5.15        21 9.77        11 19.93       14
Q921F2 Tardbp TAR DNA-binding protein 43 1.87        44 2.66        37 12.41      17 43.66       18
Q8CGF7 Tcerg1 Transcription elongation regulator 1 1.99        21 3.09        21 11.97      11 25.30       10
Q99J36 Thumpd1 THUMP domain-containing protein 1 2.96        14 3.98        4 13.80      4 21.86       4
P40142 Tkt Transketolase 1.74        91 2.52        89 10.20      29 26.95       41
Q61033 Tmpo Lamina-associated polypeptide 2, isoforms alpha/zeta 2.65        26 4.46        26 10.67      8 38.35       6
Q62318 Trim28 Transcription intermediary factor 1-beta 1.88        90 2.42        75 13.26      46 37.77       61
Q9Z1F9 Uba2 SUMO-activating enzyme subunit 2 2.46        19 3.54        13 13.69      4 29.56       5
P62983 Ubc Ubiquitin-40S ribosomal protein S27a 3.24        95 5.82        76 8.64        44 23.63       35
E9PXY8 Usp7 Ubiquitin carboxyl-terminal hydrolase;Ubiquitin carboxyl-terminal hydrolase 7 1.53        16 2.08        16 11.75      7 17.60       11
Q9R0G7 Zeb2 Zinc finger E-box-binding homeobox 2 2.51        7 3.17        4 13.82      9 16.26       8
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APPENDIX 2. Dynamic profiling of enhancers’ determinants by tc-ChroP. SILAC ratios 
and ratio countsfor the 148 proteins previously identified as specific enhancers’ 
determinants upon four time-course intriple-SILAC experiments (H3K4me1 Forward, 
H3K4me1 Reverse, Pu.1 Forward, Pu.1 Reverse). (1hr/UT correspond to M/L and H/L in 
the Forward and Reverse experiment, respectively. 4hr/UT correspond to H/L and M/L in 
the Forward and Reverse experiment, respectively). (Fwd = Forward, Rev = Reverse). 
(Red arrow = recruited, green arrow = evicted). Gene names are provided. 
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Gene 
names 1h/UT
1h/UT 
RC 4h/UT
4h/UT 
RC 1h/UT
1h/UT 
RC 4h/UT
4h/UT 
RC 1h/UT
1h/UT 
RC 4h/UT
4h/UT 
RC 1h/UT
1h/UT 
RC 4h/UT
4h/UT 
RC Dynamics
Ahcy 1.39  14 1.65     14 0.73    27 0.86    27 0.62    16 7.00    16 0.82    12 1.00    12
Akap8 1.06  1 2.30     1 0.81    8 0.94    8 2.00    2 2.15    2 1.13    4 1.06    4
Anp32a 1.26  24 1.44     24 0.68    14 0.78    14 1.57    17 1.97    17 0.82    20 0.83    20
Anp32b 1.27  5 1.43     5 0.64    12 0.81    12 1.63    8 2.05    8 0.76    10 0.86    10
Apex1 0.88  19 0.90     19 0.83    21 0.80    21 1.53    10 1.69    10 0.81    6 0.78    6
Api5 1.28  11 1.47     11 0.74    16 0.85    16 1.90    5 2.35    5 0.96    7 1.02    7
Btaf1 1.32  2 1.56     2 0.60    3 0.79    3 1.87    2 2.80    2 0.84    7 1.02    7
Ccar1 1.20  2 1.29     2 0.67    11 0.86    11 1.93    5 1.98    5 0.88    7 1.00    7
Ccar2 1.39  4 1.85     4 0.83    26 0.90    26 2.14    4 2.64    4 1.03    18 1.01    18
Cdk11b 1.23  2 1.35     2 0.84    13 0.90    13 NaN 0 NaN 0 1.10    6 0.92    6
Cenpv 1.04  6 1.21     6 0.87    13 0.84    13 1.27    11 1.60    11 0.92    8 0.90    8
Cggbp1 1.10  2 1.15     2 0.72    5 0.88    5 1.44    3 1.85    3 0.80    3 0.80    3
Chd4 1.20  15 1.41     15 0.77    34 0.86    34 1.56    39 2.11    39 0.92    49 0.96    49
Cherp NaN 0 NaN 0 0.71    1 0.97    1 1.88    1 2.72    1 NaN 0 NaN 0
Ctbp1 1.15  2 1.35     2 0.76    6 0.88    6 0.99    8 3.04    8 0.99    13 0.90    13
Ctbp2 1.09  1 1.33     1 0.90    4 0.86    4 0.97    4 2.31    4 0.98    8 0.89    8
Ctnnbl1 1.07  5 1.16     5 0.73    2 0.82    2 1.83    2 1.85    2 0.93    3 0.89    3
Ddx17 1.16  18 1.53     18 0.79    47 0.87    47 1.73    32 2.12    32 1.07    25 0.96    25
Ddx21 1.07  58 1.10     58 0.73    84 0.71    84 1.50    60 1.67    60 0.98    76 0.69    76
Ddx5 1.11  58 1.32     58 0.75    178 0.95    178 1.71    103 2.02    103 1.00    107 1.02    107
Dhx9 1.13  37 1.32     37 0.79    125 0.91    125 1.85    67 2.17    67 1.04    72 0.98    72
Dis3 1.50  1 1.48     1 0.77    14 0.87    14 1.79    13 2.21    13 0.95    25 0.97    25
Dnajc8 1.09  5 1.27     5 0.74    5 0.83    5 1.68    5 2.03    5 0.94    4 0.96    4
Dnmt1 0.89  12 1.03     12 0.64    49 0.65    49 1.28    16 1.59    16 0.77    40 0.71    40
Elavl1 1.02  7 1.11     7 0.76    26 0.82    26 1.53    20 1.68    20 1.00    16 0.95    16
Ep300 NaN 0 NaN 0 1.25    2 0.76    2 1.41    5 1.49    5 0.96    9 0.92    9
H3K4me1 Fwd H3K4me1 Rev Pu.1 Fwd  Pu.1 Rev 
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Fbl 1.15  35 1.28     35 0.84    29 0.85    29 1.39    23 1.60    23 1.12    16 0.84    16
Fen1 1.07  6 1.18     6 0.75    13 0.81    13 1.69    12 2.16    12 0.82    15 0.82    15
Fus 1.16  3 1.40     3 0.79    19 0.98    19 1.85    3 2.40    3 0.99    14 1.17    14
Gatad2a 1.11  1 1.78     1 0.79    9 0.89    9 NaN 0 NaN 0 0.92    20 0.99    20
Gatad2b NaN 0 NaN 0 0.65    8 0.72    8 3.57    2 2.77    2 0.86    11 0.85    11
Gtf2b 1.00  1 1.47     1 0.62    7 0.84    7 NaN 0 NaN 0 0.83    10 0.94    10
Gtf2e2 NaN 0 NaN 0 0.72    3 0.83    3 NaN 0 NaN 0 0.90    4 0.85    4
H2afy 0.99  37 1.03     37 0.82    58 0.82    58 1.47    9 2.13    9 1.06    16 1.02    16
h2afz 0.97  18 0.92     18 0.86    15 0.88    15 1.52    11 1.75    11 1.10    4 0.99    4
Hcfc1 NaN 0 NaN 0 0.62    8 0.86    8 1.99    1 3.77    1 0.81    17 1.10    17
Hdgf 0.83  24 0.88     24 0.85    26 0.86    26 1.50    10 2.27    8 0.94    6 1.23    6
Hist1h1a 0.87  34 0.99     34 0.80    49 0.71    49 1.17    14 1.65    14 1.18    6 0.91    6
Hist1h1b 0.94  53 0.95     53 0.81    70 0.82    70 1.39    18 1.72    18 1.10    23 1.01    23
Hmgb1 1.07  30 1.09     30 0.81    26 0.84    26 1.67    32 2.01    32 0.90    17 0.88    17
Hmgb2 1.16  45 1.06     45 0.84    49 0.91    49 1.72    61 1.97    61 0.90    28 0.92    28
Hnrnpa0 1.16  22 1.35     22 0.81    36 0.90    36 1.74    42 1.98    42 1.09    26 0.99    26
Hnrnpa1 1.22  16 1.36     16 0.79    39 0.94    39 1.76    38 1.70    36 1.08    14 1.10    14
Hnrnpa2b 1.19  64 1.40     64 0.82    140 0.92    140 1.97    105 2.10    105 1.14    82 1.06    82
Hnrnpa3 NaN 0 NaN 0 0.67    6 0.77    6 2.58    4 2.54    4 0.88    2 0.84    2
Hnrnpab 1.24  14 1.24     14 0.82    46 0.87    46 1.83    26 2.06    26 0.99    34 0.94    34
Hnrnpc NaN 0 NaN 0 0.83    2 0.87    2 1.51    2 3.22    2 NaN 0 NaN 0
Hnrnpd 1.28  15 1.38     15 0.81    46 0.92    46 1.81    36 2.18    35 1.03    26 0.95    26
Hnrnpf 1.16  13 1.33     13 0.82    49 0.94    49 1.62    22 1.86    22 0.99    27 1.04    27
Hnrnph1 1.02  8 1.08     8 0.79    44 0.89    44 1.54    24 1.97    24 1.06    21 1.00    21
Hnrnpl 1.13  20 1.28     20 0.81    84 0.92    84 1.97    25 2.19    25 1.02    44 0.98    44
Hnrnpm 1.11  68 1.29     68 0.80    241 0.91    241 2.04    138 2.50    138 1.11    130 1.05    130
Hnrnpr 1.32  6 1.43     6 0.81    40 0.88    40 2.01    18 1.91    18 1.14    15 1.06    15
Hnrnpu 1.11  98 1.11     98 0.83    189 0.87    188 1.98    115 2.15    115 1.10    93 1.01    93
Hp1bp3 1.13  102 0.99     102 0.86    87 0.86    87 1.51    12 1.93    12 1.00    14 1.03    14
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Ikzf1 NaN 0 NaN 0 0.64    8 0.73    8 1.63    6 2.11    6 0.91    22 1.00    22
Ilf2 1.27  4 1.53     4 0.77    14 0.86    14 1.88    6 2.17    6 1.06    12 0.98    12
Khdrbs1 1.22  4 1.41     4 0.75    24 0.93    24 1.31    3 1.23    3 1.11    14 1.08    14
Khsrp 1.25  18 1.52     18 0.76    62 0.90    62 1.78    34 2.16    34 0.98    46 0.92    46
Lmna 1.16  263 1.27     263 0.86    430 0.86    430 1.49    279 1.89    279 1.15    198 1.01    198
Luc7l 1.25  1 1.11     1 0.85    4 0.86    4 1.63    2 1.50    2 1.09    2 1.13    2
Luc7l2 1.03  11 1.04     11 0.88    20 0.94    20 1.70    10 1.99    10 0.99    9 1.22    9
Matr3 1.06  6 1.37     6 0.77    37 0.92    37 1.87    21 2.21    20 1.10    24 1.10    24
Mcm2 1.30  6 1.44     6 0.73    24 0.82    24 1.74    11 2.23    11 0.89    21 0.88    21
Mcm3 1.30  19 1.37     19 0.70    31 0.76    31 1.68    21 1.94    21 0.90    26 0.85    26
Mcm4 1.38  11 1.24     11 0.80    19 0.87    19 1.77    11 2.15    10 0.92    18 1.00    18
Mcm5 1.15  17 1.22     17 0.71    47 0.76    47 1.57    21 1.95    21 0.92    37 0.86    37
Mcm6 1.29  17 1.39     17 0.70    45 0.79    45 1.81    16 2.15    16 0.88    32 0.89    32
Mcm7 1.26  20 1.28     20 0.74    34 0.81    34 1.63    23 1.98    23 0.91    39 0.92    39
Mki67 NaN 0 NaN 0 0.66    79 0.76    79 NaN 0 NaN 0 0.67    27 0.77    27
Mlh1 NaN 0 NaN 0 0.66    2 0.85    2 NaN 0 NaN 0 0.80    1 0.95    1
Mpeg1 NaN 0 NaN 0 0.86    4 1.14    4 1.75    4 2.35    4 0.98    3 1.18    3
Msh6 1.14  1 1.81     1 0.72    10 0.83    10 1.76    3 2.68    3 0.74    5 0.79    5
Mta2 1.10  13 1.54     13 0.82    20 0.84    20 1.45    16 2.46    16 0.90    25 0.87    25
Mybbp1a 1.06  61 1.26     61 0.70    41 0.73    41 1.64    41 2.15    41 1.04    27 0.78    27
Ncbp1 1.08  4 1.20     4 0.75    9 0.87    9 1.99    4 2.43    4 0.91    6 1.01    6
Ncl 1.14  115 1.20     115 0.74    174 0.76    174 1.72    145 1.91    145 1.07    122 0.90    122
Nhp2l1  /  /  /  /  /  /  /  /  /  /  /  /  /  /  /  /
Nono 1.04  31 1.09     31 0.84    66 1.02    66 1.81    32 2.27    32 1.12    30 1.13    30
Nop56 1.16  48 1.31     48 0.75    31 0.83    31 1.46    33 1.82    33 1.13    15 0.86    15
Nosip 1.12  1 1.04     1 0.66    7 0.74    7 1.57    3 1.94    3 0.85    7 0.75    7
Npm1 1.13  59 1.32     59 0.74    44 0.83    44 1.66    51 2.09    51 1.07    32 0.93    32
Npm3 NaN 0 NaN 0 0.77    3 0.75    3 NaN 0 NaN 0 1.00    4 0.85    4
Nsun2 1.07  23 1.26     23 0.74    29 0.76    29 1.53    21 2.05    21 0.91    13 0.84    13
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Nudt21 0,74  5 1,34    5 0,89   10 1,08   10 NaN 0 NaN 0 1,16   3 1,03   3
Numa1 1,35  17 1,57    17 0,78   49 0,84   49 1,77   35 2,00   35 0,98   71 0,86   71
Pak1ip1 1,18  3 1,05    3 0,75   5 0,77   5 1,16   1 1,50   1 0,95   3 0,85   3
Parp1 1,19  26 1,40    26 0,79   45 0,82   45 1,53   45 2,14   44 0,86   34 0,84   34
Pbrm1 NaN 0 NaN 0 0,92   9 0,91   9 1,94   9 1,87   9 0,98   24 0,93   24
Pcna 1,12  27 1,18    27 0,70   24 0,71   24 1,25   15 1,56   15 0,74   16 0,77   16
Pds5a 1,22  6 1,45    6 0,74   19 0,89   19 1,62   12 2,25   12 0,87   30 0,93   30
Pold1 0,99  1 1,11    1 0,73   6 0,82   6 1,58   2 2,02   2 0,82   13 0,84   13
Polr2a 1,18  8 1,32    8 0,79   26 0,80   26 1,37   4 1,52   4 0,89   14 0,91   14
Prpf31 1,28  5 1,35    5 0,73   8 0,84   8 1,64   5 2,04   5 0,96   7 0,90   7
Psip1 0,93  27 1,08    27 0,85   51 0,86   51 1,53   4 2,03   4 0,90   12 0,97   12
Ptbp1 1,17  16 1,15    16 0,81   67 0,91   67 1,80   30 1,95   29 0,97   47 0,96   47
Pyhin1 1,22  1 1,22    1 0,82   8 1,26   8 1,69   3 2,05   3 1,01   15 1,44   15
Raly 1,17  14 1,28    14 0,78   46 0,88   46 1,97   19 2,13   19 1,05   32 0,99   32
Ran 1,13  20 1,15    20 0,83   30 0,88   30 1,68   23 1,95   23 0,93   18 0,94   18
Rbbp4 1,36  3 1,73    3 0,74   21 0,82   21 1,85   3 2,58   3 0,78   15 0,86   15
Rbm15 0,95  2 1,35    2 1,04   58 1,13   58 1,67   4 2,21   4 1,12   9 1,04   9
Rbm27 NaN 0 NaN 0 0,83   11 1,10   11 1,34   1 2,18   1 1,11   4 0,98   4
Rbm8a 0,94  1 0,95    1 0,78   3 0,85   3 1,55   1 1,47   1 1,03   1 1,11   1
Rbmxl1 1,30  11 1,42    11 0,85   46 0,96   46 2,40   27 2,52   27 1,23   23 1,12   23
Rbpj 1,02  11 1,11    11 0,75   25 0,81   25 1,16   4 1,51   4 0,86   12 0,86   12
Rcc1 1,07  11 1,03    11 0,87   18 0,89   18 1,51   5 1,91   5 1,09   5 0,96   5
Rcc2 1,00  58 0,95    58 0,83   76 0,89   77 1,63   24 1,84   24 0,98   30 0,96   30
Rnmt 0,96  1 1,53    1 0,86   5 0,95   5 1,47   1 1,78   1 0,82   3 0,85   3
Rpp30 1,31  2 1,14    2 NaN 0 NaN 0 1,72   2 2,00   2 1,08   2 1,02   2
Sae1 1,26  3 1,51    3 0,63   7 0,72   7 1,40   6 1,76   6 0,77   6 0,80   6
Safb 1,10  3 1,28    3 0,87   40 0,99   40 2,37   4 2,91   4 1,32   6 1,25   6
Sart3 1,30  2 1,60    2 0,65   5 0,84   5 1,67   4 2,15   4 0,85   9 0,95   9
Set 1,12  9 1,11    9 0,69   14 0,76   14 1,61   7 2,13   7 0,89   7 0,96   7
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Sf1 NaN 0 NaN 0 0.72    18 0.88    18 2.17    2 2.39    2 0.88    5 0.93    5
Sfpq 0.98  49 1.15     49 0.84    113 0.97    113 2.10    57 2.40    57 1.10    62 1.05    62
Sin3a NaN 0 NaN 0 0.60    4 0.69    4 1.36    2 1.74    2 0.87    5 0.79    5
Skiv2l2 1.23  7 1.54     7 0.74    15 0.82    15 2.01    6 2.54    6 0.98    11 1.01    11
Smarca4 1.09  4 1.35     4 0.84    25 0.84    25 1.65    22 1.97    22 0.89    52 0.85    52
Smarcc1 1.16  1 1.90     1 0.74    11 0.81    11 1.56    13 2.53    13 0.86    47 0.80    47
Smarcc2 0.85  1 49.56   1 0.92    1 0.79    1 1.81    7 2.19    7 0.90    12 0.82    12
Smarcd2 NaN 0 NaN 0 0.70    2 0.79    2 1.09    5 1.33    5 0.90    24 0.83    24
Smc1a 1.30  25 1.23     25 0.78    37 0.85    37 1.64    58 2.17    58 0.92    45 0.91    45
Smc3 1.28  22 1.33     22 0.77    38 0.81    38 1.59    56 2.13    56 0.95    59 0.91    59
Smchd1 NaN 0 NaN 0 NaN 0 NaN 0 1.60    1 1.78    1 0.90    2 0.93    2
Snrnp70 1.23  8 1.38     8 0.83    25 0.97    25 1.97    5 2.09    5 1.08    10 1.09    10
Snrpa 1.32  11 1.72     11 0.82    17 0.98    17 1.63    13 1.95    13 0.99    13 0.99    13
Snrpa1 1.17  3 1.41     3 0.78    9 0.90    9 1.98    2 1.75    2 1.01    7 1.03    7
Snrpb2 1.43  1 1.42     1 0.81    5 1.00    5 NaN 0 NaN 0 1.06    5 1.07    5
Spi1 0.85  6 1.00     6 0.79    8 0.75    8 1.17    77 1.11    77 0.91    101 0.82    102
Srrt 1.10  6 1.30     6 0.74    40 0.86    40 1.94    23 2.42    23 0.89    33 0.86    33
Srsf1 1.12  15 1.25     15 0.92    31 1.01    31 1.77    16 2.06    16 1.16    16 1.06    16
Srsf2 1.25  7 1.35     7 0.84    21 0.91    21 1.84    16 1.91    16 1.07    12 0.99    12
Srsf5 1.05  3 1.31     3 0.89    6 1.02    6 1.73    6 2.04    6 1.02    3 1.12    3
Srsf6 1.07  4 1.26     4 0.89    39 0.96    39 1.63    9 1.97    9 1.07    17 1.03    17
Srsf7 1.12  13 1.25     13 0.88    37 1.00    37 1.65    17 1.81    16 1.14    17 1.08    17
Ssb 1.18  14 1.13     14 0.77    28 0.81    28 1.50    20 1.94    20 0.99    15 1.00    15
Ssrp1 1.29  14 1.29     14 0.88    32 0.86    32 1.69    10 2.22    10 0.98    17 0.97    17
Sumo2 1.36  10 1.52     10 0.97    8 1.00    8 1.63    15 2.19    15 0.98    9 1.03    9
Supt5h 1.21  7 1.45     7 0.82    20 0.92    20 1.72    11 1.49    11 0.97    7 1.09    7
Taldo1 1.38  33 1.18     33 0.66    27 0.79    27 1.92    24 1.94    24 0.78    11 0.88    11
Tardbp 1.15  8 1.29     8 0.80    30 0.87    30 1.81    18 2.26    18 0.93    20 0.97    20
Tcerg1 1.31  2 1.96     2 0.51    8 0.84    8 1.90    8 2.18    8 0.92    14 0.98    14
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Thumpd1 1.01  3 1.11     3 0.73    5 0.87    5 1.55    5 1.92    5 0.91    5 0.90    5
Tkt 1.26  57 1.40     57 0.71    50 0.80    50 1.76    42 2.10    42 0.81    26 0.85    26
Tmpo 0.99  9 1.21     9 0.80    62 0.85    62 0.99    6 2.30    6 1.07    16 1.01    16
Trim28 1.05  20 1.36     20 0.75    49 0.80    49 1.73    65 2.23    65 0.98    72 0.94    72
Uba2 1.29  4 1.46     4 0.68    7 0.85    7 1.78    2 2.17    2 0.83    7 0.89    7
Ubc 0.90  69 0.86     69 0.79    101 0.74    101 1.15    45 1.35    45 0.93    50 0.81    50
Usp7 1.35  2 1.62     2 0.79    6 0.83    6 1.49    4 2.38    4 0.89    11 0.86    11
Zeb2 1.73  1 2.63     1 0.77    3 1.09    3 1.62    7 2.59    7 0.97    8 1.20    8
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APPENDIX 3 List of proteins newly recruited at enhancers in tc-ChroP. Proteins were 
identified based on their dynamic SILAC ratio in four X-ChroP experimental replicas 
(H3K4me1 Forward, H3K4me1 Reverse, Pu.1 Forward, Pu.1 Reverse). (1hr/UT 
correspond to M/L and H/L in the Forward and Reverse experiment, respectively. 4hr/UT 
correspond to H/L and M/L in the Forward and Reverse experiment, respectively). Fasta 
headers, Protein names and Gene names are provided together with number of peptides and 
unique peptides in all the four experiments  
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Fasta 
headers
Protein names Gene 
names
1h/UT 1h/UT 
RC
4h/UT 4h/UT 
RC
1h/UT 1h/UT 
RC
4h/UT 4h/UT 
RC
1h/UT 1h/UT 
RC
4h/UT 4h/UT 
RC
1h/UT 1h/UT 
RC
4h/UT 4h/UT 
RC
Q9JIX8
Apoptotic 
chromatin 
condensation 
inducer in the 
nucleus
Acin1 4 13 5 5 4 13 5 5 1,14  4 1,44 4 0,87  31 0,93 31 2,01 5 2,65   5 1,09 9 0,99 9
Q9QUJ7 Long-chain-fatty-
acid--CoA ligase 4
Acsl4 0 6 2 4 0 5 2 3 NaN 0 NaN 0 0,94  6 0,92 6 1,20 2 1,60   2 1,00 4 1,12 4
Q9JII6
Alcohol 
dehydrogenase 
[NADP(+)]
Akr1a1 7 5 5 5 7 5 5 5 1,33  6 1,72 6 0,70  6 0,86 6 1,79 5 2,33   5 0,82 6 1,06 6
P84091 AP-2 complex 
subunit mu
Ap2m1 0 4 5 7 0 4 5 7 NaN 0 NaN 0 0,94  3 0,97 3 0,59 2 4,26   2 1,11 6 0,90 6
Q8K019
Bcl-2-associated 
transcription factor 
1
Bclaf1 2 9 7 6 2 9 7 6 1,14  3 1,17 3 0,85  34 0,95 34 2,06 16 2,38   16 1,14 28 1,01 28
Q9DCA5
Ribosome 
biogenesis protein 
BRX1 homolog
Brix1 3 5 5 3 3 5 5 3 1,13  5 1,10 5 0,77  5 0,78 5 2,01 5 2,26   5 1,28 2 0,96 2
Q64152 Transcription 
factor BTF3
Btf3 0 4 2 3 0 4 2 3 NaN 0 NaN 0 1,02  7 0,93 7 NaN 0 NaN 0 1,19 3 1,22 3
P53569
CCAAT/enhancer-
binding protein 
zeta
Cebpz 5 4 4 2 5 4 4 2 1,11  5 1,28 5 0,66  5 0,84 5 1,89 5 2,67   5 1,20 2 0,85 2
Q8BMK4
Cytoskeleton-
associated protein 
4
Ckap4 1 11 2 5 1 11 2 5 1,19  1 1,47 1 1,09  13 0,93 13 0,56 1 0,74   1 1,16 6 1,10 6
Q9EPU4
Cleavage and 
polyadenylation 
specif icity factor 
subunit 1
Cpsf1 1 8 6 9 1 8 6 9 1,81  1 1,47 1 0,78  9 0,95 9 1,96 5 2,34   5 1,00 11 0,97 11
H3BJW3
Cleavage and 
polyadenylation 
specif icity factor 
subunit 6
Cpsf6 2 11 3 7 2 11 3 7 1,43  2 2,41 2 0,84  23 1,04 23 1,60 4 3,12   4 1,13 11 1,07 11
Q9JKB3 DNA-binding 
protein A
Csda 0 3 5 2 0 1 1 1 NaN 0 NaN 0 0,99  1 0,79 1 NaN 0 NaN 0 1,00 1 0,92 1
D3Z0M9
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 23
Ddx23 6 6 10 8 6 6 10 8 1,28  5 1,41 5 0,81  8 0,98 8 1,85 12 2,23   12 1,08 11 1,03 11
H3K4me1 Fwd H3K4me1 Rev Pu.1 Fwd  Pu.1 Rev 
Peptides
Unique 
peptides
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Q8VDW0
ATP-dependent 
RNA helicase 
DDX39A
Ddx39a 10 15 10 11 2 5 2 1 1,10  2 1,27 2 0,87  7 0,94 7 NaN 0 NaN 0 1,01 1 0,59 1
Q569Z5
Probable ATP-
dependent RNA 
helicase DDX46
Ddx46 1 21 7 14 1 21 7 14 1,23  3 1,15 3 0,83  33 0,98 33 1,95 8 2,43   8 0,96 25 1,00 25
Q9CWX9
Probable ATP-
dependent RNA 
helicase DDX47
Ddx47 0 2 4 2 0 2 4 2 NaN 0 NaN 0 0,97  2 0,82 2 0,61 3 10,92 3 0,94 1 1,11 1
A2AH85
116 kDa U5 small 
nuclear 
ribonucleoprotein 
component
Eftud2 9 19 14 16 8 18 13 15 1,12  10 1,40 10 0,77  26 0,94 26 1,98 15 2,35   15 1,04 17 1,04 17
P23116
Eukaryotic 
translation initiation 
factor 3 subunit A
Eif3a 0 16 2 6 0 16 2 6 NaN 0 NaN 0 1,15  26 1,02 26 0,87 1 9,73   1 1,20 9 1,16 9
P60229
Eukaryotic 
translation initiation 
factor 3 subunit E
Eif3e 1 6 8 3 1 6 8 3 NaN 0 NaN 0 0,94  6 0,93 6 0,69 8 7,42   8 1,01 4 1,08 4
Q9DBC3
Cap 
methyltransferase 
1
Ftsjd2 2 2 3 1 2 2 3 1 1,13  2 1,21 2 0,95  3 0,88 3 1,83 2 2,16   2 0,71 1 0,76 1
Q61598
Rab GDP 
dissociation 
inhibitor beta
Gdi2 0 6 7 2 0 6 6 2 NaN 0 NaN 0 0,66  7 0,86 7 1,31 4 11,11 4 1,17 2 1,16 2
P68040
Guanine nucleotide-
binding protein 
subunit beta-2-like 
1
Gnb2l1 10 17 11 12 10 17 11 12 1,14  11 1,06 11 0,99  23 0,89 23 1,13 16 1,55   16 1,04 14 1,02 14
Q99ME9 Nucleolar GTP-
binding protein 1
Gtpbp4 8 13 9 9 8 13 9 9 1,18  14 1,20 14 0,80  18 0,87 18 1,85 9 2,23   9 1,05 9 0,97 9
P10922 Histone H1.0 H1f0 7 9 6 6 7 9 6 6 0,95  29 0,98 29 0,89  70 0,89 70 1,24 10 1,45   10 1,26 14 1,15 14
Q6NVF4 DNA helicase B Helb 1 5 2 3 1 5 2 3 1,59  1 1,60 1 1,20  5 1,12 5 2,05 2 2,72   2 1,31 3 1,14 3
P22752 Histone H2A type 
1
Hist1h2ab 4 5 6 5 1 1 1 1 1,24  5 1,08 5 0,90  5 1,00 5 1,88 7 1,93   7 1,14 1 1,04 1
P15092
Interferon-
activable protein 
204
If i204 5 8 3 7 4 5 2 4 1,10  4 1,85 4 0,80  8 1,35 8 1,36 3 2,56   3 1,07 9 1,81 9
P09450 Transcription 
factor jun-B
Junb 1 2 3 2 1 2 2 2 NaN 0 NaN 0 2,05  2 2,80 2 2,70 3 5,32   3 2,60 5 2,90 5
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A2BE28
Ribosomal 
biogenesis protein 
LAS1L
Las1l 3 2 4 5 3 2 4 5 1,06  2 1,05 2 0,70  2 0,88 2 2,94 7 2,33   7 1,07 5 0,94 5
Q5SUF2 Luc7-like protein 3 Luc7l3 3 9 0 5 3 9 0 5 1,09  4 1,14 4 0,83  13 0,97 13 NaN 0 NaN 0 1,03 6 0,98 6
Q9WTL7 Acyl-protein 
thioesterase 2
Lypla2 0 3 2 4 0 3 2 4 NaN 0 NaN 0 0,81  3 0,72 3 1,90 4 1,74   4 1,04 7 0,93 7
D3Z3G6 Mitogen-activated 
protein kinase 3
Mapk3 2 4 4 6 1 2 3 5 1,69  2 1,95 2 1,00  5 1,02 5 2,08 5 2,61   5 0,98 6 1,13 6
D0QMC3
Myeloid cell 
nuclear 
differentiation 
antigen-like protein
Mndal 11 8 4 4 6 6 3 3 1,02  21 1,20 21 0,86  13 1,08 13 1,43 9 2,06   9 0,94 8 1,13 8
P70670
Nascent 
polypeptide-
associated 
complex subunit 
alpha, muscle-
specif ic form
Naca 3 4 2 2 3 4 2 2 1,17  5 1,04 5 1,01  12 0,88 12 1,03 5 1,32   5 1,04 2 0,97 2
Q91W39 Nuclear receptor 
coactivator 5
Ncoa5 0 10 1 6 0 3 0 2 NaN 0 NaN 0 0,81  27 0,99 27 1,93 1 3,23   1 1,32 9 1,25 9
Q3TZX8
Polynucleotide 5-
hydroxyl-kinase 
NOL9
Nol9 2 5 6 3 2 5 6 3 0,84  3 1,13 3 0,91  5 0,63 5 2,53 5 2,14   5 1,13 3 0,92 3
Q99JX7 Nuclear RNA 
export factor 1
Nxf1 5 11 5 10 5 11 5 10 1,14  5 1,34 5 0,86  16 0,97 16 1,79 8 2,16   8 1,21 14 1,07 14
P50580
Proliferation-
associated protein 
2G4
Pa2g4 8 20 18 13 8 20 18 13 1,20  13 1,00 13 1,00  44 0,92 44 0,80 30 10,77 30 1,13 18 0,99 18
P29341 Polyadenylate-
binding protein 1
Pabpc1 5 16 16 17 4 8 7 10 1,20  6 1,70 6 0,98  32 1,07 32 1,04 19 6,02   19 0,98 25 1,00 25
E9QN87 Plectin Plec 6 42 12 27 6 41 12 25 2,01  5 0,96 5 0,91  44 0,91 44 0,93 8 1,75   8 1,19 33 1,19 33
Q8BVQ9
26S protease 
regulatory subunit 
7
Psmc2 0 2 7 2 0 2 7 2 NaN 0 NaN 0 0,96  2 0,90 2 0,67 5 7,23   5 0,96 2 1,09 2
P70388 DNA repair protein 
RAD50
Rad50 1 6 5 11 1 6 5 11 1,02  1 1,23 1 0,92  7 0,93 7 1,80 5 2,44   5 1,00 12 1,01 12
Q8C2Q3 RNA-binding 
protein 14
Rbm14 10 23 11 15 7 18 8 12 1,14  13 1,55 13 0,84  69 0,99 69 2,31 15 3,13   15 1,26 28 1,25 28
Q9JJ80
Ribosome 
production factor 2 
homolog
Rpf2 7 6 6 3 7 6 6 3 1,05  8 1,12 8 0,79  6 0,81 6 1,89 7 2,22   7 1,22 3 0,86 3
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Q6ZWV3 60S ribosomal 
protein L10
Rpl10a 4 9 6 6 4 9 6 6 1,13  10 1,18 10 0,91  29 0,87 29 0,99 11 1,35   11 1,10 11 0,98 11
Q5XJF6 60S ribosomal 
protein L10a
Rpl10a 7 10 3 9 7 10 3 9 1,34  10 1,35 10 1,02  32 0,97 32 1,00 6 1,17   6 1,13 17 1,03 17
P19253 60S ribosomal 
protein L13a
Rpl13a 5 12 1 8 5 12 1 8 1,30  5 1,15 5 1,01  25 0,90 25 0,75 3 1,03   3 1,21 11 1,02 11
Q9CR57 60S ribosomal 
protein L14
Rpl14 5 7 3 6 5 7 3 6 1,33  14 1,20 14 0,98  24 0,87 24 0,96 6 1,12   6 1,14 9 1,03 9
E9QAZ2 Ribosomal protein 
L15
Rpl15 8 12 5 7 8 12 5 7 1,19  15 1,17 15 1,01  26 0,94 26 1,03 17 1,23   17 1,18 10 1,09 10
Q6ZWZ7 60S ribosomal 
protein L17
Rpl17 2 10 5 4 2 10 5 4 1,24  4 0,98 4 1,05  29 0,95 29 0,93 5 1,06   5 1,11 8 1,03 8
P35980 60S ribosomal 
protein L18
Rpl18 6 10 4 5 6 10 4 5 0,88  12 1,19 12 1,01  28 0,93 28 0,87 5 1,30   5 1,03 8 1,06 8
P62717 60S ribosomal 
protein L18a
Rpl18a 5 12 8 8 5 12 8 8 1,08  12 1,14 12 1,00  22 0,92 22 1,23 19 1,55   19 1,17 14 1,02 14
Q8BP67 60S ribosomal 
protein L24
Rpl24 4 10 4 5 4 10 4 5 1,21  12 1,18 12 1,09  29 0,97 29 1,01 10 1,27   10 1,06 8 1,03 8
P61255 60S ribosomal 
protein L26
Rpl26 4 9 2 8 4 9 2 8 1,13  4 1,24 4 1,01  29 0,89 29 1,01 3 1,08   3 1,10 11 0,99 11
P14115 60S ribosomal 
protein L27a
Rpl27a 4 5 2 4 4 5 2 4 0,88  8 1,15 8 1,03  16 0,90 16 0,77 5 0,97   5 1,17 7 1,07 7
P41105 60S ribosomal 
protein L28
Rpl28 3 10 1 7 3 10 1 7 1,16  3 1,20 3 0,99  25 0,90 25 0,98 2 1,33   2 1,12 10 0,99 10
P27659 60S ribosomal 
protein L3
Rpl3 11 24 16 16 11 24 16 16 1,19  24 1,13 24 1,05  81 0,94 81 1,14 31 1,54   31 1,18 29 1,05 29
P62911 60S ribosomal 
protein L32
Rpl32 4 11 3 7 4 11 3 7 1,13  6 1,15 6 1,01  19 0,89 19 0,90 5 0,97   5 1,17 8 1,06 8
Q9D8E6 60S ribosomal 
protein L4
Rpl4 11 28 23 10 11 28 23 10 1,32  22 1,16 22 0,95  127 0,90 127 0,35 26 17,42 26 1,17 19 1,12 19
P47962 60S ribosomal 
protein L5
Rpl5 9 12 8 8 9 12 8 8 1,20  15 1,06 15 0,99  26 0,91 26 1,20 14 1,47   14 1,06 10 0,97 10
P47911 60S ribosomal 
protein L6
Rpl6 15 19 17 15 15 19 17 15 1,22  40 1,06 40 0,97  91 0,88 91 1,20 36 1,48   36 1,17 38 1,02 38
P14148 60S ribosomal 
protein L7
Rpl7 12 23 11 14 12 23 11 14 1,27  26 1,04 26 0,95  66 0,85 66 0,82 17 1,04   17 1,14 18 1,01 18
D3Z3R0 60S ribosomal 
protein L7a
Rpl7a 13 21 14 15 13 21 14 15 1,26  31 1,13 31 0,97  80 0,92 80 1,20 23 1,49   23 1,13 33 0,98 33
P62918 60S ribosomal 
protein L8
Rpl8 7 14 7 14 7 14 7 14 1,08  14 1,18 14 1,04  50 0,92 50 0,98 18 1,39   18 1,14 28 1,03 28
P62281 40S ribosomal 
protein S11
Rps11 8 14 10 8 8 14 10 8 1,16  19 1,07 19 1,10  36 0,93 36 1,18 24 1,49   24 1,12 13 0,94 13
P62301 40S ribosomal 
protein S13
Rps13 4 6 5 6 4 6 5 6 1,56  4 1,34 4 1,14  11 1,00 11 0,89 7 1,12   7 1,16 8 1,04 8
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P62849 40S ribosomal 
protein S24
Rps24 3 6 2 3 3 6 2 3 1,26  2 1,06 2 1,10  17 0,94 17 1,12 2 1,44   2 1,24 3 1,02 3
D3Z6C3 40S ribosomal 
protein S3a
Rps3a 12 22 17 12 12 22 17 12 1,26  33 1,21 33 1,11  69 0,91 69 0,97 26 1,30   26 1,16 29 0,98 29
P62702
40S ribosomal 
protein S4, X 
isoform
Rps4x 11 22 13 17 11 22 13 17 1,13  22 1,19 22 1,00  63 0,89 63 1,00 41 1,34   41 1,07 20 0,97 20
P62754 40S ribosomal 
protein S6
Rps6 10 11 10 7 10 11 10 7 1,17  22 1,18 22 1,03  38 0,90 38 1,33 11 1,81   11 1,12 13 1,06 13
P18654 Ribosomal protein 
S6 kinase alpha-3
Rps6ka3 0 8 1 5 0 8 1 5 NaN 0 NaN 0 0,78  8 1,06 8 1,56 2 2,24   2 0,97 8 1,16 8
P62082 40S ribosomal 
protein S7
Rps7 7 13 9 10 7 13 9 10 1,34  10 1,22 10 1,20  25 0,93 25 1,02 14 1,28   13 1,23 16 1,05 16
P62242 40S ribosomal 
protein S8
Rps8 9 12 9 11 9 12 9 11 1,13  25 1,13 25 1,04  54 0,93 54 1,00 18 1,17   17 1,12 23 1,00 23
Q80YR5
Scaffold 
attachment factor 
B2
Safb2 1 16 4 4 0 11 2 4 NaN 0 NaN 0 0,82  24 0,98 24 2,19 2 3,44   2 1,36 4 1,36 4
Q8CH25
SAFB-like 
transcription 
modulator
Sltm 2 22 6 10 2 21 6 10 1,18  3 1,40 3 0,96  75 1,08 75 2,43 9 3,10   9 1,20 20 1,21 20
Q78PY7
Staphylococcal 
nuclease domain-
containing protein 
1
Snd1 3 25 11 12 3 25 11 12 1,34  3 1,37 3 1,15  41 0,87 41 1,43 14 1,43   14 1,15 18 0,98 18
P84104
Serine/arginine-
rich splicing factor 
3
Srsf3 3 6 4 5 2 5 3 4 1,04  4 1,15 4 0,88  14 0,95 14 1,60 8 1,83   7 1,12 7 1,05 7
Q8C3V4
Signal transducer 
and activator of 
transcription 1
Stat1 2 7 4 5 2 7 4 5 1,15  2 1,59 2 0,88  7 0,95 7 1,44 4 2,16   4 0,97 5 1,33 5
Q62383
Transcription 
elongation factor 
SPT6
Supt6h 4 9 2 7 4 9 2 7 1,33  2 1,51 2 0,83  10 0,93 10 2,04 1 2,81   1 0,94 7 1,09 7
H3BL37 Treacle protein Tcof1 7 9 5 2 7 9 5 2 0,76  35 0,90 35 0,66  13 1,15 13 1,24 8 1,24   8 1,06 3 1,15 3
P62996
Transformer-2 
protein homolog 
beta
Tra2b 3 7 4 3 3 5 4 3 1,17  7 1,24 7 0,88  17 0,98 17 1,93 6 2,12   6 1,19 3 1,02 3
Q640M1
U3 small nucleolar 
RNA-associated 
protein 14 homolog 
A
Utp14a 2 5 3 3 2 5 3 3 1,11  2 1,40 2 0,77  5 0,98 5 1,77 3 2,62   3 1,29 3 1,10 3
P20152 Vimentin Vim 22 29 32 29 19 26 29 27 1,02  72 1,06 72 1,01  102 0,83 102 1,14 127 1,57   127 1,22 86 1,01 86
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APPENDIX 4 hPTMs identified and quantified at enhancers. Theoretical MH+, number of lysines 
contained in the sequence and alkylated in ArgC-like digestion, m/z used for XIC reconstruction and 
retention time normally observed are provided for all the peptides on histone H3, H2A and H4 reported 
together with amino acid sequence of the peptide and residue modified (in red). 
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Modification Theoretical MH+
N° lysine (D3 
mod.) MH2+ D3 RT
H3 (3-8) peptide = TK4QTAR
K4unmod 704.4050 1 375.2208 45.89
K4me1 718.4206 1 382.2286 54.21
K4me2 732.4363 0 366.7218 29.19
K4me3 746.4519 0 373.7296 28.22
H3 (9-17) peptide = K9STGGK14APR
K9unmod/K14unmod 901.5214 2 496.2937 62.46
K9me1/K14unmod 915.5370 2 503.3016 68.84
K9me2/K14unmod 929.5527 1 487.7947 50.64
K9me3/K14unmod 943.5683 1 494.8025 50.35
K9unmod/K14Acetyl 943.5320 1 494.7843 62.67
K9me1/K14Acetyl 957.5476 1 501.7921 68.95
K9me2/K14Acetyl 917.5633 0 486.2853 51.04
K9me3/K14Acetyl 985.5789 0 493.2931 50.46
K9Acetyl/K14Acetyl 985.5425 0 493.2749 62.81
H3 (18-26) peptide = 
K18QLATK23AAR
K18unmod/K23unmod 986.6105 2 538.8383 79.16
K18me1/K23unmod 1000.6262 2 545.8461 87.46
K18Acetyl/K23unmod 1028.6211 1 537.3289 79.77
K18Unmod/K23Acetyl 1028.6211 1 537.3289 79.77
K18me1/K23Acetyl 1042.6368 1 544.3367 86.11
K18Acetyl/K23Acetyl 1070.6317 0 535.8195 80.19
H3 (73-83) peptide = 
EIAQDFK79TDLR
K79unmod 1335.6903 1 690.8635 118.49
K79me1 1349.7060 1 697.8713 125.68
K79me2 1363.7216 0 682.3644 105.25
K79me3 1377.7373 0 689.3723 107.55
H3 (27-40) peptide = 
K27SAPATGGVK36K37PHR
K27/K36/K37unmod 1433.8336 3 784.9645 84.16
K27me1 1447.8492 3 791.9723 87.82
K36me1 1447.8492 3 791.9723 87.06
K27me2 1461.8649 2 776.4655 74.1
K36me2 1461.8649 2 776.4655 78
K36me3 1461.8649 2 776.4655 73.81
K27me3 1475.8805 2 783.4733 78
K27me2/K36me1 1475.8805 2 783.4733 76.89
K27me1/K36me2 1475.8805 2 783.4733 82.02
K27me1/K36me1 1461.8649 3 798.9802 90.65
K27me2/K36me2 1489.8962 1 767.9664 69.5
K27me3/K36me1 1489.8962 2 790.4811 76.73
K27me1/K36me3 1489.8962 2 790.4811 82.02
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Modification Theoretical MH+
N° lysine (D3 
mod.) MH2+ D3 RT
H4 (4-17) peptide = 
GK5GGK8GLGK12GGAK16R 
K5/K8/K12/K16unmod 1270.7702 4 725.9476 87.59
Mono-Acetyl K 1312.7808 3 724.4381 87.75
Di-Acetyl K 1354.7914 2 722.9287 87.96
Tri-Acetyl K 1396.8019 1 721.4193 88.17
Tetra-Acetyl K 1438.8125 0 719.9099 88.24
H2A (4-11) peptide = GK5QGGK9AR
K5unmod/K9unmod 801.4690 2 446.2675 52.52
K5Acetyl/K9unmod 843.4795 1 444.7581 52.76
K5unmod/K9Acetyl 843.4795 1 444.7581 52.76
K5Acetyl/K9Acetyl 885.4901 0 443.2487 52.85
